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Viruses, derived from the Greek word ‘poison’, are a group of obligatory parasites that hijack 
the hosts’ resources to produce their progeny. Indeed, viruses are notorious for the threats 
they pose to human beings, as the name suggests. From smallpox, one of human kind’s 
greatest scourges, to HIV, an enemy that tactfully disarms the human immune system; from 
the 1918 influenza pandemic to the 2003 SARS outbreak; viruses have often been associated 
with disease and death. This reputation is, in a sense, well deserved; however, the advent 
of genomics era has started to enrich our perception of these ‘killers’. The omnipresence 
and abundance of viruses turn out to go far beyond our wildest guess. In fact, viruses are so 
pervasive that they essentially infect any form of life, and even parasitizing other viruses [1]. 
Moreover, viruses have been proposed to play major roles in the global ecosystem [2], have 
influenced and are still shaping the evolution of cellular life forms, with elements of viral 
origin embedded in host genomes. The extent of their infiltration into the human genome 
is surprising yet undeniable [3;4]. We are, for better or worse, living in a virosphere with 
viruses lurking within us.   
 Virus particles, or virions, consist of nucleic acids, the genetic material, as well as a 
protein coat, known as the capsid; in some cases, this nucleocapsid is further wrapped by an 
envelope of lipids. Different from ribosome-encoding organisms, i.e., bacteria, archaea, and 
eukarya, which all have DNA as their genetic material, viruses (defined as capsid-encoding 
organisms [5]) can also use RNA molecules to convey their genetic information. The genomic 
RNA for some viruses like reoviruses is double-stranded, while most of the RNA viruses 
possess single-stranded RNAs of either positive or negative polarity. Viruses with genomic 
RNA complementary to mRNA are denoted negative-strand RNA viruses, whereas those 
with genomic RNA of mRNA polarity are classified as positive-strand or plus-strand RNA 
(+ssRNA) viruses. The topics covered in this thesis are revolving around a group of +ssRNA 
viruses, the flaviviruses.  
Flavivirus: Phylogeny  
Flaviviruses form a genus within the Flaviviridae family that also includes the genera 
Pestivirus and Hepacivirus, as well as the newly proposed Pegivirus genus [6]. 
 The Flavivirus genus comprises more than 70 viruses, which, based on phylogenetic 
analysis, can be grouped into three clusters of related viruses that are in general distinguished 
by their route of transmission: (i) mosquito-borne, (ii) tick-borne, and (iii) no known vector 
(NKV) flaviviruses [7]. The first two clusters of flaviviruses are transmitted by arthropods, 
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mosquitoes and ticks, respectively. They are exemplified by important human pathogens 
like dengue virus (DENV), Japanese encephalitis virus (JEV), West Nile virus (WNV), yellow 
fever virus (YFV) and tick-borne encephalitis virus (TBEV). The third cluster comprises a 
less-well studied group of viruses for which no arthropod vector has been implicated in 
transmission. These viruses have been exclusively isolated from bats (such as, Montana 
myotis leukoencephalitis virus [MMLV] [8] and Rio Bravo virus [RBV] [9]) and rodents (for 
example, Modoc virus [MODV] [10] and Apoi virus [APOIV]). 
 In addition to the viruses assigned to any of the above-mentioned clusters within 
the Flavivirus genus, there are a few viruses that are currently considered tentative species 
of this genus. This group of viruses, such as cell fusing agent virus (CFAV), Kamiti River virus 
(KRV) and Culex flavivirus (CxFV), have all been exclusively isolated from mosquitoes or insect 
cell lines [11-13]. There is no evidence that these viruses are able to infect a vertebrate host 
and therefore they are referred to as insect-specific flaviviruses. 
Flavivirus: General Features
Flaviviruses share similarities in virion morphology, genome organization and replication 
strategy. The enveloped viral particles are composed of a lipid bilayer surrounding a 
nucleocapsid that consists of a single-stranded, positive-sense genome RNA complexed with 
multiple copies of a basic capsid (C) protein [14].  
 The genomic RNA is approximately 11 kb in length with a 5’ type I cap, m7GpppAmpN2, 
while lacking a 3’ poly(A) tail. As other positive-strand RNA viruses, the flavivirus genome 
plays various roles in the viral life cycle: (i) directing the synthesis of viral proteins by 
ribosomes, (ii) serving as a template for the production of negative-strand RNA, and (iii) 
as the genetic material to be encapsidated into progeny virions. The genome is translated 
into a large polyprotein that is co- and post-translationally processed into functional viral 
proteins by cellular and viral proteases (Fig.1). The N-terminal third of the polyprotein yields 
the viral structural proteins: core (C), membrane (prM/M), and envelope (E) that participate 
in virus entry and assembly. The C-terminal two-thirds of the polyprotein is cleaved into at 
least seven nonstructural (NS) proteins, namely NS1, NS2A, NS2B, NS3, NS4A, NS4B, and 
NS5, which have been implicated directly or indirectly in viral RNA replication, evasion of the 
innate immune response, as well as virus assembly [14-21]. 
 NS1 is a multifunctional glycoprotein that is localized to the replication complexes, 
expressed on the plasma membrane of infected cells and secreted into the extracellular 
milieu.  The intracellular form of NS1 was proposed to interact with NS4A and NS4B and 
plays an important role in regulating negative-strand RNA synthesis, whereas its extracellular 
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form was implicated in immune evasion [22-27]. NS2A is a small hydrophobic protein that is 
essential for virus replication and assembly and may also modulate the host innate immune 
response [17;18;28;29]. NS2B, another small membrane-associated protein, is a cofactor for 
the NS2B-NS3 serine protease that mediates cleavage of NS2A/NS2B, NS2B/NS3, NS3/NS4A, 
NS4A/NS5 junction, and generates the C-termini of mature C and NS4A [14]. In addition to 
its protease activity, NS3 also contains RNA helicase, nucleotide triphosphatase and RNA 
triphosphatase activities [30-33]. Both NS4A and NS4B are small hydrophobic proteins that 
co-localize to ER-derived membrane structures presumed to be the site of replication [34]. 
NS5, a large and highly conserved flaviviral protein, functions as an RNA-dependent RNA 
polymerase and contains methyltransferase activity that is required for the formation of a 5’ 
type I cap as well as internal adenosine 2’-O methylation of the viral genome [14;35-37]. 
 Flaviviruses enter the cell by receptor-mediated endocytosis via clathrin-coated 
pits [38;39]. The viral particles are subsequently trafficked to prelysosomal endocytic 
compartments where low pH induces a conformational change in the envelope protein, 
triggering the fusion between the viral and the endosomal membranes [38;40-43]. The 
nucleocapsid is thus released into the cytoplasm, where membrane-associated translation-
Figure 1. Flavivirus Genome Organization
The flavivirus genome encompasses a single open reading frame that is flanked by 5′ and 3′ untranslated regions 
(UTRs), within which high-ordered RNA structures are formed. Stem loop (SL) structures are indicated with dots 
representing the loop and short lines for stems. Location of the conserved sequences (CS) and the upstream AUG 
region (UAR) that are involved in cyclization of the genomic RNA are indicated. The polyprotein is co- and post-
translationally cleaved into three structural proteins (in green) and seven nonstructural proteins (in red). Putative 
functions of these proteins during infection are described. aa, amino acids; C, capsid protein; E, envelope; M, 
membrane; RdRp, RNA-dependent RNA-polymerase
(Adapted from Cell Host & Microbe, 2009 Apr 23;5(4):318-28,  Fernandez-Garcia MD, Mazzon M, Jacobs M, Amara 
A., reprinted with permission)
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replication complexes are formed [34;44;45]. Newly produced nucleocapsids further acquire 
the envelope upon budding into the endoplasmatic reticulum (ER) lumen. The immature 
viral particles are then transported to the Golgi apparatus, where E/prM heterodimers are 
dissociated and the formation of homodimers allows the cleavage of prM by the Golgi-
resident protease furin [34;46-50]. Mature virions are released via the exocytosis pathway 
for the next round of infection [14]. (Fig. 2)
Flavivirus: 3’-UTR and sfRNA
The flavivirus genome contains a single open reading frame (ORF) flanked by 5’ and 3’ 
untranslated regions (UTRs). The sequence of the 5’-UTR is not well conserved among 
different flaviviruses, although common secondary structures have been identified within 
this region that influence translation and function in viral replication (reviewed in [51]).  
 The 3’-UTR varies in length from about 350 to 800 nucleotides. This heterogeneity in 
length is mainly due to the variation in the so-called variable region (VR), which is located 
Figure 2.  Flavivirus Life Cycle
(1) receptor-mediated endocytosis; (2) fusion of the virus envelop with the endosomal membrane induced by 
the acidification (red) of the endosomes; (3) release of the genome into the cytoplasm; (4) topology of the viral 
proteins at the endoplasmic reticulum (ER) membrane, polyprotein cleavage mediated by host signalases and 
the viral serine protease NS3 are indicated with black and blue arrows, respectively; (5) assembly of membrane 
associated replication complex; (6) assembly and budding of the progeny virions into the lumen of the ER; (7) virion 
maturation during transportation through the trans-Golgi network; (8) virion release via exocytosis 
(Adapted from Cell Host & Microbe, 2009 Apr 23;5(4):318-28,  Fernandez-Garcia MD, Mazzon M, Jacobs M, Amara 
A., reprinted with permission)
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proximal to the translation termination codon and characterized by extensive sequence 
duplications and deletions, even among strains of the same virus, and by an apparent lack 
of sequence conservation. The high variability of this region among different natural strains 
suggests it is non-essential for viral replication. Indeed in the context of infectious cDNA 
clones, the whole VR can be deleted without significantly compromising viral viability or 
virulence in either cell culture or mice [52-56].   
 In contrast, the distal part of the 3’-UTR exhibits more sequence and/or structure 
similarities among flaviviruses, with even more conservation within each cluster. This “core 
element” of the 3’-UTR contains RNA motifs and structures that have been shown to be 
essential for viral translation, replication, and possibly assembly [56-63]. 
 A universal feature that has been identified in every flavivirus studied thus far is the 
presence of a large, stable stem-loop structure formed by the last 90 to 120 nts of the genome 
(3’ SL). Sequence conservation within this structure, on the other hand, is only restricted to 
the 3’ terminal dinucleotide 5’-CU-3’ and the pentanucleotide (PN) motif 5’-CACAG-3’ in the 
top loop of the 3’ SL in arthropod-borne flaviviruses (reviewed in [51]). This PN motif is also 
rather conserved among the NKV flaviviruses, albeit with limited sequence variability [64]. 
For tick-borne flaviviruses, the sequence of the bottom stem of the 3’ SL is well conserved 
and was proposed to be involved in genome “cyclization” with a complementary sequence 
present in the 5’-UTR. This cyclization is generally believed to be an essential prerequisite 
for viral replication [14;65]. Conserved sequence motifs for genomic RNA “cyclization” have 
also been reported for the mosquito-borne flaviviruses [14;65;66], although in these viruses 
the 3’ cyclization sequence (3’CS) is located upstream of the 3’ SL. The 3’CS forms a long-
range RNA-RNA interaction with a complementary conserved sequence (5’ CS) near the 5’ 
end of the genome, downstream of the translation initiation codon in the capsid gene [66] 
that is critical for viral RNA synthesis [52;67-72]. Recent studies have identified an additional 
long-range RNA-RNA interaction that also plays a role in promoting genome cyclization. This 
interaction involves complementary sequences at the 5’ end, located immediately upstream 
of the AUG start codon region (UAR), and at the 3’ end within the bottom part of the 3’ SL (3’ 
UAR) [72]. This pair of complementary sequences has been shown to be important for viral 
replication [71;73-77]. In dengue virus and West Nile virus yet a third interaction important 
for genome circularization and RNA replication was recently identified between nucleotides 
downstream of the AUG region (5’ DAR) and nucleotides downstream of the 3’CS (3’ DAR) 
[78-80]. Similar RNA elements involved in long-distance RNA interaction have also been 
proposed for NKV flaviviruses [81]. 
 Upstream of the cyclization sequence, another stretch of conserved nucleotides 
approximately 24 nucleotides in length was identified among mosquito-borne flaviviruses, 
designated as CS2. YFV contains only one copy of CS2 but this motif is duplicated (RCS2) 
in members of the JEV and DENV subgroups [66]. Deletion of CS2 has little effect on viral 
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RNA synthesis but appears to affect cytopathogenicity of at least YFV and DENV, as mutants 
lacking CS2 form turbid plaques [52;67]. Dengue viruses lacking this sequence are attenuated 
in rhesus monkeys, suggesting its role in pathogenesis [67]. A region encompassing CS2 
within the 3’-UTR of mosquito-borne flaviviruses was predicted to fold into a dumbbell-
like structure from which a loop is to be involved in the formation of an RNA pseudoknot 
with downstream sequences [82]. A similar dumbbell-like structure has also been predicted 
to be formed in the 3’-UTR of NKV flaviviruses that includes a conserved sequence motif 
homologous to CS2 [81], whereas the CS2 containing structure appears to be absent in tick-
borne flaviviruses.
 The accumulation of a small RNA species co-linear with the distal part of the viral 
3’-UTR was recently discovered in cells infected with arthropod-borne flaviviruses and this 
feature was later found to be conserved among the whole Flavivirus genus [83-88]. This small 
flavivirus (sf) RNA results from incomplete degradation of the viral genomic RNA by the host 
5’>3’ exoribonuclease, XRN-1 [89], which is the main cytoplasmic ribonuclease associated 
with 5’ to 3’ mRNA decay that takes place in cytoplasmic processing bodies [90] (reviewed 
in [91-93]). WNV sfRNA was demonstrated to be associated with viral pathogenicity and 
contribute to viral evasion of host innate immune response [89;94]. Recent studies proposed 
sfRNA as a repressor for RNA interference in both mammalian and insect cells [95], and as 
an antagonist for XRN-1 thus perturbing cellular mRNA stability [96]. A pseudoknot forming 
stem-loop structure located upstream of the CS2-containing dumbbell-like structures in the 
mosquito-borne flavivirus 3’-UTR was proposed to be the signal for the stalling of XRN-1 
[87;97]. Similar structures were also predicted to be present in the 3’-UTR of tick-borne, 
NKV, as well as insect specific flaviviruses [88;98], although the molecular basis underlying 
XRN-1 stalling still remains to be elucidated.
Yellow Fever Virus 
Yellow fever virus is the prototype virus of the Flavivirus genus. In fact, the genus name 
flavi- is derived from the Latin word flavus, meaning “yellow”. It is postulated that the virus 
originated in Africa and was subsequently introduced from the Old World into the Americas 
during the slave trade period in the 16th century (reviewed in [99]). In 1900, an American 
commission headed by Walter Reed demonstrated that yellow fever was caused by a 
filterable agent that can be transmitted to humans by mosquitoes [100]. In 1927, Mahaffy 
and Bauer first isolated the virus by inoculation of a rhesus monkey with the blood of an 
YFV-infected Ghanian male named Asibi [101]. 
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 Yellow fever virus is endemic in tropical regions of Africa and South America, where 
the enzootic transmission cycle involves hematophagous mosquitoes (primarily Aedes or 
Haemagogus spp.) and non-human primates. Occasional transmission to human beings 
who enter the tropical rainforests leads to sylvatic (or jungle) yellow fever. Other types of 
transmission include: intermediate yellow fever caused by semi-domestic mosquitoes (that 
breed in the wild and around households), leading to small-scale epidemics, and urban 
yellow fever, large epidemics that occur when infected humans introduce the virus into 
densely populated areas, where a large number of non-immune people is susceptible to 
infection mediated by domestic mosquitoes [102]. With over 900 million people at risk, 
there are an estimated 200,000 cases of yellow fever worldwide each year, causing 30,000 
deaths [102]. Small numbers of imported cases are also reported in countries outside the 
endemic region [102]. 
 YFV infection presents a broad clinical spectrum varying from mild, non-specific 
febrile illness to a fulminating, sometimes fatal hemorrhagic fever, with a biphasic pattern. 
Once contracted, the virus incubates in the body for 3 to 6 days, followed by the first, 
“acute” phase with symptoms like fever, muscle pain, prominent backache, headache, 
shivers, loss of appetite, and nausea or vomiting. During this phase, patients are viremic 
and infectious to mosquitoes. Most patients improve and their symptoms disappear after 3 
to 4 days. However, 15% of the patients would enter a second, more toxic phase within 24 
hours of the initial remission. High fever returns and several body systems are affected. The 
patient rapidly develops jaundice and complains of abdominal pain with vomiting. Bleeding 
can occur from the mouth, nose, eyes or stomach. Once this happens, blood appears in the 
vomit and faeces. Kidney function deteriorates. This is the so-called “period of intoxication”, 
and up to 50% of the patients who enter the toxic phase die within 10 to 14 days, while the 
rest recover without significant organ damage. (reviewed in [99;102;103])
Yellow Fever Vaccine 
There is no cure for yellow fever; vaccination is the single most important measure for 
preventing the disease [102]. The YFV-17D vaccine was empirically developed in the 1930s 
by Theiler and Smith [104], for which Theiler was awarded the 1951 Nobel Prize in medicine. 
The YFV Asibi strain was attenuated by serial passages in various animal tissues, which 
resulted in 68 nucleotide and 32 amino acid changes [104;105]. Attenuation was clearly 
demonstrated by the lack of neurotropism, viscerotropism, and lethality upon intracerebral 
inoculation of rhesus monkeys and subcutaneous vaccination of naive human subjects [106], 
although the mechanism underlying attenuation is not fully understood. The 12 amino acid 
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changes clustered in the envelope gene were thought to alter receptor binding and cellular 
tropism, possibly affecting the virulence [107]. 
 Since its development, the YFV-17D vaccine has been administered to over 540 million 
human beings globally, and has stood as a paradigm for a successful vaccine with a great 
record of both safety and efficacy [108]. Vaccination is well tolerated, with only rare cases 
of severe adverse reactions (reviewed in [102;109;110]). In 95% of the vaccinees, protective 
immunity develops within 10 days against all known wildtype strains [109], although the 
molecular determinants of its immunogenicity are yet to be defined. 
 Vaccination with YFV-17D results in a transient viremia that peaks at days 5-7 post 
immunization and subsequently dissipates [111].  Viral RNA is undetectable by day 14 in 
plasma. This restricted viral replication, however, is sufficient to induce robust and polyvalent 
adaptive immune responses including the production of cytotoxic T cells, a mixed T helper 1 
(Th1) and Th2 cell profile and robust neutralizing antibodies that can persist up to 40 years 
after vaccination [109]. The production of neutralizing antibodies most likely accounts for 
the effectiveness of the vaccine, since passive immunization in monkeys [112] and mice 
[113] protects more than 90% of these animals against a challenge with wildtype virus. 
However, a role for cell-mediated immunity in generating an effective immune response 
has also been suggested, with both YFV specific effector and memory CD8+ T cell responses 
detected [114-117]. With the increasing knowledge of innate immunity, attention was 
also drawn to the interaction between YFV-17D and the innate immune system, as well as 
the importance of this interaction in determining the breadth, magnitude and duration of 
the adaptive immune responses. YFV-17D was found to infect human dendritic cells and 
activate multiple TLRs, priming DCs for the presentation of YFV antigens and coordinating 
the adaptive immunity [118;119]. Systems biology studies revealed YFV-17D vaccination 
induced integrated multilineage and polyfunctional immune responses that includes 
several effector arms of innate immunity, such as complement, the inflammasome, and 
the interferons [119;120]. In fact, the study of molecular signatures induced by YFV-17D 
prompted the development of systems vaccinology, i.e., using a vaccine chip to predict the 
immunogenicity and/or protective capacity of future vaccine candidates [110].
YFV-17D Vectored Recombinant Vaccines
In view of the great success of YFV-17D vaccine and the availability of a full-length cDNA 
clone [52], possibilities have been explored to utilize YFV-17D backbone as the vector for the 
construction of vaccine candidates against other diseases. 
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 The most promising YFV-17D based vaccine candidates are chimeric vaccines for 
related flaviviruses, such as DENV, WNV, and JEV, which are establishing in new habitats 
and infesting an ever increasing population [121-123]. Various social and environmental 
factors contribute to the re-emergence and spread of these arbo-flaviviruses that can cause 
diseases ranging from mild febrile illness to severe meningoencephalitis or hemorrhagic 
fever. Although vaccines are available to prevent JEV, the expensive and time-consuming 
vaccination regimen of the inactivated virus vaccine (INV) restricted its application mainly 
within the developed countries, while a live-attenuated vaccine (LAV) was only approved in 
a limited number of Asian countries, due to concerns over cell substrate certification. An 
inactivated WNV vaccine is also available but is only licensed for use in livestocks [124;125]. 
As for DENV, it is even more challenging to make a safe and effective vaccine, because low 
levels of cross-reactive immunity to each of the four individual serotypes of DENV have been 
shown to be a risk factor for developing severe forms of the disease. Therefore, a safe and 
efficacious DENV vaccine must be tetravalent, and simultaneously inducing strong immunity 
against all four serotypes (reviewed in [124]). Vaccine candidates have been made for JEV, 
WNV and DENV using the ChimeriVax platform, which is based on the finding that chimeric 
viruses encoding the PrM/E gene of other flaviviruses in the context of YFV-17D backbone 
can be produced without significantly compromising virus replication and production. The 
expressed prM and E of the donor virus will drive the efficient assembly and budding of an 
enveloped virion, in which the recombinant RNA is complexed with the YFV C protein. These 
chimeric viruses will trigger an immune response against the donor virus upon vaccination. 
IMOJEV(®), a Japanese encephalitis vaccine developed based on the Chimerivax platform 
has already been licensed for human use in Australia [126], and Chimerivax-WNV and 
tetravalent Chimerivax-DENV have also shown encouraging results in phase II clinical trials 
[127;128]. 
 YFV-17D has also been successfully exploited as a vector for the expression of foreign 
T cell or B cell epitopes, as potential vaccine candidates against malaria [129;130] or as 
a potential therapeutic anticancer vaccine [131]. Moreover, recombinant YFV-17D viruses 
expressing heterologous antigens were proposed as bivalent vaccine candidates against 
Lassa virus [132;133] or as alternative vaccine vectors for malaria [134] and HIV [135;136]. 
In vitro studies demonstrated that these recombinant viruses were viable and could express 
both YFV and foreign proteins; besides, small-scale animal experiments showed promising 
results in terms of immunogenicity and protection. Nevertheless, the genetic stability of 
these YFV-17D recombinants has been an issue especially with larger inserts, a problem 
attributed to the limited packaging capacity of the icosahedral capsid [133;134;137]. 
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Scope and Outline of The Thesis
Full-length infectious clones for +ssRNA viruses have served as valuable tools in studying 
various aspects of virus biology with reverse genetics approaches. The construction of 
stable full-length clones for flaviviruses, however, was not always straightforward, as 
insert instability has been encountered during plasmid DNA propagation in bacterial hosts. 
Laborious in vitro ligation procedures were therefore used for the production of DNA 
templates for the generation of infectious RNA transcripts for certain flaviviruses [138-140], 
until the instability problem was circumvented by cloning the cDNA into low copy number 
plasmid vectors [52;141].  The successful construction of infectious clones for Kunjin virus 
(KUNV) [142], West Nile virus (WNV) [143] and dengue virus (DENV) [144;145], as well as 
tick-borne encephalitis virus (TBEV) [146] have not only facilitated the research on molecular 
virology of flaviviruses, but also opened up new possibilities of attenuating these viruses for 
the development of vaccine candidates against these medically important flaviviruses. The 
availability of the YFV-17D infectious clone [52;138] had a more profound significance in the 
sense that it can serve as the backbone for recombinant or chimeric vaccines without raising 
much controversy over vector safety. 
 In this thesis, an example of a recombinant vaccine based on YFV-17D clone was 
described in Chapter 2, in which sequences encoding Lassa virus (LASV) glycoproteins 
were inserted into the YFV-17D background. The recombinant viruses thus constructed 
could replicate efficiently in cell culture and grow to high titers. Both YFV proteins as well 
as LASV glycoproteins were expressed and properly released from the polyprotein. YFV/
LASV vaccination could induce specific cellular immune response to LASV, and could protect 
animals against lethal challenge.  
 To explore the feasibility of incorporating the commendable features of a DNA vaccine 
with those of the live attenuated YFV-17D vaccine, a DNA-launched YFV-17D infectious clone 
was constructed by cloning the full-length YFV-17D cDNA in between the cytomegalovirus 
promoter and the hepatitis delta virus ribozyme. The DNA/LAV (live attenuated vaccine) 
layered approach could potentially simplify vaccine production, transportation and 
storage while retaining high immunogenicity characteristic of an LAV. The construction and 
characterization of the DNA-launched YFV-17D infectious clone was described in Chapter 3. 
To evaluate the potential of this novel DNA launched YFV-17D vaccine platform, mice were 
immunized with the construct in parallel with a couple of mutants, and immune responses 
induced were analyzed in detail. 
 As mentioned above, in addition to the arthropod-borne flaviviruses, there is a third 
cluster of flaviviruses that have been exclusively isolated from rodents or bats. Designated 
as NKV flaviviruses, this group of viruses is less-well studied, which is in part due to the 
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lack of infectious clones. Chapter 4 describes the construction and characterization of 
the first NKV flavivirus infectious clone, which was further utilized to study the functional 
significance of RNA elements present in Modoc virus 3’-UTR, as a representative of the NKV 
flaviviruses. The differences/similarities between NKV flavivirus 3’-UTR and that of vector-
borne flaviviruses were explored and their implications were discussed. 
 A new common feature for flaviviruses, i.e., the production of a small flavivirus 
RNA (sfRNA) in infected cells or animals, was recently discovered. Attempts were made to 
unravel the sequence/structure requirements for the production of YFV sfRNA, as described 
in Chapter 5. Mutations were introduced into the XRN-1 stalling site in the context of YFV-
17D full-length clone, and the influence of these mutations on sfRNA production and viral 
cytopathogenicity were analyzed in detail.
 For a more comprehensive understanding of sfRNA function, mammalian cell lines that 
constitutively express sfRNA from YFV-17D and WNV were established and characterized, as 
described in Chapter 6. The ability of these cell lines to trans-complement sfRNA-deficient 
YFV mutants in inducing cytopathic effects was studied, and possible mechanism behind the 
trans-complementation is discussed. 
 Chapter 7 is an epilogue, in which the findings presented in the previous chapters 
are summarized and discussed. Hurdles encountered in the development of YFV-17D based 
vaccine systems are summarized, and possible improvements and applications for the 
YFV-17D based vaccine platforms are proposed. Findings from the sfRNA expressing cell 
line approach are discussed in reference to previously published results regarding sfRNA 
function, and future directions are suggested for further solving the enigma surrounding 
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Yellow Fever (YF) and Lassa Fever (LF) are two prevalent hemorrhagic fevers co-circulating in 
West Africa and responsible for thousands of deaths annually. The YF vaccine 17D has been 
used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) or their subunits, 
GP1 (attachment glycoprotein) and GP2 (fusion glycoprotein). Cloning shorter inserts, LASV 
GP1 and GP2, between YF17D E and NS1 genes enhanced genetic stability of recombinant 
viruses, YF17D/LASV-GP1 and –GP2, in comparison with YF17D/LASV-GPC recombinant. 
The recombinant viruses were replication competent and properly processed YF and LASV 
GP proteins in infected cells. YF17D/LASV-GP1&GP2 induced specific CD8+ T cell responses 
in mice and protected strain 13 guinea pigs against fatal LF. Unlike immunization with live 
attenuated reassortant vaccine ML29, immunization with YF17D/LASV-GP1&GP2 did not 
provide sterilizing immunity. This study demonstrates the feasibility of YF17D-based vaccine 
to control LF in West Africa.
Key words: Yellow Fever, Lassa Fever, YF17D vaccine, recombinant vaccines
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1. Introduction
Yellow Fever 17D is one of the most efficacious and safe vaccines ever developed with a 
highly favorable benefit-risk profile and excellent cost-effectiveness. In YF endemic areas 
a vaccinated child is fully protected over a 50-year life time against different genotypes of 
YF for an investment of a few cents per year [1, 2]. Since 1937 more than 540 million doses 
have been delivered world-wide and no reversion to wild-type YF virus has been reported. 
Rare observed adverse effects seem to be associated with host factors and are not due to 
virus reversion [3-5]. 
 After sub-subcutaneous inoculation, YF17D minimally replicates in local DCs and 
stimulates DC subsets via multiple Toll-like-receptors (TLRs) to elicit pro-inflammatory 
cytokines [6-8]. Cytokine-activated and mature dendritic cells (DCs) become protected 
against YF-induced cytopathogenicity and migrate to regional lymph nodes to elicit a broad 
spectrum of innate and adaptive immune responses [9-13]. A systems biology approach 
confirmed that YF17D induces integrated multi-lineage and poly-functional immune 
responses including activation of effector mechanisms of innate immunity (complement,  
multiple TLRs, cytokines/cytokine receptors, and interferons), as well as adaptive immune 
responses through an early T cell activation followed by  robust B cell responses [14, 15]. 
Computational analyses identified a gene signature, B cell growth factor TNFRS17, predicting 
with up to 100% accuracy the neutralizing antibody response, a well- established correlate 
of protection [15].
 The introduction of active immunization programs and vector control measures in 
1937-1938, transformed YF from a major human plague to a medical curiosity by the end of 
World War II [1, 16, 17]. However, during the past 20 years the absence of effective public 
health policy, social-ecological factors and vaccine shortage resulted in a resurgence of 
YF (~ 200,000 cases and 30,000 deaths annually) in South America and Africa.  Thirty-two 
African countries with a total population of 610 million people including more than 219 
million urbanites are now considered at risk for YF. The vast majority of cases and deaths 
take place in sub-Saharan Africa, where YF is a major public health problem occurring in 
epidemic patterns [1].  In 2007 WHO–UNICEF recommended including YF17D vaccine in 
routine infant immunization programs and initiated mass vaccination campaigns to rapidly 
increase population immunity in high-risk areas [18].
 Based on outstanding YF17D safety records and recent success in molecular biology 
of flaviviruses, the genetic backbone of YF17D has been used for construction of chimeric 
YF17D-based viruses expressing prM and E proteins of closely-related flaviviruses, Japaneses 
encephalitis, Dengue, and West Nile virus. ChimeriVax™-based vaccines against these 
flaviviruses are currently undergoing Phase II-III clinical testing (reviewed by [19]). Insertion 
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of short immunogenic peptides into E surface glycoprotein protein did not compromise 
the morphological structure and attenuated phenotype of YF17D. Recombinant YF17D-
based vectors have also been used in the development of promising new vaccines carrying 
immunogenic epitopes of flavivirus-unrelated pathogens (influenza, malaria, oncogenes) [6, 
20-23]. 
 We recently developed a novel strategy to express relatively large foreign genes using 
the YF17D backbone. We used this strategy to design a bivalent YF17D-based recombinant 
vaccine against Lassa Fever (LF) caused by Lassa virus (LASV). LASV circulates in YF endemic 
areas in West Africa and is responsible for thousands of deaths annually [24, 25]. Prospective 
serological and epidemiological studies performed in Sierra-Leone, Guinea, and Nigeria 
revealed the population at risk to be 59 million with an estimated annual incidence of illness 
of 3 million [25-28].  The sizeable disease burden makes a strong case for LASV vaccine 
development [29-31]. 
 Like other members of the Arenaviridae, LASV has a bi-segmented (L and S) 
ambisense RNA genome [32, 33]. The L RNA encodes a large protein (L, or RNA-dependent 
RNA polymerase) [34], and a small zinc-binding Z protein  [35]. The S RNA encodes the major 
structural proteins, nucleoprotein (NP) and glycoprotein precursor (GPC), cleaved into GP1, 
GP2, and a stable signal peptide, SSP [36-38]. In contrast to YF, CD8+ T cell responses play 
a major role in protection against LASV. Live replication-competent vaccine candidates 
based on vaccinia [31], vesicular stomatitis virus (VSV) [39], and Mopeia virus (MOPV), a 
non-pathogenic arenavirus relative of LASV [40, 41], have been proposed as potential 
vaccine candidates. However, vector safety concerns remain a major obstacle for further 
development of these vaccines. We designed a recombinant LASV vaccine based on the 
YF17D vector which, as it has been mentioned, was extensively tested in humans. 
 A LASV truncated GPC gene (with SSP deletion) was cloned between the E and NS1 
genes of YF17D. The YF17D/LASV∆GPC recombinant virus was replication-competent, 
deeply attenuated, induced immune responses against both pathogens, YFV and LASV, 
and protected guinea pigs against fatal LF in proof-of-concept challenge experiments  [42]. 
However, our further attempts to scale-up this technology were complicated by instability 
of the YF17D/LASV∆GPC recombinant viruses. The LASV∆GPC insert within a monocistronic 
YF17D vector was stable only during the first 5 passages and the insert was randomly deleted 
after passage no. 5. In this paper, we describe our approaches to increase stability of LASV 
inserts cloned into the YF17D vector. The YF17D-based recombinant LASV vaccines with 
enhanced genetic stability have been tested in challenge experiments in strain 13 guinea 
pigs.
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2. Materials and methods
2.1. Viruses and cells
LASV, strain Josiah/SL, was obtained from the Centers for Disease Control (Atlanta, GA). 
All work with LASV-infectious samples was performed within the maximum containment 
laboratory at the Southwest Foundation for Biomedical Research in San Antonio, Texas. 
YF17D-204 was purchased from ATCC (Manassas, VA). The viruses were grown on Vero 
E6 cells cultured in Dulbecco’s modified minimum Eagle’s medium (DMEM, GIBCO-BRL) 
with 2% fetal calf serum (FCS, GIBCO-BRL), 1% penicillin-streptomycin,  and L-glutamine (2 
mM) at 37° C in 5% CO2 [41] by using a multiplicity of infection of 0.01. Supernatants were 
collected at 72 hours post-infection (LASV) or when cytopathic effect was clearly developed 
(YF17D), titrated on Vero cells as previously described [42], and virus stocks (1-5 x 107 PFU/
ml) were stored at -70° C. 
2.2. Construction of YF17D/LASV recombinant viruses
The YF17D/LASV-GPC plasmid was constructed in the background of the full-length YFV17D 
cDNA clone by fusion PCR mutagenesis [42].  The recombinant plasmid was linearized by 
XhoI and used for in vitro RNA transcription. In vitro RNA transcription, electroporation of 
the BHK-21J cells, in vivo RNA labeling, preparation of virus stocks, immunofluorescence 
and plaque assays were previously described [42, 43].  LASV-GPC subunits, GP1 (aa 59-259) 
and GP2 (aa 260-491), were cloned between E and NS1 genes using similar techniques. 
Recombinant YF17D/LASV-GP1 viruses were replication competent and grew to titers (7-8 
log10 PFU/ml) comparable with the YF17D virus. The initial attempts to construct YF17D/
LASV-GP2 did not result in production of infectious virus despite detectable viral RNA 
synthesis and positive immunofluorescence staining for YF NS1. This was probably due 
to the lack of cleavage between the YF17D E and LASV GP2 protein, which was supposed 
to be mediated by cellular signalase.  To solve this problem, two new YF17D/LASV-GP2 
recombinants with modified YF17D E – LASV GP2 fusion sequences were designed. In the 
first set of recombinant, YFV17D/LASV-GP2BglII, the naturally occurring YF17D E – NS1 
cleavage site was restored by mutating the first amino acid of GP2 from Leu to Asp, which 
resulted in the production of a properly sized LASV GP2 and created a BglII site as indicated 
by the name of the construct. In the second sets of recombinants, YFV17D/GP2fus, the 
sequence encoding the first 14 aa of LASV GP1 was inserted between YF17D E and LASV 
GP2. This resulted in the production of a GP2 with a small N terminal GP1 extension.  Both 
approaches gave infections recombinant viruses with high titer (1.0-2.0 x 107 PFU/ml) and 
stable LASV GP2 expression.
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2.3. Analysis of genetic stability of recombinant viruses
To test the genetic stability of the recombinant viruses, virus stocks recovered from 
YF17D/LASV-GP1 or –GP2-electroporated cells were passed 10 times in BHK-21J cells 
[43]. Supernatants of the infected cells were routinely harvested 24 hours post infection, 
diluted to 1:10 with phosphate buffered saline (PBS) and used to inoculate fresh cells. Two 
independent passage experiments were performed for each recombinant virus, YF17D/LASV-
GP1 and –GP2. Electroporated and/or infected cells were labeled with 3[H]-Uridine in the 
presence of actinomycin D, intracellular RNA was isolated and analyzed by electrophoresis 
as previously described [42].
2.4. Detection of YF17D-specific and LASV-specific proteins in infected 
cells
To determine whether YF17D proteins were properly processed and released from the 
recombinant polyprotein-precursor containing LASV-GP1 and -GP2 protein-inserts, infected 
cells were incubated with radioactively labeled amino acids and processing of YF-specific 
proteins was monitored in pulse-chase experiments. The virus-specific proteins were 
immunoprecipitated with mouse polyclonal hyperimmune ascitic fluid to YF (ATCC),   and 
subjected to SDS-PAGE analysis. For detection of LASV-GP1 and -GP2, transfected or infected 
cell lysates were subjected to SDS-PAGE separation and proteins were electroblotted 
to PVDF membranes (Hybond-P, Amersham, Piscataway, NJ). Monoclonal anti-GP1 and 
polyclonal rabbit anti-GP2 antibodies (gift from W. Garten, the Institut für Virologie der 
Phillips-Universität Marburg, Germany) were used to identify the LASV glycoproteins after 
incubation with an appropriate secondary goat IgG conjugated to alkaline phosphatase 
using NBT/BCIP (Invitrogen, Carlsbad, CA) as chromogenic substrate.
2.5. Immunogenicity studies in CBA/J mice
Four-week-old female CBA/J mice from Jackson Laboratories were used for immunogenicity 
studies. Previously, we showed that CBA/J mice are a useful small animal model to evaluate 
immunogenicity of a LASV vaccine candidate, the reassortant ML29 [41, 44]. In general, 
this reassortant encodes major immunogenic proteins, GPC and NP, from LASV and RNA 
polymerase and Z protein from MOPV. It also contains 5 non-conserved amino acid 
substitutions, mostly in L protein, that distinguished ML29 from the parental viruses.   A 
single-shot immunization with ML29 induces broad CD8+ T cell-mediated sterilizing immunity 
in all tested animal models including non-human primates (review in [45-47]). In this study, 
ML29 was used as a positive vaccination control and for mapping immunodominant LASV 
GPC H2k-restricted CD8+ T cell epitopes. CBA/J mice were immunized intraperitoneally (i.p.) 
or subcutaneously (s.c.) with 1000 PFU of ML29 and euthanized on a weekly basis.  Bulk 
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splenocytes were used for flow cytometry to evaluate the activation status of populations of 
CD3+CD8+ T lymphocytes using an antibody to CD11b. For detection of virus-specific T cells 
and mapping GPC H2k-restricted epitopes, immune splenocytes or in some experiments 
purified CD8+ T cells (MACS, Miltenyi Biotec Inc, Auburn, CA) were stimulated with a 
peptide library consisting of overlapping 21-mer peptides (MIMOTOPES, Australia) derived 
from LASV GPC, GP1, and GP2. Purified splenocytes from immunized or naïve mice were 
plated in a PVDF membrane-bottomed 96-well plate and stimulated with GPC-, GP1-, GP2-
derived peptides (100 ng), ConA (10 μg) or RPMI medium. Cells were incubated overnight 
and processed the next day according to the protocol for mouse IFN-γ ELISPOT (U-CyTech 
biosciences, Utrecht, The Netherlands), as provided by the manufacturer. In brief, after the 
stimulation, the cells were washed, re-suspended in the same medium, and 0.3 – 0.4 x 106 
cells per well were added to ELISPOT 96-well plates pre-coated with antibodies specific to 
mouse  IFN-γ. The plates were incubated at 37°C for 5 h and the cells were washed away. 
Biotinylated detection antibodies were then added and the plates were incubated for 1 h at 
37°C. Plates were washed, incubated with anti-biotin antibody labeled with gold particles. 
The spot-forming cells (SFC) secreting IFN-γ were detected and enumerated with C.T.L. Ltd 
Immunospot® S5 Micro-analyzer and Immunospot® V 4.0 software. 
 For an immunogenicity study, CBA/J mice (4 animals per group) were immunized 
s.c. or i.p. with YF17D, YF17D/LAS-GPC, or YF17D/LAS-GP2 (1 x 106 PFU/mice in 0.1 ml) 
and boosted on day 14 with the same amount of the vaccines. Immunized animals were 
sacrificed on day 14 after the boost and secreted IFN-γ was evaluated by ELISPOT using bulk 
splenocytes stimulated with GPC-, GP1-, and GP2-derived peptides.
2.6. Vaccination-challenge experiments in strain 13 guinea pigs
Strain 13 guinea pigs (300-500 g, female) were purchased from USAMRIID (Fort Detrick, 
Frederick, MD).  Animals (four to six animals per group) were vaccinated with YF17D/LASV-
GP1&GP2 s.c. Both recombinant vaccines expressing GP1 and GP2 with infectious titers of 5 
x 106 PFU/ml were equally mixed in PBS and injected in 0.5 ml in two separate sites on the 
back of animals. As a positive vaccination control 1,000 PFU of reassortant ML29 vaccine 
was inoculated s.c.   As a negative vaccination control, animals were inoculated with PBS in 
0.5 ml. On day 14, animals from the experimentally vaccinated group were boosted with the 
same dose of YF17D/LASV-GP1&GP2. On day 44, animals were challenged s.c. with LASV 
(Josiah), 1,000 LD50/ml.  
 The animals were observed twice daily for clinical manifestations according to an 
approved scoring sheet (temperature, weight, decreased activity, ruffled fur, loss of weight, 
labored breathing, hunched posture). Temperature was monitored by using implanted 
chips. Death or survival past 25 days was defined as an endpoint [40, 48]. Previously we 
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showed that animals past this time point did not change survival outcome during extended 
follow-up period [41]. Animals which survived to day 25 or animals which met euthanasia 
criteria (fever, weakness, labored breathing, >25% loss in weight) were euthanized and 
sacrificed for histological studies as previously described [41].    For detection of viral RNA, 
tissue samples from vaccinated and challenged animals were submerged in RNAlater and 
cryopreserved. RNA was extracted later on using RNeasy mini kit (Qiagen, cat. no. 75142). 
RNA was converted into cDNA and amplified with 36E2 and 80F2 primers targeting LASV-
GPC gene [49]. Standards used in qRT-PCR were generated from RNA isolated from serial 
10-fold dilutions (101- 10-7 PFU/ml) of LASV Josiah/SL  viral stocks that were enumerated in 
triplicate by conventional plaque assay as previously described [41]. Sensitivity of qRT-PCR 
was around 100-300 viral RNA copies per g of tissue.  
2. 7. Data analysis 
Statistical analyses (mean, SD, T-test) and graphics were performed using the Origin 6.0 
package (Microcal Software, Inc., Northampton, MA).
3. Results 
3.1. Further development and improvement of YF17D recombinant 
technology based on foreign gene insertion between E and NS1 genes 
Foreign gene inserts between the YF17D E and NS1 genes must be stable for at least 10 
passages to consider this cloning strategy for further scale-up development. Ten passages will 
be enough to produce master-seed-lots and manufacture non-GMP bulk lots for pre-clinical 
studies [19].  As mentioned, our recombinant YF17D/ LASV∆GPC viruses were reasonably 
stable for at least 5 passages [42]. However, some virus stocks lost the inserted cassettes 
when the passages were extended. Similar observations were made by Bonaldo et al. [50]. 
To track the LASV∆GPC cassette integrity in Vero cells, a cassette region containing the insert 
and flanking sequences (Fig. 1A) was amplified (sense:  AGGAAAGTTGTTCACTCAGACCATG; 
antisense: CAAGCTTCACAGG ATCTTCTGGATA) and analyzed by gel electrophoresis. The size 
of the cassette with the LASV∆GPC insert was 1.8 kb. The 1.8 kb amplicon was detected in 
passage 3-5 viruses (P3-P5). However, P6 viruses displayed a diverse electrophoresis profile 
indicating the loss of the LASV∆GPC inserts as confirmed by further sequence analysis (not 
shown). 
 This loss of the insert during multiple cycles of viral RNA replication was originally 
attributed to homologous recombination, due to the duplication of the transmembrane 
region of YF17D E coding sequence flanking the LASV∆GPC insert [42]. In an attempt to 
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Fig. 1. Construction of genetically stable YF17D/LASV-GP vaccines. (A) Schematic representation of recombinant 
YF17D-LASV virus carrying the ∆GPC in er . In the initial constructs [42] the insert (1,365nt) was flanked by 
homologous E-derived sequences (red box) to insure the proper processing of recombinant polyprotein.  In 
a new set of recombinant viruses, the fusion sequence between GP2 and NS1 (pink box) was substituted with 
heterologous sequences derived either from WNV or artificially designed (Art) to reduce homology with YF17D. 
Arrows indicate the sequences designed for PCR amplification of LASV ∆GPC insert and flanking areas to track the 
insert size during passages in BHK-21J cells. (B) Genetic stability of recombinant YF17D/LASV-∆GPC. Virus-specific 
RNA was labeled with 3[H]-Uridine in the presence of actinomycin D and intracellular RNA at passage 1, 5 and 10 
was analyzed by gel electrophoresis. The RNA from YF17D-infected cells was used as a control. Arrows indicate 
recombinant YF17D/LASV∆GPC RNA, 12,227nt; and parental YF17D RNA, 10,862nt. (C), (D) Genetic structure of 
recombinant YF17D/LASV-GP1 and –GP2 viruses, respectively.  Cleavage site between the YF17D E and GP2 protein 
was designed as described in Materials and Methods. (E)  The size of LASV GP inserts after electroporation (Elpo) 
or after 10 passages in BHK-21J. Two independent passage experiments were performed, Exp1 and Exp2. Arrows 
indicate recombinant YF17D/LASV-GP1 RNA, 11,609nt; and parental YF17D RNA, 10,862nt. The size of YF17D/
LASV-GP2 RNA is 11,672nt.
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reduce recombination and enhance the stability of LASV∆GPC insert, the downstream 
transmembrane E sequence was substituted with a heterologous sequence with the similar 
function ensuring insertion of the YF17D into the endoplasmic reticulum.  We suggested that 
the lower homology of the ∆GPC-NS1 fusion sequence to the C-terminal part of E protein 
can enhance the stability of the recombinant virus. Two new linkage sequences were tested 
(Fig. 1). The 1st fusion sequence was derived from West Nile virus (WNV). The 2nd one was an 
artificial heterologous sequence encoding a signal sequence motif for flavivirus NS1 protein. 
 Insertion of these sequences between ∆GPC and NS1 genes improved stability of 
the GPC cassette, but did not completely resolve the instability problem. As seen in Fig. 
1B, the YF17D/LASV∆GPC viruses made according to this strategy had enhanced stability. 
At least some P10 clones with WNV fusion sequence contained the full ∆GPC insert as was 
judged by RT/PCR analysis (not shown). Nevertheless, P10 recombinant viruses were still 
not fully stable in terms of preservation of integrity of LASV∆GPC sequences. The observed 
heterogeneity of the P10 virus population suggested that the loss of the LASV ∆GPC insert 
was a gradual process and not the result of the recombinant event. Apparently RNA with a 
length close to the parental YF17D virus has an advantage in replication and/or packaging 
over recombinant RNA containing large inserts like the LASV ∆GPC gene. 
 In further experiments, we decided to reduce the size of LASV inserts and separately 
clone LASV GP1 and GP2 between E and NS1 genes as described in Materials and Methods. 
Based on our previous observations, we have reasonably assumed that LASV GP1 and 
GP2 maturation does not interfere with proteosomal degradation and binding with MHC-I 
molecules. At least LASV GPC, with deleted SSP [42] or with genetically modified GP1-GP2 
cleavage site  and deleted GP2 transmembrane domain (Lukashevich et al., unpublished), 
induced protective virus-specific CD8+ T cell responses in guinea pigs and in mice.  We do 
see any concerns associated with the fusion sequences derived from WNV. Nevertheless, in 
further experiments we used an artificial fusion sequence between GP1 or GP2 and NS1.
3.2. Genetic stability of a new generation of YF17D/LASV-GP recombinant 
vaccines
As seen in Fig. 1, size reduction of cloning inserts combined with introduction of modified 
fusion sequences between the GP insert and NS1 gene resulted in recovery of YF17D-based 
recombinant viruses with enhanced genetic stability. To test the genetic stability of the 
recombinant viruses, virus stocks recovered from YF17D/LASV-GP1 or –GP2-electroporated 
cells were passed 10 times in BHK-21J cells. Supernatants of the infected cells were routinely 
harvested 24 hours post infection, diluted and used to inoculate fresh cells. Two independent 
passage experiments were performed for each recombinant virus, YF17D/LASV-GP1 and –
GP2. Electroporated and/or infected cells were labeled with 3[H]-Uridine in the presence 
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of actinomycin D, intracellular RNA was isolated and analyzed by electrophoresis. A single 
RNA band was detected in passage 10 (P10) cells as well as in transfected cells. This RNA 
band migrated slightly slower than those from YF17D-infected cells and contained LASV GP1 
and GP2 inserts as was confirmed by RT/PCR analysis.  Interestingly, radioactive labeling 
revealed reduced RNA content in cells infected with YF17D/LASV-GP1 virus vs. –GP2 virus. 
Variations in infectivity during the passages and/or accumulation of defective interference 
particles can be possibly responsible for this observation.    
3.3. Phenotypic features and stability in vitro
Recombinant YF17D/LASV-GP1 and -GP2 viruses induced pronounced cytopathogenic 
effects in BHK-21J and Vero cells and virus yields in these cells were  around 1-2 x 107 PFU/
ml. The recombinant viruses produced clear plaques, which appeared to be smaller than 
those produced by the parental virus, YF17D (Fig. 2), in line with our previous observation 
[42]. This plaque phenotype was stable for P1-P10 viruses. 
    Both YF17D/LASV-GP1 and -GP2 RNA-transfected cells, as well as cells infected with 
recombinant viruses, passage 1 (P1) and passage 10 (P10) viruses, were positively stained 
with anti-YF17D NS3 antibody, showing typical perinuclear staining. Also, LASV GP1 and YFV 
NS3 were found to be co-localized when double labeling was performed on YF17D/LASV-
GP1-transfected cells (Fig. 3). Staining of cells transfected and/or infected with YF17D/LASV-
GP with polyclonal antibodies against GP-derived peptide gave similar results [42]. 
  Cells infected with recombinant YF17D/LASV-GP1 and –GP2 viruses were capable 
of expressing properly processed YFV antigens. As seen in Fig. 4, YF17D-specific antibodies 
Fig. 2.
Plaque morphology of YF17D/LASV-GP viruses. YF17D/LASV-GP2 (A) and YF17D (B)
viruses recovered after electroporation were plated on confluent monolayers of BHK-21J
cells in 6-well plates and viruses were titrated by plaque assay as previously described [42].
The transfected cells were incubated for 96 hours, fixed with 8% formaldehyde and stained
with crystal violet. The final titer was 1 × 108 and 2 × 107 PFU/ml for YF17D and YF17D/
LASV-GP2, respectively.
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Fig. 2. Plaque morphology of YF17D/LASV-GP viruses.   YF17D/LASV-GP2 (A) and YF17D (B) viruses recovered after 
electroporation were plated on confluent monolayers of BHK-21J cells in 6-well plates and viruses were titrated 
by plaque assay as previously described  [42]. The transfected cells were incubated for 96 hours, fixed with 8% 





Immunofluorescence staining of transfected cells. Cells transfected with YF17D/LAS-GP1
were fixed at 24 hours post electroporation, followed by staining for YF17D NS1 (green)
and LASV GP1 (red). Nuclei were stained with Hoechst (blue). Magnification: × 40.
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Fig. 3. Immunofluorescence staining of transfected cells. Cells transfected with YF17D/LAS-GP1 were fixed at 24 
hours post electroporation, followed by staining for YF17D NS1 (green) and LASV GP1 (red). Nuclei were stained 
with Hoechst (blue). Magnification: x 40.
Fig. 4.
Pulse-chase labeling of YF17D proteins. Cells infected with either YFV17D or the
recombinant viruses were radioactively labeled for 4 hours, or pulsed 30 min, followed by
chasing for either 1 hour or 3.5 hours. Cell lysates were subjected to immunoprecipitation
with mouse hyperimmune ascetic fluid to YF17D (ATCC). The precipitates were separated
on 12.5% SDS-PAGE gel, and analyzed by phosphor-imaging. 1, label 4 hours; 2, pulse-
labeling, 30 minutes; 3, 1 hour chase; 4, 3.5 hours chase. Viral proteins: NS5 (103 kDa),
NS3 (70 kDa), E (50 kDa), NS1 (46 kDa), NS4B (27 kDa), PrM (26 kDa), NS2A (22 kDa),
and NS2B (14 kDa) could be seen. Molecular weight markers are indicated on the left side.
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Fig. 4. Pulse-chase labeling of YF17D proteins.  Cells infected with either YFV17D or the recombinant viruses were 
radioactively labeled for 4 hours, or pulsed 30 min, followed by chasing for either 1 hour or 3.5 hours. Cell lysates 
were subjected to immunoprecipitation with mouse hyperimmune ascites fluid to YF17D (ATCC). The precipitates 
were separated on 12.5% SDS-PAGE gel, and analyzed by phosphor-imaging. 1, label 4 hours; 2, pulse-labeling, 30 
minutes; 3, 1 hour chase; 4, 3.5 hours chase. Viral proteins: NS5 (103 kDa), NS3 (70 kDa), E (50 kDa), NS1 (46 kDa), 
NS4B (27 kDa), PrM (26 kDa), NS2A (22 kDa), and NS2B (14 kDa) could be seen. Molecular weight markers are 
indicated on the left side.
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precipitated from infected cells YF NS1, NS2A, NS2B, NS3, NS4B, NS5, PrM and E proteins. 
These results indicate that monocistronic recombinant mRNA translated into a polyprotein-
precursor, and the processing of YF17D polyprotein-precursor was not affected by the LASV 
GP1 and GP2 inserts.  
 Finally, LASV-specific proteins, GP1 and GP2, were detected in YF17D/LASV-GP-
infected cells by Western blot using GP1 monoclonal and GP2 polyclonal antibodies as 
previously described [42]. These results (Fig. 5) demonstrate that both LASV glycoproteins, 
GP1 and GP2, were translated from recombinant monocistronic mRNA and properly 
processed and released from the recombinant YF17D/LASV-GP1 and –GP2 polyprotein.    
3.4. YF17D/LASV-GP1 and –GP2 recombinant viruses induce specific CD8+ 
T cell responses in CBA/J mice
It is important to evaluate the immunogenicity of experimental vaccines in small animal 
models before testing putative vaccine candidates in expensive vaccination-challenge 
experiments. Currently, there is no mouse model of human LF. The outcome of LASV 
infection in immunocompetent mice depends on H2 genotype, age, routes of infection, and 
resembles LCMV-like immunopathology (review in [46]). In contrast, virulence of LASV in man 
and in non-human primates is directly related to virus load [25, 40, 51] and is not associated 
Fig. 5.
Western-blot analysis of LASV-specific glycoproteins in cells infected with recombinant
YF17D/LAS-GP1 and –GP2 viruses. The analysis was carried out with a 1:2,000 dilution of
anti-GP1 and anti-GP antibodies as previously described [42]. Markers in kilodaltons are
indicated on the side. The arrow in (A) indicates GP1 and in (B) indicates GP2
glycoproteins. The recombinant YF17D/LASV-GP2BglII contained natural YFV E – NS1
cleavage site with Leu/Asp mutation in the first amino acid of GP2. The recombinant
YF17D/LASV-GP2fus contained a sequence encoding the first 14 aa of LASV GP1 inserted
between YF17D E and LASV GP2 (see Materials and Methods for details).
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Fig. 5. Western-blot analysis of LASV-specific glycoproteins in cells infected with recombinant YF17D/LAS-GP1 and 
–GP2 viruses. The analysis was carried out with a 1:2,000 dilution of anti-GP1  and anti-GP antibodies as previously 
described [42]. Markers in kilodaltons are indicated on the side. The arrow in (A) indicates GP1 and in (B) indicates 
GP2 glycoproteins. The recombinant YF17D/LASV-GP2BglII contained natural YFV E – NS1 cleavage site with Leu/
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the first 14 aa of LASV GP1 inserted between YF17D E and LASV GP2 (see Materials and Methods for details).
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with immunopathology. We previously showed that young adult CBA/J mice inoculated 
s.c. or i.p. with the MOP/LAS (ML29) reassortant induced protective CD8+ T cell responses 
[41, 45, 47] and can be used as an economical assay for vaccine immunogenicity to access 
capacity to elicit specific CD8+ T cell responses that  play a major role in LASV protective 
immunity [45, 47].  After ML29-immunization, activation of CD8+ T cells peaked on day 14 
and this time-point was used for collection of splenocytes for mapping immunodominant 
epitopes. Immune splenocytes stimulation with pools of peptides (Fig. 6B) or with individual 
peptides (not shown) reveled that LASV GPC H2k-restricted epitopes were located within 
GP1 glycoprotein at aa positions 57-83, 218-244 and within GP2 glycoprotein at positions 
400-426.
 Immunization of CBA/J mice with recombinant YF17D/LASV-GP1 or -GP2 vaccines, 
but not with parental YF17D vaccine, induced LASV antigen-specific CD8+ T cell immune 
responses detected in IFN-γ ELISPOT (Fig. 6C). Extracellular secretion of IFN-γ was detected 
after stimulation of immune GP1- or GP2-specific splenocytes either with peptide cocktails 
derived from LASV GPC or from GP1 and GP2, respectively. The level of extracellular IFN-γ 
production after stimulation of immune splenocytes with LASV GP-specific peptides was 
approximately 6-fold lower after immunization of mice with YF17D-based recombinant GP1 
Fig. 6.
Evaluation of immunogenicity of LASV vaccine candidates in CBA/J mice. (A) Vaccination
control group: activated CD3+CD8+ cells peaked on day 14 after immunization. (B)
Mapping of GPC H2k-restricted epitopes: on day 14 after vaccination splenocytes were
stimulated with a peptide library consisting of overlapping 21-mer peptides derived from
LASV GPC. Stimulated splenocytes were incubated in wells of the ELISPOT plates pre-
coated with Abs against mouse IFN-γ and washed away. Cytokine-secreting cells or spot-
forming cells (SFC) cells were detected and enumerated according to the manufacturer’s
instructions for mouse IFN-γ ELISPOT (U-CyTech biosciences, Utrecht, The Netherlands).
Responses to peptides derived from GP1 and GP2 are indicated by black bars. (C) CD8+ T
cell responses in mice immunized with recombinant YF17D/LAS-GP1 and –GP2 viruses.
Splenocytes from immunized mice were stimulated with peptide cocktails derived from full
GPC (black boxes) or from GP1 or GP2 subunits (sparse boxes).
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and GP2 vaccines in comparison with ML29 reassortant expressing naturally processed LASV 
GPC.
3.5. Recombinant YF17D/LASV-GP1 and –GP2 vaccines protected strain 13 
guinea pigs against fatal LF disease but did not prevent LASV infection
Individually expressed in vaccinia virus, LASV GPC subunits, GP1 and GP2, did not protect 
non-human primates against fatal LF [30]. Based on this observation, recombinant YF17D-
based viruses expressing GP1 and GP2 were equally mixed and used for immunization of 
strain 13 guinea pigs.  These animals are extremely sensitive to LASV with LD50 < 1 PFU/
ml [40, 52] and all non-vaccinated control animals met euthanasia criteria 2 weeks after 
challenge. The most prominent manifestations of the disease included fever, weight loss, 
and elevated liver enzymes; pathohistological findings included intestinal pneumonia with 
septal and alveolar edema, and hepatitis with hepatocytic vacuolization and lipidosis [46, 
53]. Vaccination control group animals were fully protected against LASV challenge and had 
no signs of the disease. In these animals LASV was only marginally detected by RT-PCR in 
peritoneal lymph nodes in good confirmation with our previous results [41, 53]. Five of 
six guinea pigs vaccinated with YF17D/LASV-GP1&GP2 were also protected against fatal 
LF. However, surviving animals expressed clinical symptoms of LF, had an elevated body 
temperature, lost body weight, and LASV was detected in tested tissues. Still, viral titers as 
well as clinical symptoms were lower than in non-vaccinated control group and animals with 
disease signs recovered at the end of the observation period (Fig. 7).  These results indicate 
that immunization with recombinant YF17D/LASV-GP1&GP2 vaccine protected guinea pigs 
against fatal LASV disease but did not prevent LASV infection.
4. Discussion
Due to its outstanding safety record, YF17D has been used as a promising vector for the 
development of vaccines against arthropod-borne flaviviruses and against non-flavivirus-
related pathogens [6, 22, 54-57].  The YF17D-based ChimeriVax™ technology [58] replaces 
the prM and E genes of YF17D with the corresponding genes of the closely-related 
flaviviruses, Dengue, WNV, and Japanese encephalitis. These vaccines are in advanced 
stages of development and ChimerixVax™-WN vaccine (PreveNile) was licensed in the U.S. 
for veterinary applications (rev. [19]).  
 Various insertion locations in structural and non-structural genes and in the 3′UTR 
of YF17D were used to clone and express flavivirus-unrelated foreign inserts. The E protein 
is the major flavivirus antigen inducing neutralizing antibodies and represents an attractive 
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site for insertion of foreign epitopes. However, the structural limitations of the flavivirus E 
protein allowed expression of relatively short inserts, ~ 30-35 aa  [21]. Importantly, these 
inserts resulted in additional attenuation of recombinant YF17D viruses concomitant with 
enhanced safety profiles of chimeric YF17D-based vaccines (rev. [19]). The NS1 protein also 
induces antibody responses contributing to protection against flaviviruses.  In a recent study 
the M2e peptide (23 aa) of influenza virus was successfully cloned into the NS1 gene using 
transposon-mediated insertion [59].
 Non-flavivirus CTL epitopes have been also cloned between the NS2B-NS3 cleavage 
site. The insertion of the H-2Kd-restricted CTL epitope of the circumsporozoite protein of P. 
yoelii at this site resulted in a recombinant virus which was replication competent, stable, 
and diminished the parasite burden in the liver by ~70% [22]. Immunization of mice with 
Fig. 7.
YF17D/LASV-GP1&GP2 vaccination protects guinea pigs from fatal outcome but does not
prevent LASV infection. (A) Survival rate and clinical scores (insert). Clinical scoring was
based on evaluation of responsiveness, edema, dehydration, rash, appearance, petechia, feed
consumption, anorexia, stool, urine, fluid uptake (0, normal; 1, mild; 2, moderate; 3, severe.
(B) Temperature (°F) was monitored by sensor-implants and recorded twice per day for each
animal. (C) Weight of animals on day of challenge was assayed as 100%. Open circles,
animals vaccinated with YF17D/LASV-GP1&GP2; open squares, animals vaccinated with
ML29 (positive control); closed squares, negative control (animals inoculated with media).
(D) Viral loads (LASV RNA copies) in vaccinated-challenged animals. Black boxes,
animals challenged with LASV (no vaccine); white boxes, animals vaccinated with YF17D/
LASV-GP1&GP2; spare boxes, animals vaccinated with ML29 (positive control).
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Fig. 7. YF17D/LASV-GP1&GP2 vaccination protects guinea pigs from fatal outcome but does not prevent LASV 
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with YF17D/LASV-GP1&GP2; open squares, animals vaccinated with ML29 (positive control); closed squares, 
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recombinant YF17D carrying ova-specific T-cell epitope, SIINFEKL, between NS2B and NS3, 
induced a specific CD8+ T-cell population and protected animals from lethal challenge with 
an aggressive lethal melanoma cell line  [54]. 
 We cloned a relatively large gene encoding LASV ∆GPC glycoprotein (433 aa) between 
YF17D E and NS1 genes in attempts to design bivalent YF17D-LASV vaccine to control both 
infections in co-endemic areas of Africa [42]. The recombinant virus induced humoral and 
cell-mediated immune responses against YF and LASV, respectively, and protected guinea 
pigs against fatal LF disease. In spite of these encouraging results, we [42] and others [50] 
faced instability problems when large inserts were cloned at the E-NS1 site. It has been 
suggested that duplication of flavivirus sequences flanking an inserted gene contributed to 
the genetic instability of the virus. In the current study two approaches have been used to 
address this problem: (i) insertion of modified fusion sequences between the C-terminal 
part of foreign inserts and NS1 gene to prevent possible recombination events resulting 
in deletion of the foreign gene; and (ii) reduction of insert size. We have shown that 
modification of fusion sequences improved stability but did not preserve the large ∆GPC 
insert from the deletion during 10 passages in tissue culture. When the size of the insert 
was reduced almost 2-fold, GP1 and GP2 sub-units of LASV GPC were successfully cloned at 
the E-NS1 site and these inserts were stable during 10 passages. The size of the LASV GP1 
is 200 aa and the size of GP2 is 231 aa residues. In accord with our results, a similar sized 
insert, 224 aa residues, from SIVmac239 Gag was cloned between the genes encoding the 
viral proteins E and NS1. The resulting recombinant virus, the YF17D/SIVGag45-269, was stable 
in vivo and able to induce SIV-specific CD8+ T cell responses in rhesus macaques [60]. 
 The size limitation of foreign gene inserts in YF17D vector seems not to be unique 
for the E-NS1 site. Recently recombinant YF17D vaccine was engineered by cloning CSP (aa 
57-344) from P. yoelii using a novel insertion site, the capsid gene. The insert was cloned in 
frame between the highly conserved cyclization sequences (nt 1-75) and FDMV 2A and Ubi 
genes which were inserted to ensure appropriate  cleavage [61]. Notably, the CSP insert was 
intact up to 6 passages in tissue culture and became undetectable by RT/PCR by passage 
7. We have used a similar strategy with limited success in attempts to clone and express 
overlapping fragments of LASV NP resembling in some ways cytoplasmic YF core protein 
(Bredenbeek, unpublished).   
 Taken together these results indicate that a monocistronic YF17D genome encoding 
a relatively large flavivirus-nonrelated gene inserts at the E-NS1 site or in the C gene can 
produce viable recombinant viruses in cell cultures. However, genetic stability of recombinant 
viruses is the major problem because these viruses lose genetic material after more than 
10 passages. We have shown here that cloning of inserts of moderate size (200-230 aa 
residues) between the genes encoding the viral proteins E and NS1 resulted in genetically 
stable recombinant viruses during 10 passages in tissue culture. The YF17D genome itself is 
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remarkably stable [62]. Ten passages of recombinant YF17D-based viruses will be sufficient 
to manufacture non-GMP lots for toxicology and pre-clinical studies and for making Phase I 
lots during vaccine development [19].  
 Insertion of foreign genes into the YF17D genome resulted in additional attenuation 
of chimeric or recombinant YF17D-based viruses. In plasma and tissue of vaccinated guinea 
pigs [42] and marmosets (Lukashevich, unpublished) YF17D/LASV-GPC was not detectable 
by plaque assay and only transient and limited replication was confirmed by co-cultivation 
in Vero and/or by RT/PCR in line with previously published data [19, 63, 64]. Still, we were 
able to detect anti-YF antibodies in YF17D/LASV∆GPC-immunized animals. Nevertheless, for 
bivalent recombinant YF17D-based vaccines anti-YF efficacy must be additionally evaluated 
in challenge experiments with wild-type YF virus to confirm efficacy of the parental vaccine, 
YF17D.
 In the recent review [19] theoretical safety (reversion to virulence and potential 
viscero- and neurotropism, recombinantion with different flaviviruses or distantly-related 
RNA viruses) and enviromental concerns (transmission by arthropod vectors) of YF17D-
based vaccines have been carefully addressed and evaluated in support of their further 
late development and registration. Importantly, YF17D is safe and effective in HIV-infected 
individuals with CD4 cell counts above 200 cell/mm3, even if they have previously developed 
AIDS or if their viral load is above 10,000 copies/ml [65, 66]. Moreover, flaviviruses decrease 
CD4 expression and inhibit HIV-1 replication in human CD4+ T cells [67]. We have recently 
showed that our live attenuated reassortant ML29 expressing LASV GP and NP is safe and 
immunugenic in SIV-positive rhesus macaques [68]. Takent together these results suggest 
that YF17D-vectored LASV vaccines will be safe in HIV-infected individuals representing the 
most vulnerable group among immunocopromized populations in West Africa.  
 As mentioned above, low or marginal transient viremia in animals immunized 
with recombinant YF17D-based vaccines seems to be associated with relatively low 
immunogenicity. As a result, for recombinant YF17D-based vaccines, in contrast to parental 
YF17D, a prime-boost immunization protocol is often required to induce antigen-specific 
immune responses. To avoid anti-vector immunity and stimulate specific immunity the 
optional prime-boost strategy has to include different vectors. For example, priming with 
recombinant BCG expressing SIV antigens increased the frequency of the SIV-specific CD8+ 
T-cell responses after boosting of rhesus monkeys with recombinant rYF17D/SIVGag45-269 
[60]. However, we and others [61] showed that prime-boost immunization with YF17D-
based recombinant vaccines does not necessarily induce specific responses against cloned 
foreign antigens and/or undesirable anti-vector immunity. In our experiments with YF17D/
LASV-GPC [42] or –GP&GP2 vaccines (this study) we did not see differences in protective 
efficacy after single shot or prime-boost vaccination. Based on the nature of protective 
immune responses against certain pathogens, it is reasonable to consider other possible 
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approaches to enhance specific immune responses against protective antigens cloned into 
YF17D vector. At least in the case of anti-LASV immunity, rational design of the GP antigen 
seems to be a promising approach. Preliminary experiments with structurally stable trimeric 
LASV GP showed that CD8+ T cell cross-priming can additionally contribute to effects of 
immunization based on conventional MHC type I antigen presentation.  
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Yellow fever virus (YFV)-17D is an empirically developed, highly effective live-attenuated 
vaccine that has been administered to human beings for almost a century. YFV-17D has 
stood as a paradigm for a successful viral vaccine, and has been exploited as a potential 
virus vector for the development of recombinant vaccines against other diseases. In this 
study, a DNA launched YFV-17D construct (pBeloBAC-FLYF) was explored as a new modality 
to the standard vaccine to combine the commendable features of both DNA vaccine and live 
attenuated viral vaccine. The DNA launched YFV-17D construct was characterized extensively 
both in cell culture and in a small animal model. High titers of YFV-17D were generated upon 
transfection of the DNA into cells, whereas a mutant with deletion in the capsid coding 
region (pBeloBAC-YF/ΔC) was restricted to a single round of infection, with no release of 
progeny virus. Homologous prime-boost immunization of mice with both pBeloBAC-FLYF 
and pBeloBAC-YF/ΔC elicited specific dose-dependent cellular immune response against 
YFV-17D.  Neutralizing antibodies were only detected when A129 mice that were deficient in 
innate immunity were vaccinated with pBeloBAC-FLYF. These promising results underline the 
potential of the DNA launched YFV both as an alternative to standard YFV-17D vaccination 
but also as a vaccine platform for the development of DNA-based recombinant YFV vaccines. 
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Introduction
Flaviviruses are a group of small enveloped viruses that contain a plus-strand RNA 
genome of around 11kb in length. The genome encompasses a 5’ untranslated region 
(5’-UTR), followed by a single large open reading frame and a highly structured 3’-UTR 
[1]. Many flaviviruses, especially the ones causing diseases in humans, are arthropod-
borne pathogens (arboviruses) that are transmitted by either mosquitoes or ticks. Clinical 
presentation of human infection ranges from mild febrile illness to severe haemorrhagic 
fever or meningoencephalitis [2].  Yellow fever virus (YFV) is the prototype of the Flavivirus 
genus and causes haemorrhagic fever featured by liver dysfunction and jaundice [3]. There 
is no cure for yellow fever, and vaccination is the single most important preventive measure 
against the disease [3]. 
 The YFV-17D vaccine is a live attenuated vaccine empirically developed in the 1930s 
by Theiler and Smith [4], which granted Theiler the 1951 Nobel Prize in medicine. Ever 
since its development, YFV-17D vaccine has been administered to over 540 million humans 
globally, and has stood as a paradigm for a successful vaccine with a great record of both 
safety and efficacy [5]. The vaccine is well tolerated, with only rare cases of severe adverse 
reactions (reviewed in [3;6;7]). Over 95% of the vaccinees will develop protective immunity 
against all known wildtype YFV strains within 10 days after vaccination [6], although the 
molecular determinants of its attenuation and immunogenicity are not yet fully understood. 
A single immunization induces a broad spectrum of immune responses, including cytotoxic 
T lymphocytes (CTLs), a mixed T helper type I (TH1)-TH2 profile, and neutralizing antibodies 
that can persist for up to 30 years [8]. These adaptive immune responses are preceded by 
the activation of several effector arms of innate immunity and the induction of a network 
of antiviral genes, including various cytokines (IP-10, IL-1α), molecules involved in sensing 
viruses (TLR-7, RIG-I and MDA-5), as well as transcription factors that regulate type I 
interferons (IRF7 and STAT1) [9;10]. 
 The broad spectrum of the immune response triggered by YFV vaccine renders it 
an interesting candidate as a vector for the development of recombinant vaccines. Indeed, 
YFV has been used as the backbone in chimeric vaccines against other flaviviruses of clinical 
significance, such as West Nile virus (WNV) [11;12], Japanese encephalitis virus (JEV) [13-
16] and Dengue virus (DENV) [17-19]. These YFV-based chimeric vaccines were found to 
be safe and highly immunogenic in both preclinical and clinical trials, with IMOJEV(®), a 
YFV-17D-based Japanese encephalitis vaccine passing phase III clinical trials and licensed 
for human use in Australia [20]. YFV-17D has also been successfully exploited as a vector for 
the expression of foreign T cell or B cell epitopes, as potential vaccine candidates against 
malaria [21;22] or as therapeutic anticancer vaccine [23]. Moreover, recombinant YFV-17D 
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viruses expressing heterologous antigens were proposed as bivalent vaccine candidates 
against Lassa virus [24;25] or as alternative vaccine vectors  for malaria [26]  and HIV [27;28]. 
In vitro characterization demonstrated that these recombinant viruses were viable and 
could express both YFV and foreign proteins. Experiments in small animal models showed 
promising results in terms of immunogenicity and protection. Despite these encouraging 
results, genetic instability has been encountered for these recombinant viruses, especially 
with larger inserts, which is attributed to the limited packaging capacity of the icosahedral 
virion [25;26;29]. 
 Despite the availability of a highly effective YFV vaccine, the number of yellow 
fever cases has increased over the past two decades, due to the declining immunity to 
YFV infection in the population, deforestation, urbanization, population movements, poor 
vector control and climate change [3]. Until recently the vaccine was still in short supply, and 
vaccine coverage is low in high-risk areas [30].  Alternative strategies to facilitate vaccine 
production, transportation or storage would therefore help accommodate the increasing 
needs for YFV vaccine.
 Compared to conventional live-attenuated vaccines, DNA vaccines are temperature-
stable, easily stored and can be manufactured on a large scale [31]. Although the concept 
of DNA vaccination has generated a great deal of excitement ever since its introduction in 
the early 1990s, no DNA vaccine has been approved for human use. Significant challenges 
will need to be overcome before DNA vaccines achieve mainstream acceptance, especially 
regarding effective delivery and augmenting antigen expression level for a sufficiently potent 
immune response [31;32]. 
 With the objective of combining the commendable qualities of DNA vaccines with 
those of a live-attenuated vaccine, a DNA launched YFV-17D vaccine was constructed using 
a similar strategy as described for a Kunjin virus based DNA vaccine [33]. This infectious YFV-
17D DNA was stable in E.coli host, and was extensively characterized both in cell culture and 
in mice to evaluate its potential as an alternative vaccine platform. In addition, deletions/
mutations were introduced into the sequence encoding the viral capsid and RNA dependent 
RNA polymerase (RdRP), rendering the virus deficient in either virus packaging or genome 
replication. Murine immune responses induced by these DNA launched YFV mutants were 
determined and compared to those triggered by DNA launched, replication and packaging 
competent YFV-17D.  
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Materials and Methods
Cell cultures and YFV-17D stocks
BHK-21J cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies, 
Carlsbad, USA) supplemented with 8% fetal calf serum (FCS). YFV-17D stocks were obtained 
by harvesting the medium of BHK-21J cells that were transfected with in vitro-transcribed 
RNA of an infectious YFV-17D cDNA clone [34]. Virus titers were determined by plaque 
assays on BHK-21J cells, as described previously [35].
Construction of infectious YFV-17D DNA clones
General standard nucleic acid methodologies were used throughout this study [36], unless 
described in more detail. Chemically competent Escherichia coli DH5α cells were used for 
cloning [37], except for BACmid construction, for which DH10B competent cells (Invitrogen) 
were used. Nucleotide numbering of the YFV clones was based on GenBank accession no. 
X03700 [38] 
 The CMV promoter and hepatitis delta virus ribozyme (HDVr) sequences were 
amplified from pcDNA3.0 (Invitrogen) and RlucRep-HDVr [39] plasmids and fused to the 
penultimate nucleotides at the 5’ and 3’ untranslated regions of the viral genome by fusion 
PCR [40]. Primers used in PCR were listed in Table 1. The resulting PCR products were cloned 
into pACNR-FLYFX [34] to yield  pACNR-CMVp-FLYF-HDVr in which the 5’ end of the full-length 
YFV insert was directly fused to a CMV promoter and the HDVr was engineered to ensure 
the production of a YFV RNA with an authentic 3’ end. For the construction of pBeloBAC-
FLYF, the complete insert of pACNR-CMVp-FLYF-HDVr encompassing the CMV promoter, 
YFV-17D cDNA and the HDVr was moved as a NotI – AflII fragment into a modified version of 
the BACmid pBeloBAC11 with unique NotI and AflII sites in the polylinker sequence. 
 A Quick-Change mutagenesis based strategy (Stratagene, La Jolla, USA) was used to 
create two mutants of pBeloBAC-FLYF. The pBeloBAC-YF/∆C contains an in-frame deletion 
of 49 amino acids (nt 185 to 331) in the capsid gene of YFV-17D [41]. In pBeloBAC-YF/GSA, 
the GDD motif (amino acids 3171 to 3173) of the viral RNA dependent RNA polymerase NS5 
was mutated to GSA [41;42]. Primers used for the construction of these two derivatives are 
listed in Table 1.
Transfection of BHK-21J cells with the YFV-17D DNA driven constructs
BACmid DNA was prepared using Nucleobond Xtra Maxi EF (Macherey-Nagel, Düren, 
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checked with electrophoresis, and the concentration was determined using a NanoDrop 
photospectrometer. 
 BHK-21J cells were transfected with 5 µg of BACmid DNA by electroporation as 
described previously [43]. Transfected cells were fixed with 3% paraformaldehyde at various 
time points after electroporation for immunofluorescense assay, and supernatants were 
collected for virus titration by plaque assay, as described above. 
Immunofluorescence Assay
Transfected cells seeded on coverslips were fixed with 3% paraformaldehyde in PBS (pH 7·4) 
at 24 h, 48h, and 72h post-electroporation (p.e.) for at least 30 min and washed with PBS 
containing 10 mM glycine. Following permeabilization with 0·1% Triton X-100 in PBS, indirect 
immunofluorescence was carried out with rabbit anti-YFV NS3 antiserum diluted 1:2000 
in PBS/5% FSC, and visualized with a secondary Alexa488-conjugated goat anti-rabbit IgG 
(Invitrogen, Carlsbad, USA) antibody with a dilution of 1:300 in PBS/5%FCS. 
Animals and immunization schemes
Female, 6 – 8 week old, transgenic AAD mice expressing the α1 and α2 domains from the 
human HLA-A2.1 and the α3 domain of the murine H-2Db in the C57BL/6 background were 
obtained from Dr. Ralph Steinman’s lab and were used in groups of 5-6 mice for immunization 
studies. Mice were immunized intramuscularly by electroporation [44] with 10ng, 100ng, or 
1 μg of endotoxin-free pBeloBAC-FLYF-17D or derivatives per mouse on days 0 and 14. 
 For additional studies on viremia and the production YFV neutralizing antibody 
titers, 6-8 week old A129 mice that are deficient in interferon (IFN) a and b receptors and 
congenic 129 mice (obtained from Dr. Charles Rice lab) were immunized intramuscularly 
with 106 PFU of YFV-17D or 5 μg of pBeloBAC-FLYF. Blood was drawn every other day up till 
29 days post immunization. Plaque assays and plaque reduction neutralization assays were 
used to determine the titers of YFV-17D and virus neutralizing antibody levels in the serum. 
All animal work was in compliance with approved institutional protocols.
ELISpot assays for enumeration of IFN-γ spot-forming cells (SFC)
Two weeks after the final immunization, AAD mice were sacrificed and their spleens were 
removed to prepare splenocytes as described previously [28]. ELISpot assays (BD-Biosciences 
PharMingen, San Diego, USA) were performed to determine the frequency of IFN-γ excreting 
cells, according to the manufacturer’s protocol. Briefly, splenocytes were cultured in the 
presence of concanavalin A (2.5 μg/ml; Sigma, St. Louis, USA) or YFV-specific CD8+ and CD4+ 
T cells peptides [45] at a concentration of 1 μg/ml. A YFV-17D-specific peptide (CD4/E15L; 
ERWFVRNPFFAVTAL) with a greatly reduced capacity to stimulate YF17D-specific CD4+ T 
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cells [45] was used as a negative control. After 16h of culture, the plates were processed to 
determine the frequency of IFN-γ SFC [28]. Briefly, the plates were washed and incubated 
with biotinylated anti-IFN-γ for 2 h at room temperature, followed by HRP-conjugated avidin 
for 1 h at room temperature. Reactions were developed with AEC substrate (Calbiochem-
Novabiochem Corporation, San Diego, CA). Final enumeration of IFN-γ SFC was performed 
using the Immunospot Analyzer ELISpot reader with the aid of the Immunospot software 
version 3.0 (Cellular Technologies Ltd., Shaker Heights, OH). Data are presented as SFC/106 
cells. Results were considered positive if the number of SFC was above 20 and higher than 
the background (culture with medium alone). The results are presented after subtraction of 
the background, which was consistently found to be 10–25 spots/106 cells throughout the 
experiments. 
Intracellular cytokine staining (ICCS) and flow cytometry
Splenocytes from immunized mice were analyzed by ICCS for Interleukin 2 (IL-2) and IFN-γ 
production after stimulation with YF17D-specific, 15 aa long peptides as described previously 
[28]. Cultures without stimulation or those treated with concanavalin A served as negative 
or positive control, respectively. 
 Stained cells were analyzed with the BD LSR-II flow cytometer using FACSDiva software 
(BD Biosciences, San Jose, USA). The data were processed with FlowJo 8.6.1 software (Tree 
Star, Ashland, USA).
Plaque reduction neutralization test (PRNT)
YFV-17D-specific neutralizing antibody titers were determined by 50% endpoint PRNT in 
6-well plates of BHK-21J cells using a standard PRNT protocol. Briefly, a two-fold serial dilution 
of mouse serum was prepared in PBS/2%FCS; 5 μl serum of each dilution was incubated with 
5 μl of PBS/2%FCS containing approximately 80 pfu of YFV-17D virus. After 1h of incubation 
on ice, the serum-virus mixtures were diluted with 300 μl PBS/2%FCS and inoculated onto 
BHK-21J cells. After an hour of incubation at 37°C the inocula were removed, and an overlay 
of DMEM/2% FCS with1.2% Avicel was added. Plaques were visualized by staining with 0.1% 
crystal violet after 4 days of incubation.
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Results 
Construction of an infectious DNA clone of YFV-17D
The characteristics of the DNA construct that was created to launch infection of YFV-17D 
from DNA are shown in Figure 1. The 5’-UTR of the viral RNA was fused to a cytomegalovirus 
(CMV) promoter so that cellular RNA polymerase II would initiate transcription of the YFV-
17D genome. The hepatitis delta virus ribozyme (HDVr) was engineered precisely after 
the last nucleotide of YFV genome to ensure the production an authentic 3’-end of the 
transcribed viral RNA. Initially the CMV promoter and HDVr cassettes were cloned into the 
pACNR-FLYFx [34]. However, the resulting plasmid pACNR-CMVp-FLYF-HDVr was found to be 
genetically instable during propagation in E. coli DH5α. Attempts to stabilize the plasmid by 
using different bacteria strains or alternative culture conditions were unsuccessful. To further 
decrease the copy number for the stabilization of the construct, the BACmid pBeloBAC11 
was evaluated as a vector for the DNA launched YFV-17D cassette. The resulting BACmid 
pBeloBAC-FLYF was shown to be genetically stable at least up to 20 passages in either E.coli 
DH5α or DH10B (data not shown).   
 To determine the contribution of viral replication and virus spread to the 
immunological characteristics of a DNA launched YFV-17D vaccination regime, two other 
pBeloBAC-based DNA launched YFV plasmids were constructed using pBeloBAC-FLYF as a 
template. In pBeloBAC-YF/GSA, the GDD motif of the viral RNA dependent RNA polymerase 
(RdRP) was mutated to GSA, which inactivated the RdRP [42], whereas in pBeloBAC-YF/∆C, 
nt 185 to 331 in the nucleocapsid gene were deleted [41]. The latter should result in the 
CMV promoter driven transcription of replication competent YFV-17D RNA that is unable to 
produce infectious virus. 
Characterization of DNA launched YFV-17D in cell culture 
The pBeloBAC-FLYF, pBeloBAC-YF/∆C and pBeloBAC-YF/GSA DNA were transfected into 
BHK-21J cells by electroporation. The transfected cells were fixed at 24hrs, 48hrs, and 
72hr post electroporation (p.e.) and the expression of YFV NS3 was analyzed by indirect 
immunofluorescence. At 24 hr p.e., a small percentage of NS3 positive cells were observed 
in the cells that were transfected with pBeloBAC-FLYF and pBeloBAC-YF/∆C (Fig. 2A), 
respectively. As anticipated, the proportion of NS3 positive cells increased for the cells 
transfected with pBeloBAC-FLYF BACmid, while remaining at a low percentage for the YFV 
capsid deletion mutant (Fig. 2A). No positive signal for YFV NS3 was detected in the cells 
transfected with pBeloBAC-YF/GSA DNA (Fig. 2A). Medium of the DNA transfected cells was 
sampled at 24 hr intervals and used to determine virus production by plaque assays. As 
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Figure 1. Schematic representation of the genetic structure of pBeloBAC11-FLYF 
Colored boxes indicate from left to right the CMV promoter (CMVp) (red), the YFV-17D ORF (blue), the hepatitis 
delta virus ribozyme (yellow) and the RNA polymerase II transcription terminator (red). The 5’ and 3’ YFV UTR 
sequences are depicted as a black line. The most 5’ YFV nucleotides that originate from the CMV promoter driven 
RNA polymerase II transcription and the last two nucleotides of YFV genome that are produced by cleavage of the 
ribozyme are also indicated. 
Figure 2. Characterization of DNA launched YFV-17D clones in BHK cells 
BHK cells were electroporated with pBeloBAC-FLYF, pBeloBAC-YF/ΔC and pBeloBAC-YF/GSA and analyzed for the 
expression of YFV antigen (A) and virus production (B).
A) Indirect immunofluorescence staining of YFV-17D NS3 protein. Cells were fixed at the indicated times p.e. and 
stained as described in the Materials and Methods section. YFV NS3 shows up as green (Alexa 488) and the 
nuclei of the cells were stained with Hoechst and show up as blue. 
B) Kinetics of virus production in BHK-21J cells transfected with pBeloBAC-FLYF (green), pBeloBAC-YF/ΔC (yellow) 
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transfected with pBeloBAC-FLYF, reaching a titer of over 107 PFU/ml at 72 hr p.e., whereas 
no virus production was detected in the supernatants collected from cells transfected with 
pBeloBAC-YF/∆C or pBeloBAC-YF/GSA DNA. The results of both the immunofluoresence 
assay and the plaque assay confirmed that as expected, only the cells that were transfected 
with pBeloBAC-FLYF DNA were able to spread and produce infectious virus. The RNA 
transcribed from pBeloBAC-YF/∆C was able to replicate as demonstrated by the readily 
detectable expression of YFV NS3, but was incapable of producing infectious progeny virus 
due to the lack of a functional capsid protein. 
 To further investigate the YFV RdRP driven intracellular RNA synthesis, cells transfected 
with pBeloBAC-FLYF were labeled with 3[H]-uridine in the presence of actinomycine D (Act.D) 
with 6-hour intervals. 3[H]-labeled viral RNA was first detected at 33 h p.e. and the amount 
of labeled RNA gradually increased over time, probably reflecting the spread of infection 
to cells that were initially not transfected (Fig. 3A). Careful inspection of the fluorogram 
revealed a faint and faster migrating RNA species in samples collected at later time points, 
suggesting the presence of a YFV replicon RNA. Flavivirus replicons are RNAs that are able to 
replicate autonomously, but cannot form virus particles due to an in-frame deletion within 
the region encoding the structural genes. Trans-complementation by functional structural 
proteins can lead to the formation of replicon containing virus particles [46]. 
 To test for the presence of YFV replicon RNA in the virus stocks derived from the 
DNA launched system, BHK-21J cells were infected with YFV-17D virus derived from in vitro 
transcribed infectious RNA or from pBeloBAC-FLYF transfection. The infected cells were 
labeled with 3[H]-uridine in the presence of Act.D and the intracellular RNA was analyzed 
by electrophoresis of denatured RNA. A band, suggestive of YFV replicon RNA was easily 
detected in the cells infected with the virus stock obtained from DNA transfected cells, 
whereas this band was not seen in cells infected with virus derived from in vitro transcripts 
(Fig. 3B).   
 Different from BHK-21J cells transfected with in vitro transcribed YFV RNA, the 
infectious YFV DNA pBeloBAC-FLYF has to be transcribed in the nucleus of cells, exposing 
the viral genome RNA to splicesomes. Computer-aided prediction revealed several potential 
splice donor and acceptor sites within the sequence of the YFV structural genes (Fig. 3C). A 
splicing event with the use of the predicted splice donor site at nt. 708 (score 1) and splice 
acceptor site at nt. 2440 (score 0.99) would result in an in-frame deletion of nt 708 to 2440 
that could yield an RNA transcript that functioned as a YFV replicon. 
 RT-PCR was performed on total intracellular RNA isolated from BHK-21J cells infected 
with the DNA launched virus to determine whether splicing at these predicted, favorable 
splice donor and acceptor sites was the origin of the YFV replicon-like RNA. Based on the 
predicted splice donor and acceptor sites, a forward primer corresponding to nt 40-64 
within viral 5’ UTR and a reverse primer complementary to nt 2491-2513 in the NS1 gene 
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15h          21h          27h          33h          39h          45h              1          2          3          4
Start End Score Exon Intron Start End Score Intron Exon
157 171 0,91 caatatg gtacgacg 858 898 0,72tgaggaaccccttttttgcag tgacggctctgaccattgcc
701 715 1 gcatatg gtaagtgt 2282 2322 0,93gtgtttggctctgcctttcag gggctatttggcggcttgaa




























Figure 3. Characterization of YFV-17D replicon RNA that is produced by RNA splicing in pBeloBAC-FLYF transfected 
BHK cells
A) Analysis of intracellular YFV RNA synthesis by 3[H]-uridine labeling and gel electrophoresis. BHK cells transfected 
with pBeloBAC-FLYF were labeled for 6 hrs in the presence of Act.D with 6 hr interval from 15 hr p.t. onwards. 
B) Analysis of viral RNA synthesis in BHK cells infected with YFV-17D derived from in vitro transcribed RNA (lane 1), 
viruses derived from pBeloBAC-FLYF DNA (lane 3), or pBeloBAC-FLYF-G709C DNA (lane 4). Lane 2 is RNA from 
mock infected cells. 
C) Prediction of splice donor and acceptor sites in the sequence of the YFV structural genes. The splice donor and 
acceptor sequences that were used based on sequencing result shown in Fig. 3D are indicated in yellow and 
pink respectively.  
D) Part of the nucleotide sequence of the 750 bp PCR product demonstrating the in-frame deletion in the YFV 
structural genes resulting in the production of the replicon RNA. Nt 701-707 upstream of the splice donor site 
at nt. 708 are highlighted in yellow, while nt 2441-2450 that are downstream of the splice acceptor site at nt 
2440 are highlighted in pink.
E) Growth kinetics of viruses derived from pBeloBAC-FLYF and pBeloBAC-FLYF-G709C. BHK-21J cells were infected 
at M.O.I. 1 and virus production was determined by plaque assays with supernatants collected at the indicated 
times p.i. 
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were selected for this analysis. In addition to the approximately 2.5kb product that was 
expected to be produced with this primer set from full-length viral RNA, a smaller fragment 
with a length of around 750bp was amplified, among other less prominent bands (data not 
shown). The 750 bp product was gel purified and sequenced. Sequence analysis revealed an 
in frame deletion of nucleotides 708 – 2440 (Fig. 3D), strongly suggesting that the predicted 
splice donor and acceptor sites were indeed used on a fraction of the CMV driven transcripts 
in the nucleus which resulted in the production of a YFV replicon RNA. Considering the 
possible influence of this splicing event on the efficiency of this DNA launched system, a 
silent mutation (G→C) was introduced at position 709 to disrupt the splice donor site, and 
the resulting construct pBeloBAC-FLYF-G709C was transfected into BHK-21J cells in parallel 
with the original construct. As predicted, this mutation abolished the production of replicon 
RNA in the DNA-launched YFV-17D transfected cells, as the faster migrating band was not 
visible in the 3[H]-uridine gel (Fig. 3B, lane 4). Surprisingly, when virus production in BHK-21J 
cells transfected with pBeloBAC-FLYF-G709C and pBeloBAC-FLYF were compared, this silent 
point mutation was found to have an unexpected negative effect on viral production (Fig. 
3E). Therefore, the immunogenicity studies were all conducted with the original construct. 
In vivo characterization of DNA launched YFV-17D constructs 
The induction of cellular and humoral immune responses against YFV-17D was investigated 
by delivering pBeloBAC-FLYF, pBeloBAC-YF/∆C and pBeloBAC-YF/GSA with an electroporation 
device to transgenic AAD mice using a homologous prime-boost immunization regimen. 
Three doses were used: 10ng, 100ng, or 1 μg. Two weeks after the boost immunization, 
serum was collected from the DNA or mock electroporated animals and neutralizing 
antibody titers against YFV were determined by PRNT. Mice were subsequently sacrificed 
and their spleens were collected and used to determine the frequency of IFN-γ producing 
cells after exposure to YFV peptides identified as dominant HLA-A2-restricted CD8+ and CD4+ 
T-cell epitopes in an ELISpot assay. 
 A dose-dependent cellular immune response against YFV was clearly detectable in 
mice vaccinated with pBeloBAC-FLYF or pBeloBAC-YF/∆C (Fig. 4A and 4B). Irrespective of the 
amount of DNA used, mice electroporated with pBeloBAC-YF/GSA were unable to produce 
significant response when compared to PBS treated mice. Incubation of the splenocytes 
with the control peptide induced no significant response (Fig. 4C), confirming the specificity 
of the T cell response induced by DNA vaccination with pBeloBAC-FLYF or pBeloBAC-YF/∆C. 
Both CD8+ T-cell and CD4+ T-cell responses were highest following a dose of 1μg of priming 
and boosting, with levels comparable between the full-length construct and the capsid 
mutant (Fig. 4A and 4B). 
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 Intracellular cytokine staining (ICCS) was performed on CD8+ T cells to evaluate the 
quality of cellular immune response against YFV upon DNA immunization. Again, a dose-
dependent response was observed for YFV-specific CD8+ T-cells producing IL-2 and/or IFN-γ 
(Fig. 5). For the dose-range tested in this study, it was obvious that mice immunized with 
the highest dose (1 µg) of either pBeloBAC-FLYF or pBeloBAC-YF/∆C produced the highest 
percentage of cytokine secreting T-cells (Fig. 5).The ICCS analysis also revealed that although 
the majority of the CD8+ T-cells were producing only IFN-γ, there were also a fraction of CD8+ 
T-cells that secreted either only IL-2, or both IFN-γ and IL-2 (Fig. 5). 
 In contrast to the induction of specific and mutli-functional T cell response, results 
of the PRNT for the evaluation of humoral immune response were rather disappointing. 
Irrespective of the vaccination dosage, no production of neutralizing antibodies was 
detected in mouse sera obtained two weeks after the boost (data not shown). To determine 
whether the murine innate immune response was restricting the production of YFV 
neutralizing antibodies, an additional experiment was performed using A129 mice that 
are deficient in expressing the IFNα/β receptor. The A129 and the congenic 129 mice were 












































































































































































































































































Figure 4. YFV-specific T-cell responses
Splenocytes from individual mice were prepared for IFN-γ ELISpot analysis. Results are presented as mean SFCs 
responding to a YFV-specific CD8+ T-cell peptide (CD8/C9V; CYNAVLTHV) (A), CD4+ T-cell peptide (CD4/A15R; 
AIDLPTHENHGLKTR) (B), or a CD4+T-cell peptide (CD4/E15L; ERWFVRNPFFAVTAL) with greatly reduced capacity to 
stimulate YF17D-specific CD4+ T cells as a negative control (C).
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17D respectively. Serum was drawn every other day for the analysis of viremia and YFV 
antibody production. No virus was detected in the sera of 129 mice that were transfected 
with pBeloBAC-FLYF, or infected with YFV-17D at any time during the experiment. For the 
YFV-17D infected A129 mice, only serum samples collected on day 3 showed low levels of 
viremia (103 and 3 x 103 PFU/mL). Despite the transient and low level of viremia, YFV-17D 
virus vaccinated A129 mice produced significant amounts of neutralizing antibodies against 
YFV. The PRNT50 value of sera collected on day 9 was determined to be above 1280, which 
remained high till the end of the experiment (day 30). Despite the fact that no virus was 
detected at any time-point in the sera of A129 that were immunized with pBeloBAC-FLYF, 
these animals produced specific YFV-17D neutralizing antibodies. The PRNT50 value peaked 
on day 11 post immunization for these animals with values of 320 and 640 for the two 
subjects respectively (Fig. 6), although these were clearly lower than those observed for 
the YFV-17D infected A129 mice. On the contrary, the congenic, fully immuno-competent 
129 mice did not produce detectable YFV neutralizing antibodies after immunization with 
pBeloBAC-FLYF. 
Fig. 5



















































































































































































Figure 5. Intracellular cytokine staining analysis (ICCS)
Splenocytes from mice vaccinated with 10ng of DNA (A), 100ng of DNA (B), or 1μg of DNA (C) were prepared, and 
ICCS results are presented as the mean percentage of splenocytes positive for IFN-γ, IL-2, or both cytokines after 
in vitro incubation with a YFV-17D specific CD8+ T-cell peptide pool. Results are representative of two independent 




Introduced in the early 1990s, the concept of vaccination using naked DNA has gained 
widespread recognition, due to its apparent advantages over conventional vaccines, such 
as ease of production and quality control as well as low cost of propagation [31;32;47]. The 
low immunogenicity in humans, however, is a major obstacle that has stymied the field 
[31;32;47]. In contrast, live-attenuated virus vaccines induce strong humoral and/or cellular 
immune responses. YFV-17D, the attenuated YFV strain that is used as a vaccine to protect 
against potentially lethal YFV infection is one of the most successful attenuated vaccines 
ever developed (reviewed in [7]). Attenuation was achieved by repeated passaging of the 
highly virulent YFV Asibi strain in  suckling mice and chicken eggs [4].
 In this report, the construction, molecular and immunological characterization of 
a DNA launched YFV-17D in the artificial bacterial chromosome pBeloBAC11 is described. 
The initial attempt was aimed at constructing a CMV promoter driven expression plasmid 
containing a full-length YFV-17D insert followed by a hepatitis delta virus ribozyme (HDVr) in 
the low copy number plasmid pACNR1180 [34;48]. Despite the success of using this plasmid 





























Figure 6. Plaque reduction neutralization test (PRNT) results of A129 mice vaccinated with pBeloBAC-FLYF DNA
Sera drawn from A129 mice at day 1, day 3, day 5, day 7, day 9, day 11, day 14 and day 29 post pBeloBAC-FLYF DNA 
vaccination were diluted and tested for YFV plaque reduction neutralization capacity as described in the Materials 
and Methods section. Percentages of subjects (mice) are plotted against PRNT50 value. 
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CMV promoter and the HDVr rendered this recombinant YFV plasmid instable in E. coli, as 
reflected by random deletions within the YFV insert (data not shown). The genetic instability 
of the insert was overcome by using pBeloBAC11 as a vector and the recombinant plasmid 
was proven to be stable for at least 20 passages in E. coli strains DH5α and DH10B. In 
addition to pBeloBAC-FLYF, two derivatives were constructed. In a replication incompetent 
pBeloBAC-YF/GSA, the viral RNA dependent RNA polymerase (RdRP) was inactivated by 
mutating the crucial GDD motif to GSA [41;42], whereas pBeloBAC-YF/∆C expresses a YFV 
replicon RNA that is capable of autonomously replicating its RNA, but requires in trans 
complementation of the capsid protein for virion formation [41]. These three BACmids 
were initially characterized in cell culture. Cells transfected with pBeloBAC-FLYF were able 
to produce infectious YFV virus, although the growth kinetics of virus production were 
approximately 24 hours delayed when compared to the kinetics of YFV production in BHK-
21J cells transfected with infectious YFV-17D RNA trancripts [34].    
 A severe handicap in YFV research is the lack of readily affordable small animal 
models that manifest clinical symptoms representative of what are seen in primates without 
the necessity of host adaptation of the virus [49]. Mice possessing functional innate immune 
systems are disease-resistant to both wildtype and vaccine strains of YFV after subcutaneous 
inoculation, with restricted viral dissemination. Neither morbidity nor mortality was 
exhibited [49]. Intracerebral inoculation can cause encephalitic disease in mice [50], which 
nonetheless lacks relevance to human infection that exhibits viscerotropism with possible 
lethal outcomes. Despite these drawbacks, mice are the only affordable small animal model 
for the initial testing of a DNA-launched YFV vaccination approach as presented in this 
report.  
 To compensate for a possible under-estimation of the immunogenicity of the YFV-
17D infectious DNA in mice due to murine restriction on YFV replication and dissemination 
[49;51], in vivo electroporation (EP) was employed to deliver DNA into HLA-A2.1 transgenic 
C57BL/6 mice, a method proven to logarithmically increase antigen expression and the 
resulting immune responses in various animals [44;52-58]. The same EP device was also 
successfully used in HIV-1 DNA vaccine human trials [59;60]. Since previous studies [19;24;25] 
with recombinant YFV-17D-based vaccines showed that anti-vector immunity was a minor 
concern during prime-boost immunization, a prime-boost vaccination regimen was adopted 
to further augment the immune responses. Nevertheless, in vivo delivery of YFV infectious 
DNA by EP failed to induce YFV neutralizing antibodies in HLA-A2.1 transgenic C57BL/6 
mice, despite readily detectable CD8+ T cell responses, whereas YFV-17D vaccination of 
BALB/c mice was reported to yield a balanced Th1/Th2 immune response [28]. The mouse 
strain used could be one of the reasons for the skewed immune responses observed, since 
C57BL/6 mice and BALB/c mice are genetically predisposed to develop Th1 or Th2 immune 
responses, respectively [61]. Therefore, it will be interesting to test the YFV infectious DNA 
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in BALB/c mice, or to try gene-gun for DNA delivery, which was demonstrated to direct the 
immune responses toward a predominantly Th2 profile, regardless of the genetic background 
of the mouse strain [62]. Another factor that could contribute to the Th1-biased immune 
response is the nature of the plasmid DNA that contains unmethylated CpG motifs, which 
was shown to induce lymphoid cells to release cytokines such as IFN-γ, IL-12, IL-18 [63;64]. 
Nevertheless, YFV infectious DNA is expected to produce virions in susceptible cells that 
should change the way of immune priming, and thus the cytokine profile. Unfortunately, 
we did not analyze the biodistribution of YFV antigens at the site of injection or the spread 
of virus to draining lymph nodes or other organs, so it could only be hypothesized that the 
murine myocytes and mononuclear cells might not support productive YFV-17D infection. 
The observation that the capsid mutant induced cellular immune responses with similar 
magnitudes compared to those induced by the wildtype construct further supported the 
aforementioned hypothesis, since the deficiency in virus assembly didn’t seem to influence 
the cellular immune responses elicited by vaccination.  
 To further confirm whether the Th1-biased immune response was somehow 
correlated with the restriction of YFV production and dissemination by murine innate 
immune responses and the inability of YFV to evade these antiviral countermeasures in a 
non-natural host [49], humoral immune responses produced in A129 mice was analyzed 
in parallel with those produced in congenic 129 mice after YFV-17D or YFV infectious 
DNA vaccination. A129 mice that have deficiencies in innate immunity were proposed to 
represent a biologically more relevant animal model for studying viscerotropic infection and 
disease development following wildtype YFV inoculation, as well as mechanisms of 17D-204 
vaccine attenuation [49]. In consistent with previous findings, viremia was detected in A129 
mice inoculated with YFV-17D, whereas no viremia was detected in serum samples at any 
time point in YFV-17D vaccinated 129 mice, strongly indicating that murine type-I interferon 
signaling pathway is important in restricting YFV replication.  Despite the lack of obvious 
viremia, A129 mice were able to mount an efficient humoral immune response after YFV 
DNA vaccination, which laid down the basis for carrying out more extensive immunization 
studies with these small animal models. 
 To our knowledge, this is the first publication describing the successful launch of 
YFV-17D infection in vivo and the induction of YFV-specific cell-mediated immunity and 
neutralizing antibodies in experimental animals. Of course, to better evaluate the potential 
of this DNA launched YFV vaccine platform and its possible applications in human beings, 
the immunogenicity and efficacy as well as the safety profile of the DNA-based YFV vaccine 
should be more appropriately assessed in non-human primates. Besides, vaccination 
dosage needs to be adjusted based on the size and the susceptibility to YFV infection of 
the vaccinated species. Furthermore, novel DNA formulations and delivery routes could be 
explored to achieve better immunogenicity and acceptability. Although the EP method used 
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in this study has been widely tested in a broad range of animals and has shown promising 
results in human clinical trials with DNA vaccines [59;60], intradermal EP delivery of DNA 
vaccines has started to attract more attention, due to the accessibility of the skin and the 
abundance of antigen-presenting cells (APCs) in the epidermis and dermis [65-67]. With the 
advances in DNA formulation and delivery technologies, the DNA launched YFV-17D vaccine 
may prove to be a stable, facile-to-produce and effective alternative for the current YFV live 
attenuated vaccine, and further holds promises as a platform for the development of YFV-
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The Flavivirus genus can be divided into three different groups depending on the vector of 
transmission: i) mosquito-borne, ii) tick-borne, and iii) no known vector (NKV) flaviviruses. 
The third group is less-well studied, partly due to the lack of full-length cDNA clones. In this 
paper, the construction and characterization of the first infectious cDNA clone of an NKV 
flavivirus, Modoc virus (MODV) is described. The full-length MODV clone pACNR-FLMODV6.1 
was shown to be genetically stable in E. coli. The viruses derived from this clone exhibited 
similar plaque morphology and growth kinetics as the parental MODV. Chemical probing 
was performed on the 3’-UTR region of the MODV genome, to corroborate the highly-
ordered RNA structures predicted to be formed in its 3’-UTR. Subsequently, deletions and 
substitutions were introduced into the full-length clone to study the functional significance 
of these conserved RNA motifs and structures in the 3’-UTR of the NKV flaviviruses. The 
Y-shaped structure (region III) and the 3’ stem-loop structure (region IV) were found to be 
indispensable for viral replication, whereas more upstream regions were not absolutely 
required for viral RNA synthesis, although they are probably involved in other aspects of 
virus life cycle, such as cytopathogenicity and/or virus dissemination.  
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Introduction
Based on phylogenetic analysis, members of the Flavivirus genus can be grouped into three 
clusters of related viruses that largely reflect their route of transmission. The clusters of 
mosquito-borne and tick-borne flaviviruses include important human pathogens such as 
dengue virus (DENV), yellow fever virus (YFV), and tick-borne encephalitis virus (TBEV). The 
third cluster, on the other hand, comprises less-well studied flaviviruses that have been 
exclusively isolated from bats (Montana myotis leukoencephalitis virus [MMLV] and Rio 
Bravo virus [RBV] [1]) and rodents (Modoc virus [MODV] [2] and Apoi virus [APOIV] [3]), and 
for which no arthropod vector has been implicated in transmission. An increasing number 
of these no known vector (NKV) flaviviruses have been isolated and sequenced [4-6]. Like 
arthropod-borne flaviviruses, NKV flaviviruses encode a single large polyprotein that is co- 
and post-translationally cleaved into three structural and seven non-structural proteins: C, 
prM/M, E, NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 [4-6]. 
 Modoc virus (MODV) was initially isolated from white-footed deer mouse (Peromyscus 
maniculatis) in Modoc County, California [7], and was shown to cause a persistent infection 
in rodents [8]. The virus has not been implicated in human disease, although a serological 
survey provided evidence for the occurrence of natural human infection without disease 
among inhabitants of Alberta, Canada [2]. MODV is neuroinvasive and causes lethal 
encephalitis in SCID mice and hamsters, rendering it a potential model for the study of 
flavivirus-induced encephalitis in humans [9]. The viral prM and/or E proteins were shown 
to be important for the neuroinvasive properties of MODV in SCID mice [10]. Protease and 
NTPase/helicase/RNA triphosphatase domains were identified in the NS3 of MODV [6], 
whereas conserved motifs associated with methyltransferase activity and RNA-dependent 
RNA polymerase (RdRp) domains were mapped to the MODV NS5 protein [6]. The crystal 
structure of the methyltransferase domain of MODV NS5 was recently solved [11].
 The single ORF of the flavivirus genome is flanked by 5’- and 3’-untranslated regions 
(UTRs). Conserved RNA motifs and structures within the UTRs of mosquito-borne flaviviruses 
have been recognized as essential elements for genome replication, translation and/or 
pathogenesis, such as the well conserved stem-loop structure formed by the terminal ~100 
nucleotides of the 3’-UTR (3’SL) and the pentanucleotide (PN) motif located in the top loop 
of the 3’SL, the conserved sequences CS1 and CS2, the RNA pseudoknot interactions PSK1 
and PSK2, as well as the RNA structure involved in the production of subgenomic flavivirus 
RNA (sfRNA) [12-23]. 
 Computer-aided sequence analysis and RNA folding of MODV, APOIV, RBV and MMLV 
genome revealed the presence of four regions within the distal part of the viral 3’-UTR that 
appeared to be conserved in RNA structures [5]. Region I was predicted to form a long hairpin 
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with a branching stem–loop. The loop sequence within this region (nt 10,294 – 10,298) was 
proposed to be involved in a pseudoknot interaction with downstream nucleotides [24]. The 
formation of this particular type of pseudoknot was reported to be essential for the stalling of 
the host ribonuclease XRN-1 in the production of small flavivirus RNA (sfRNA) [21;22;24;25]. 
Region II was predicted to form a dumbbell like structure, the 3’ arm of which contains 
the CS2 sequence [5’-G(A/U)CUAGAGGUUAGAGGAGACCC-3’] that is well conserved among 
NKV flaviviruses and mosquito-borne flaviviruses [5;12]. CS2 was shown to be nonessential 
for replication of mosquito-borne flaviviruses in cell culture, although YFV-17D and DENV 
viruses lacking CS2 appear to be less pathogenic [13;14]. Region III was proposed to fold into 
a Y-shaped structure that bears resemblance to the Y-shaped structure present in tick-borne 
flaviviruses [26], while mosquito-borne flaviviruses seem to lack similar structures. The two 
loops of the “Y” structure are formed by a conserved stretch of nucleotides. However, the 
sequences of the stems carrying these loops are not conserved, but rather show a large 
number of compensatory base changes [5]. The 3’-terminal nucleotides of the 3’-UTR of the 
NKV flaviviruses were predicted to form a long stem-loop (3’ SL), a feature conserved among 
all flaviviruses. At the 5’ side of the 3’ SL, a small stem–loop was predicted which, together 
with 3’SL, belongs to region IV. Despite the predicted similarity in the RNA folding of this 
region, sequence conservation is restricted to the pentanucleotide (PN) motif and terminal 
dinucleotide only. The predicted structures for the 3’-UTR of the NKV flaviviruses have not 
been verified by RNA structure probing and investigation into their function(s) was hindered 
by the lack of infectious cDNA clones for the NKV flaviviruses. 
 This chapter describes the construction and characterization of the first stable full-
length NKV cDNA clone, which serves as a versatile tool to address basic questions concerning 
e.g. replication, tropism, and host-virus interactions of the NKV flaviviruses. In this study, 
the biological relevance of conserved RNA sequences and predicted RNA structures in NKV 
3’-UTR was analyzed in detail. The predicted RNA topology of the MODV 3’-UTR was first 
corroborated by using chemical probing. Selected mutations were subsequently introduced 
into the full-length clone to study the functional significance of these conserved RNA 
elements in the MODV replicative cycle. 
83
MODV infectiOus clOne 
Material and Methods
Cell culture and virus
The origin and culture conditions of the BHK-21J cells that were used throughout this 
study were described before [13]. The Modoc virus strain M544 was obtained from Prof. 
J. Neyts (Leuven, Belgium) during collaborative research [10] and was originally purchased 
from the American Tissue Culture Collection (ATCC, Manassas, USA). Stocks of MODV M544 
were produced by infecting BHK-21J cells at a multiplicity of infection (MOI) of 0.1 in PBS 
containing 2% fetal calf serum (FCS) for 1 hr and subsequent incubation at 37°C with 5% 
CO2 in DMEM/2%FCS. After 3 to 4 days, when cytopathic effect (CPE) became visible, the 
medium was harvested and centrifuged at 3,000 x g for 5 min to remove cellular debris. The 
supernatant was used as a virus stock. Stocks of the cDNA-derived viruses were obtained by 
electroporating BHK-21J cells with full-length RNA transcripts [27]. 
Recombinant DNA techniques and plasmid constructions
General standard nucleic acid methodologies were used throughout this study [28] unless 
described in more detail. Chemically competent E. coli DH5α cells were used for cloning 
[29]. Nucleotide numbering of the various constructs containing MODV-derived inserts and 
the resulting full-length clones was based on the MODV sequence deposited in GenBank 
(AJ242984 [6]).
 MODV cDNA was prepared using a one-step RT-PCR system containing a modified 
M-MLV reverse transcriptase for the cDNA reaction and a mixture of Taq polymerase and 
Pyrococcus GB-D polymerase (Invitrogen, Carlsbad, USA) for the PCR. RT-PCR reactions 
contained 1 µg of total RNA from MODV-infected cells. Reaction conditions were as 
suggested by the supplier. Oligonucleotides were designed based on the published MODV 
sequence. The most 5’ oligonucleotide (NKV41, fig.1) contained the T7 Ф2.5 promoter [30], 
so that T7 RNA polymerase driven transcription would start on the “A” residue that is the 
first nucleotide of the MODV genome. In the oligonucleotide that hybridized to the extreme 
3’ end of MODV (NKV40, Fig. 1) the complement of the two last viral nucleotides were 
fused to 3’ TAAG 5’ to yield an unique AflII restriction enzyme site. Relative positions of the 
oligonucleotides used for the cDNA reconstruction of MODV are depicted in Fig. 1.  
 3’-UTR mutants were constructed in the background of pACNR-FLMODV6.1. 
Quickchange mutagenesis was used for nucleotide deletion/substitution in the construction 
of pACNR-FLMODV-YFVpk3’, pACNR-FLMODV-YFVpk3, pACNR-FLMODV-YFVpk3’pk3, 
pACNR-FLMODV-Δ10370-10393, pACNR-FLMODV-ΔCS2, pACNR-FLMODV-AACC, pACNR-
FLMODV-BB, pACNR-FLMODV-AA, pACNR-FLMODV-BA as well as pACNR-FLMODV-Δpn; 
while deletion of the predicted RNA secondary structures, i.e., region I, region II, region III, 
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region IV, was achieved by engineering unique restriction enzyme recognition sites at the 
ends of the PCR products that were joined with the use of these restriction sites.  
RNA transcription
Plasmid DNA for in vitro run-off RNA transcription was purified using the Nucleobond AX 
DNA isolation kit (Macherey-Nagel, Düren, Germany). pACNR-FLMODV plasmids were 
linearized with AflII, followed by proteinase K treatment and phenol/chloroform extraction. 
Approximately 1 µg of linearized DNA was used as a template for in vitro transcription 
using the Ampliscribe™ T7 high-yield transcription kit (Epicentre, Madison, USA). For the 
production of 5’-capped full-length MODV transcripts, the UTP, GTP and CTP concentration 
was 7.5 mM, whereas the ATP concentration was adjusted to 2 mM. G(5’)ppp(5’)A (NEB, 
Ipswich, USA) was added as RNA cap analog to a final concentration of 6 mM. After a 2 hr 
incubation at 37°C, DNase I was added and the incubation was continued for another 15 min. 
The RNA transcripts were subsequently purified by LiCl precipitation and the concentration 
was determined by spectrophotometry.
RNA transfection and analysis of viral RNA synthesis
BHK-21J cells were transfected with 5 µg of full-length MODV RNA as described previously 
[27]. For RNA analysis, 2.5 ml (approximately 1.5 x 106 cells) of the transfected BHK-21J cell 
suspension was seeded in a 10 cm2 plate. Total RNA was isolated from the transfected cells 
at 30 h post electroporation (p.e). Analysis of RNA synthesis by 3[H]-uridine labeling was 
performed as described before [13]. Tripure (Roche, Mannheim, Germany) was used for cell 
lysis and subsequent RNA isolation. 3[H]-Uridine labelled RNAs were denatured with glyoxal 
and analyzed on 0.8% agarose gels [28].
Northern blotting and hybridization 
Samples containing 10 µg of total RNA from electroporated cells were denatured using 
formaldehyde, separated in a formaldehyde-containing 1.5% agarose gel, and blotted onto 
a Hybond-N+ membrane (GE Healthcare, Buckinghamshire, UK). The blots were hybridized 
with 32P-labeled oligonucleotides as described previously [31;32].
RNA structure determination by selective 2’-hydroxyl acylation and 
primer extension (SHAPE) probing
A pBluescript plasmid containing MODV nucleotides 9651-10506 was used to generate a PCR 
fragment of 383 nts, with oligonucleotide NKV45 that contained a T7 promoter sequence 
fused to nts complementary to MODV 10244-10269 and M13 reverse oligonucleotide as 
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primers. The resulting PCR product was used as template for in vitro RNA transcription 
(T7 MEGAscript kit; Ambion). Transcripts were treated with DNase I and purified by LiCl 
precipitation as recommended by Ambion, and used for SHAPE probing as described 
previously [22;33]. NMIA-induced modifications in the MODV transcript were identified by 
primer extension using 32P-labeled oligonucleotide T3 primer, NKV 20, NKV 53 and NKV 161, 
which binds to the T3 promoter, nt 10332-10356 (linker between region I and II), nt 10399-
10420 (the CS2 motif), and nt 10433-10452 (linker between region II and III and the 5’ arm 
of the bottom stem of region III) respectively. 
Immunofluorescence microscopy 
At 30 h p.e., control and infected cells were washed once with PBS and prepared for 
immunofluorescence microscopy as described previously [13]. Commercially available 
immune ascitic fluid obtained from mice infected with MODV (ATCC, Manassas, USA) 
was used as primary antibody in a 1:1000 dilution. Alexa Fluor® 488 goat anti-mouse IgG 
(Invitrogen) was used in a 1:500 dilution as secondary antibody.
Immunostaining of plaque assays
After the regular 4 days of incubation, the Avicel overlay was removed and the cells were 
fixed with 3.5% formaldehyde for 20 min, followed by 3 washes with PBS-Glycine (10mM), 
and permeabilized with 0,5% Triton X-100 in PBS for 15 min. After 3 additional washes with 
PBS, the individual 10 cm2-wells were incubated with 200 μl of a 1:500 dilution of the MODV 
hyperimmune serum in PBS/10% horse serum/0,05% Tween-80 for 1 h, followed by 3 x 5 min 
washes with PBS/0.05% Tween-80, and subsequent incubation with Goat-anti-Mouse-HRP 
(Dako, Glostrup, Denmark), diluted 1:1000 in PBS/10% horse serum/0.05% Tween-80 for 
1h. After 3 washes with PBS/0.05% Tween-80 and a short rinse with 0.1 M Sodium Acetate 
buffer (pH 5.0), cells were incubated with 3-amino-9-ethylcarbazole as substrate in the dark 
at RT for >30 min. The peroxidase reaction was stopped by washing with milli-Q water when 
foci of infected cells were clearly visible. 
Viral growth kinetics determination by qRT-PCR 
For analysis of the viral growth kinetics, BHK-21J cells were infected at an MOI of 1 and the 
medium was subsequently collected and replaced by the same volume of fresh medium 
at 6-h intervals. Plaque assays were used when comparing the growth kinetics of parental 
MODV and the MODV-6.1(wt) viruses, whereas qRT-PCR was used to determine the growth 
kinetics of the MODV 3’-UTR mutants. Briefly, Triton X-100 was added to the collected 
medium to a final concentration of 0.1% for the disruption of virion structure and thus 
releasing the viral genome. 5 μl of the treated samples were used without any additional 
86
Chapter 4
purification steps in a qRT-PCR reaction using a one-step RT-PCR kit (Qiagen) and primers as 
previously described [9].
Results 
Construction and characterization of a full-length MODV cDNA clone 
The construction of full-length cDNAs for the transcription of infectious flavivirus RNA was 
often hampered by genetic instability of these clones in E. coli [34-39]. Given the positive 
experience with a pACNR1180-derived vector [40] for the construction of a stable full-
length YFV-17D clone [13], this low-copy number vector was selected as the vector for the 
construction of an infectious MODV cDNA. 
 The full-length MODV cDNA was assembled in a modified pACNR-FLYF17Da vector [13], 
in which most of the YFV sequences were deleted while simultaneously creating unique NotI, 
HindIII, and SalI restriction sites. Three RT-PCR products (Fig. 1A) were sequentially inserted 
in the 5’ to 3’ direction to create the full-length MODV cDNA. Primer NKV41 contained the 
T7 RNA polymerase φ2.5 promoter sequence fused to the first 19 nucleotides of MODV 
5’-UTR, whereas in oligonucleotide NKV40, nucleotides complementary to the last 28 nt 
of the MODV genome were fused to an AflII recognition sequence, which served as run-off 
site for in vitro transcription. Upon transfection into BHK-21J cells, in vitro-generated RNA 
transcripts of several plasmids harbouring the full-length MODV cDNA were analyzed for 
viral RNA synthesis and protein expression by 3[H]-uridine labeling and immunofluorescence 
assays, respectively. Among all the analyzed clones, the transcripts of pACNR-FLMODV 6.1 
yielded higher virus titers compared to the other tested clones (data not shown) and virus 
derived from this clone was characterized and compared in more detail to the parental 
MODV. 
 The genetic stability of pACNR-FLMODV6.1 in E. coli strain DH5α was evaluated by 
repeated passaging. One passage was defined as growing the bacteria for more than 12 h in 
2 ml of LB medium containing 50 μg/ml ampicillin, followed by a streak on selective medium 
to obtain a single colony for the next cycle. After the 10th streak, a bacterial colony was 
picked and used to prepare plasmid DNA (pACNR-FLMODV6.1-p10). No differences were 
observed in immunofluorescence and 3[H]-RNA labeling (fig.1B and 1C) of cells transfected 
with RNA transcripts of the original plasmid and the passage 10 plasmid. More importantly, 
viruses derived from both pACNR-FLMODV6.1 and pACNR-FLMODV6.1-p10 showed very 
similar growth kinetics and plaque morphology in BHK-21J cells when compared to the 
parental MODV (Fig. 1D and 1E). 
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Figure 1. Construction and characterization of the pACNR-MODV6.1 infectious cDNA clone
A)  Schematic representation of the construction of the MODV full-length clone. 
 The large boxes represent the viral ORF encoding the structural and non-structural proteins. The oligonucleotides 
that were used to generate the cDNA fragments for constructing the clone are indicated by triangles. The open 
circle upstream of the MODV insert represents the T7 Ф2.5 promoter. The restriction sites that were utilized for 
the assembly of the clone as well as the Sal I site that was deleted are indicated. 
B)  Immunofluorescence staining of BHK-21J cells infected with wt-MODV or transfected with in vitro transcribed 
full-length MODV RNA derived from pACNR-MODV6.1 and the passage 10 plasmid respectively. Cells were fixed 
at 30 hrs p.i. or p.e. and stained with the MODV hyperimmune serum.
C)  Viral RNA synthesis in BHK-21J cells transfected with in vitro transcribed RNA of the pACNR-MODV6.1 (lane2), 
pACNR-MODV6.1-p10 (lane 3). RNA isolated from cells infected with parental MODV virus (lane 2) and that 
from mock infected cells (lane 1) were loaded as controls. 
D)  Viral growth kinetics. BHK-21J cells were infected with the parental MODV (diamond), virus derived from 
pACNR-MODV6.1 (square) or virus derived from pACNR-MODV6.1-p10 (triangle) at an MOI of 1; the medium of 
the infected cells was harvested at the indicated time points p.i. and the viral titer was determined by plaque 
assays. 




 The nucleotide sequence of pACNR-FLMODV6.1 was determined and compared 
to the only other full-length MODV sequence (accession number AJ242984) that was 
available in GenBank. As summarized in table 1, the 22 nucleotide differences detected 
when comparing pACNR-FLMODV6.1 and the Genbank entry were scattered throughout 
the coding sequence. Most amino acid substitutions (8) were present in NS5, the largest 
virus-encoded protein. Surprisingly, the rather small (254-amino acid) NS4B protein, which 
is generally well conserved among flaviviruses, contained 4 amino acid substitutions. None 
of the mutations found in NS3 or NS5 were located within the functional domains that were 
previously proposed for these viral proteins [6]. 
MODV 3’-UTR folds into four discrete stem-loop regions.
As schematically depicted in Fig. 2A, MODV 3’-UTR as well as the distal part of the 3’-UTR 
of other NKV viruses, was proposed to fold into four highly ordered RNA structures [5]. To 
verify the predicted RNA topology of the MODV 3’-UTR, nt 9,651-10,,506 were subjected 
to selective 2’-hydroxyl acylation and primer extension (SHAPE) probing.  This region 
covers the complete 3’-UTR except for the terminal ~100 nt, which are predicted to fold 
into the well conserved long stem-loop structure (3’SL) designated as region IV [5] (Fig. 
2A). The susceptibility of the nucleotides to N-methylisatoic anhydride (NMIA) treatment 
is summarized in Fig. 2C, with colors indicating strong (red), weak (yellow) or noisy (blue) 
reactivity. Apart from nucleotides comprising the CS2 motif, the bases predicted to be 
involved in basepairing showed little or no reactivity to NMIA, supporting their participation 
in higher-order RNA structures. Nucleotides predicted to be present in loop structures also 
correlated rather well with the chemical probing data, although their reactivity varied. 
Strong reactivity was observed for most of the nucleotides positioned in between region I 
and II, confirming the presence of a non-structured linker sequence between the depicted 
stem-loop structures. Discrepancy between chemical probing result and the RNA structure 
prediction, however, was noticed for nucleotides separating region II and III, which showed 
weak or no reactivity, instead of high reactivity that was expected for the predicted single-
stranded conformation. 
 To investigate the roles that these primary and secondary RNA structures play in viral 
life cycle, deletion and substitution were introduced into these regions. The constructed 
mutants are listed in Table 2, where detailed information is provided on the nucleotides that 
were deleted or mutated.    
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Table 1. Summary of the nucleotide differences between the MODV AJ242984 and the MODV clone 6.1 sequence
Changes are grouped by encoded viral proteins. Positions, actual nucleotide change as well as the amino acid 
substitutions are shown. Nucleotide or amino acid to the right indicates MODV NCBI AJ242984 followed by the 
nucleotide or amino acid encountered in the MODV6.1 genome. 
Gene Position Nucleotide Amino Acid
prM 610 U  C silent
Env 1543 U  G Phe  Leu
NS1 2776 C  U silent
3089 C  A Gln  Arg
NS2A 3529 A  G Ile  Met
NS2B 4410 A  G Glu  Gly
NS3 4861 A  G silent
6312 U  A Leu  Gln
NS4B 6837 U  C Ile  Thr
7098 G  A Ser  Asn
7444 C  G silent
7445 C  G Leu  Val
7503 U  A Leu  His
NS5 7756 G  A silent
7767 G  C Ser  Thr
7938 G  C Arg  Thr
8141 C  G Arg  Ala
8142 G  C Arg  Ala
8612 C  G Gln  Glu
8920 U  A Ser  Arg
9120 A  G Lys  Arg
9990 A  G Asp  Gly
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Figure 2. Prediction and verification of RNA secondary structure of MODV 3’-UTR 
A)  Schematic representation of predicted RNA structure of MODV 3’-UTR. Sequences conserved in the 3’-UTR 
of NKV flaviviruses are highlighted: CS2 (orange), the Pentanucleotide motif (PN) (red) and the UUGG loop in 
Region III (purple). The sequences (PK’ and PK) involved in the formation of the predicted RNA pseudoknot are 
highlighted in blue. 
B)  A representative radiograph of a SHAPE probing experiment. Template RNA was produced and treated with 
NMIA and analyzed as described in the Material and Method section. Primer extension was performed using 
primer NKV 161 that binds to nt10,433-10,452 of the MODV genome. Primer extension was performed on 
NMIA treated (+) or not treated (-) RNA.  
C)  Results of SHAPE probing for nt 10,252–10,492 within MODV 3’-UTR. NMIA reactivity is summarized with colors 
indicating differences in reactivity: red, strong reactivity; yellow, weak reactivity; blue, similar reactivity in mock 
and NMIA treated RNA; no color indicates that these nucleotides were not reactive to NMIA.  
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The 3’-terminal stem-loop structure is indispensable for MODV 
replication.
Deletion of the 3’-terminal SL structure (region IV according to the nomenclature of [5]) 
was lethal to the virus, as no viral RNA synthesis was detected when 3[H]-RNA labeling was 
performed on BHK-21J cells transfected with the construct in which the whole region IV was 
deleted (Fig. 3A, lane 8), nor could any virus be detected by plaque assays with the medium 
collected from the transfected cells. In fact, the mere deletion of the MODV 5’ CUCAG 3’ 
pentanucleotide (PN) motif (nt 10552–10556) was sufficient to completely abolish viral 
RNA synthesis (Fig. 3A, lane 9).
The Y-shaped RNA structure upstream of the 3’ SL is required for MODV 
replication. 
The proposed RNA folding of region III into a Y-shaped structure correlated well with the 
results of the SHAPE probing (Fig. 2C). Nucleotides in the loop region were quite accessible 
Table 2. Characteristics of MODV 3’-UTR mutants constructed and analyzed in this study
Column one lists all the mutants constructed. Details of the nucleotides substituted or deleted are shown in 
column two, and the positions of changed nucleotides within the full-length genome are indicated in column three. 
MODV mutants 
Construct
Number of deleted (Δ) or 
substituted (x→y) nts.
Position of the mutated nts. in 
the MODV genome
1 pACNR-FLMODV-Δregion IV Δ 93 10506 – 10599
2 pACNR-FLMODV-Δpn Δ 5 10552 – 10556
3 pACNR-FLMODV-Δregion III Δ 39 (+AGAT) 10447 – 10485
4 pACNR-FLMODV-AACC 4 (TTGG → AACC) 10460 – 10463
5 pACNR-FLMODV-BB 6 (TTGGTG → CGCCAA) 10451 – 10456
6 pACNR-FLMODV-AA 6 (CGCCAA → TTGGTG) 10468 – 10473
7 pACNR-FLMODV-BA 6 (TTGGTG → CGCCAA)
6 (CGCCAA → TTGGTG)
10451 – 10456
10468 – 10473
8 pACNR-FLMODV-Δregion II Δ 64 10360 – 10423
9 pACNR-FLMODV-Δ10370-10393 Δ 24 10370 – 10393
10 pACNR-FLMODV-ΔCS2 Δ 20 10400 – 10419
11 pACNR-FLMODV-Δregion I Δ 67 (+ AAGCTT) 10253 – 10319
12 pACNR-FLMODV-YFVpk3’ 5 (ATGAC → GCTGT) 10294 – 10298
13 pACNR-FLMODV-YFVpk3 5 (GTCAT → ACAGC) 10336 – 10340
14 pACNR-FLMODV-YFVpk3’pk3 5 (pk3’; ATGAC → GCTGT)





to modification by NMIA, while nucleotides in the predicted stems were in general non-
reactive, with discrepancies being observed for only a few nucleotides. 
 This structure was shown to be absolutely required for viral replication, since no RNA 
synthesis was detected in cells transfected with MODV-ΔregionIII RNA (Fig. 3A, lane 3). To 
dissect the functional elements within this region, additional mutations were introduced 
to either change the loop sequence 5’ UUGG 3’ that is conserved in all NKV flaviviruses, 
MODV-6.1 (wt) MODV-AACC MODV-BA
Fig. 3
    1          2          3          4          5          6          7          8          9 
B) 
A) 
MODV-6.1 (wt) MODV-AACC MODV-BA
Fig. 3
    1          2          3          4          5          6          7          8          9 
B) 
A) 
Figure 3. Characteristics of the MODV RegionIII and Region IV mutants 
A)  Viral RNA synthesis was analyzed by 3[H]-RNA labeling as described in the Material and Methods section. BHK-
21J cells were infected (M.O.I. 1) with MODV-6.1 (wt) (lane 2), MODV-Δregion III (lane 3), FLMODV-AACC (lane 
4), MODV-BB (lane 5), MODV-AA (lane 6), MODV-BA (lane 7), MODV-Δregion IV (lane 8), MODV-ΔPN (lane 9) 
and mock infected (lane 1). 
B)  Plaque morphology (upper panel) and foci formation (lower panel) of MODV-6.1(wt) (column 1), MODV-AACC 
(column 2), and MODV-BA (column 3) on BHK-21J cells. Plaque assay and immunostaining methods were 
performed as described in the Materials and Methods section. 
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to 5’ AACC 3’ (highlighted in purple, Fig. 2A), or to disrupt the base-pairing of the stem 
(highlighted in green, Fig. 2A). Substituting the sequence 5’ GUGGUU 3’ (nt. 10,451 – 
10,456) with 5’ CGCCAA 3’, which is present at position 10,473-10,468, or vice versa, 
resulted in the construction of mutants MODV-BB and MODV-AA, respectively. Base pairing 
of the 5’ stem of region III was predicted to be disrupted in these two mutants, whereas 
the base pairing potential was restored in mutant MODV-BA, in which the 5’ and 3’ arm of 
the duplex were swapped. As shown in Fig. 3A, no viral RNA synthesis was detected in cells 
transfected with either MODV-BB (lane 5) or MODV-AA RNA (lane 6). In contrast, cells that 
were electroporated with the MODV-BA transcript showed efficient viral RNA synthesis (Fig. 
3A, lane 7), underlining the importance of this stem-loop structure for MODV replication. 
Accordingly, no virus was detected in the medium of the cells transfected with either the 
MODV-BB or the -AA transcript, whereas cells electroporated with the MODV-BA transcript 
produced similar amounts of virus with identical plaque and foci morphology as the wt 
MODV-infected cells (Fig. 3B). Although the conserved loop sequence 5’ UUGG 3’ was 
dispensable for viral replication, its mutagenesis dramatically influenced the efficiency of 
RNA synthesis (Fig. 3A, lane 4).  Virus derived from MODV-AACC RNA transfection produced 
smaller plaques and foci on BHK-21J cells compared to wtMODV (Fig. 3B). From these results 
it can be concluded that this particular RNA stem-loop structure is important for optimal 
MODV replication.  
The CS2-containing dumbbell-like RNA structure is nonessential for viral 
replication.
The SHAPE probing results (Fig. 2C) did not fully support the predicted RNA structure for 
region II. Although the lack of reactivity to NMIA of the nucleotides that formed the bottom 
and the longer 5’ stem structure of region II was in agreement with the predicted RNA 
structure, most nucleotides within the CS2 motif reacted strongly with NMIA, indicating 
that this part of region II was not involved in the formation of secondary or any higher-order 
RNA structures. The CS2 motif was therefore depicted as a single-stranded loop in Fig. 2C.
 Three deletion mutants were constructed to analyze the role of region II in the viral 
life cycle. In MODV-ΔregionII, the complete sequence of region II (nt 10360-10423) was 
deleted, while in MODV-Δ10370-10393 and MODV-ΔCS2 the 5’ arm of the dumbbell-like 
structure and the CS2 motif were deleted respectively. Surprisingly, cells transfected with 
RNA from these three mutants all showed a similar level of viral RNA synthesis as cells 
electroporated with the wt MODV control transcript (Fig. 4A). Crystal violet staining of MODV-
ΔregionII plaque assays did not show visible plaques on BHK-21J cells whereas plaque assays 
for MODV-Δ10370-10393 and MODV-ΔCS2 revealed the formation of rather small and not 
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Figure 4. Characteristics of the MODV Region II mutants
A)  Analysis of MODV RNA synthesis by 3[H]-RNA labeling. BHK-21J cells were infected (M.O.I. 1) with MODV-6.1(wt) 
(lane 1), MODV-Δregion II (lane 3), MODV-Δ10370-10393 (lane 4), MODV-ΔCS2 (lane 5) and mock infected (lane 
2). RNA was labeled, isolated, and analyzed as described in the Materials and Methods section. 
B)  Analysis of plaque (upper panel) and infectious center formation (lower panel) on BHK-21J cells by MODV-
6.1(wt) (column 1), MODV-Δregion II (column 2), MODV-Δ10370-10393 (column 3) and MODV-ΔCS2 (column 
4). Plaque assays and immunostaining methods were performed as described in the Materials and Methods 
section. 
C)  Viral growth kinetics of the MODV 3-UTR region II mutants. BHK-21J cells were infected with MODV-6.1(wt), 
MODV-Δregion II,  MODV-Δ10370-10393 and MODV-ΔCS2 at an MOI of 1; the medium of the infected cells was 
harvested at the indicated time points p.i. and the amount of viral genome copies was determined by qRT-PCR 





MODV infectiOus clOne 
BHK-21J cells efficiently as was demonstrated by the clearly visible foci of virus-infected cells 
upon immunostaining of plaque assays on BHK-21J cells. The diameter of the foci formed 
by MODV-ΔCS2 was similar to those produced by wt MODV, and MODV-Δ10370-10393 
produced foci were only slightly smaller than those produced by wt MODV. Compared to the 
wt virus, significantly smaller yet still clearly visible foci were produced by ΔregionII mutant 
(Fig. 4B). The differences in plaque forming capability and foci morphology, however, were 
not associated with virus production efficiency. Similar growth kinetics was observed for all 
these three mutants, which produced marginally lower titers of viruses from 18 to 36 h post 
infection compared to wtMODV (Fig. 4C). 
Region I is involved in sfRNA production.
The results of the SHAPE probing correlated rather well with the RNA structure predicted 
for region I, especially for the nucleotides that were predicted to form the stems of this 
particular RNA structure. Surprisingly little or even no reactivity to NMIA was observed for 
the nucleotides that were predicted to form the loop regions of the predicted structure. 
For instance the sequence 5’ CAACC 3 ’ (nt 10269-10273) that was predicted to form a 
single-stranded bulge in between two stems did not show reactivity to NMIA (Fig. 2C). 
Interestingly, the sequence 5’ AUGAC 3’ (nt 10,294-10,298) that was predicted to form 
an RNA pseudoknot [24] by baseparing with the downstream sequence 5’ GUCAU 3’ (nt 
10,336-10,340) showed a weak but reproducible reactivity to NMIA. For the predicted 
pseudoknot partner 5’ GUCAU 3’, three (GUC) out of the five nucleotides did not react to 
NMIA, while the other two nucleotides reacted strongly. These results suggested that the 
predicted RNA pseudoknot was at least not the thermodynamically favored RNA structure 
under the conditions used for these probing experiments. Despite the ambiguous probing 
results for these particular nucleotides, these sequences were found to be essential for 
MODV sfRNA production. No MODV sfRNA could be detected when the pk’ sequence (Fig. 
2A, nomenclature according to [20]) AUGAC was mutated to GCUGU  (sequence involved 
in pseudoknot formation and sfRNA production in YFV 3’-UTR [20;22]; Fig. 5B). Likewise, 
mutagenesis of the predicted interacting pk sequence GUCAU to ACAGC (interaction partner 
for GCUGU in the YFV 3’-UTR) also abolished sfRNA production (Fig. 5B). Surprisingly, 
MODV-YFVpk3’pk3 in which the above-mentioned mutations were combined to restore the 
predicted RNA pseudoknot formation, was still unable to produce detectable amounts of 
MODV sfRNA, as was MODV Δregion I mutant. Viral genomic RNA synthesis, on the other 
hand, appeared to be only slightly compromised for all of the above-mentioned mutants, as 
judged by the intensity of the MODV genomic RNA band in the Northern blot and the results 
of the intracellular 3[H]-uridine labeling of viral RNA (Fig. 5A and 5B). Interestingly, BHK-
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Figure 5. Characteristics of the MODV Region I mutants
A)  Analysis of viral RNA synthesis was analyzed by 3[H]-RNA labeling. BHK-21J cells were infected (M.O.I. 1) with 
MODV-6.1(wt) (lane 1), MODV-Δregion I (lane 3), MODV-YFVpk3’ (lane 4), MODV-YFVpk3 (lane 5), pACNR-
FLMODV-YFVpk3’pk3 (lane 6) or mock infected (lane 2). RNA was labeled and analyzed as described in the 
Materials and Methods section. 
B)  Analysis of MODV sfRNA production by Northern blotting. BHK-21J cells were infected (M.O.I. 1) with MODV-
6.1(wt) (lane 1), MODV-Δregion I (lane 2), MODV-YFVpk3’ (lane 3), MODV- YFVpk3 (lane 4), MODV-YFVpk3’pk3 
(lane 5) and FLMODV-Δregion II (lane 6). Intracellular RNA was isolated at 30hrs p.i. and analyzed by Northern 
blotting as described in the Materials and Methods section.
C)  Analysis of plaque (upper panel) and infectious center formation (lower panel) on BHK-21J cells by MODV-
6.1(wt) (column 1) and MODV-Δregion I (column 2). Plaque assays and immunostaining were done as described 
in the Materials and Methods section. 
D)  Viral growth kinetics. BHK-21J cells were infected with MODV-6.1(wt), MODV-Δregion I, MODV-YFVpk3’, 
MODV- YFVpk3, or MODV- YFVpk3’pk3 at an MOI of 1; the medium of the infected cells was harvested at the 
indicated time points p.i. and the amount of viral genome copies was determined by qRT-PCR as described in 
the Materials and Methods section. 
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pk mutants did not show any visual CPE at time points when CPE was clearly detectable in 
wtMODV RNA transfected cells (data not shown). In addition, no plaques were observed 
by crystal violet staining on BHK-21J cells for any of these MODV mutants that were unable 
to produce sfRNA. Nevertheless, immunostaining of cells infected with these MODV region 
I mutants showed clearly detectable yet small foci (Fig. 5C). The viral growth kinetics of 
MODV region I mutants on BHK-21J cells revealed that these viruses produced virus titers 5- 
to 10-fold lower compared to those of wtMODV during the exponential phase of the growth 
curve (Fig. 5D).
Discussion
Unlike for the mosquito- and tick-borne flaviviruses, no arthropod vectors have been 
identified for NKV flaviviruses thus far. It is therefore interesting to study the similarities 
of this group of flaviviruses compared to their vector-borne counterparts, as well as to 
identify unique features that distinguish them from arbo-flaviviruses. Unfortunately, these 
basic studies have been hindered by the lack of infectious full-length cDNA clones for NKV 
flaviviruses, while those of vector-borne flaviviruses have significantly facilitated research 
on yellow fever virus (YFV) [13;36], Kunjin virus (KUNV) [41], West Nile virus (WNV) [42], 
dengue virus (DENV) [43;44] and tick-borne encephalitis virus (TBEV) [45].  Construction 
of stable full-length clones for flaviviruses, however, has not always been straightforward, 
as genetic instability in E. coli hosts was often encountered. For certain flaviviruses [35-
37], labor-intensive in vitro ligation procedures were used initially for the production of 
full-length cDNA templates for infectious RNA transcripts, until the instability problem was 
circumvented by cloning the cDNA into low-copy number plasmid vectors [13;34].  
 The low-copy number plasmid pACNR1180, previously used for the cloning of viral 
sequences that are not well tolerated by E. coli [13;40], was therefore chosen as the vector 
for the construction of full-length MODV clone. Clone pACNR-FLMODV6.1 was proven to be 
genetically stable upon repeated passages in E. coli. Attempts to clone the full-length MODV 
insert from pACNR-FLMODV6.1 into high copy number plasmids like pBluescript or pUC 
met no success (unpublished results). Viruses derived from the full-length clone (pACNR-
FLMODV6.1) possessed similar characteristics as the parental MODV, in terms of genome 
replication efficiency, growth kinetics, and plaque morphology, establishing a reverse 
genetics system for the study of MODV molecular biology. Besides the functional analysis 
of RNA structures present in the 3’-UTR as described in this chapter, the construction of 
chimeric flaviviruses by exchanging the prM and E genes of NKV and arthropod-borne 
flaviviruses could create valuable tools to elucidate the molecular basis for flavivirus host-
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range restrictions and pathogenicity, as illustrated by studies using a yellow fever virus 
in which prM and E were replaced by their counterparts of MODV [10;46]. These studies 
concluded that the neuroinvasive character of MODV in mice was mediated by prM and E, 
while the inability of MODV to replicate in arthropod hosts was determined by a post-entry 
event [10;46]. The availability of an infectious MODV cDNA allows construction of similar 
MODV chimeric viruses in which the MODV prM and E are replaced by the comparable genes 
of YFV or other flaviviruses to corroborate the results obtained with the YFV-MODVprM-E 
chimera. 
 Flavivirus genomes contain a single open reading frame (ORF) flanked by 5’-UTR and 
3’-UTR. The 3’-UTR varies in length from about 350 to 800 nucleotides. This heterogeneity 
in length is mainly due to the variation in the so-called variable region (VR), which is 
located proximal to the stop codon. It is characterized by extensive sequence duplications 
and deletions, even among strains of the same virus, and by an apparent lack of sequence 
conservation. In contrast, the distal part of the 3’-UTR exhibits more sequence and/or 
structure similarities among flaviviruses. Since this part of the 3’-UTR contains RNA elements 
essential for viral translation, replication, and possibly assembly [47-54], it is referred to as 
the ‘core element’. With a length of only 366 nucleotides, MODV has the shortest 3’-UTR 
among all flaviviruses sequenced thus far. In comparison to other flaviviruses, the MODV 
3’-UTR comprises only the core element and probably represents the minimal requirements 
for the 3’-UTR of NKV flaviviruses. The region was predicted to fold into four well-conserved 
RNA structures [5]. In this study, SHAPE RNA probing was used to validate three out of 
the four predicted RNA structures for the MODV 3’-UTR. Except for the CS2 sequence in 
region II, probing results were generally in agreement with the predicted structures. These 
RNA structures were deleted and mutated accordingly, and the effect of these mutations on 
viral RNA synthesis and virus productions was analyzed to determine the role of these RNA 
elements in the viral life cycle. 
 The well-conserved 3’-SL and the PN motif (within region IV) were indispensable 
for MODV replication, as was shown for vector-borne flaviviruses [13;42;55-58]. Using a 
primer extension analysis and an alphavirus-based expression system [24], region I was 
previously predicted to serve as the stalling site for the host ribonuclease XRN-1, resulting 
in the production of the MODV sfRNA [21;22;24]. As demonstrated in this study, region I is 
non-essential for viral RNA synthesis or virus production but plays a critical role in stalling 
the host ribonuclease XRN-1, resulting in the production of sfRNA that is characteristic for 
every flavivirus [21;22;24]. Although mutation of the sequences proposed to be involved 
in pseudoknot formation [24] illustrated the importance of these nucleotides in sfRNA 
production, SHAPE probing results did not confirm their participation in pseudoknot 
formation. This discrepancy between the biochemical probing results and the model 
proposed could be due to the fact that the RNA structure probing involved only part of the 
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viral 3’-UTR and that folding of this particular region might be different in the context of 
the whole viral genome and the presence of viral and/or host factors interacting with the 
viral 3’-UTR. An alternative explanation which poses more challenges for future research is 
that the current model of the folding of region I or in more general terms the XRN-1 stalling 
site in the 3’-UTR of the flavivirus genome is too simplistic and might be incorrect. After all 
it is rather surprising that such a relatively simple RNA structure is able to stall the highly 
processive XRN-1. In vivo probing with a recently described method that allowed structural 
determination of RNA molecules in a physiologically more relevant setting would hopefully 
provide more insights into the RNA structure of this region in living cells [59], and it would 
be interesting to determine the 3D structure of the MODV or a related flavivirus XRN-1 
stalling site by NMR.  
 In between region I (XRN-1 stalling site) and region IV (3’SL), two other conserved 
highly-ordered RNA structures were predicted for all NKV flaviviruses [5]. Interestingly, the 
structure of region II is predicted to be similar to the CS2-containing structure in mosquito-
borne flaviviruses which appears to be absent in tick-borne flaviviruses, whereas a conserved 
Y-shaped RNA structure similar to the region III of NKV flaviviruses has been identified in 
tick-borne flaviviruses and has no counterparts in mosquito-borne flaviviruses. It appeared 
that the conserved structures of region II and III in NKV flaviviruses also bear functional 
similarities to their counterparts of the vector-borne flaviviruses. Region II encompassing 
the CS2 containing dumbbell-like RNA structure is not required for RNA synthesis and virus 
production. Given the effect of mutations in MODV region II on cytopathogenicity in cell 
culture, the RNA elements within this region are probably involved in virus-host interactions. 
Similar observations have been reported for mutations involving the CS2-containing region 
of DENV and YFV [13;14;60]. The Y-shaped structure (region III) that has a structurally and 
positionally similar counterpart in TBEV is, just like in TBEV, indispensable for viral replication 
[13;14;60;61]. 
 Using the first infectious cDNA clone for a NKV flavivirus, this study provides valuable 
information on the functional significance of conserved RNA sequences/structures in the life 
cycle of these flaviviruses. It still remains to be elucidated at which stage of the viral life cycle 
the changes of these motifs and/or structures exert their influence and which viral or cellular 
proteins are involved in the interaction. Besides, it is still beyond our understanding how an 
element promoting cytopathology could benefit NKV flaviviruses that in general establish 
persistent infection in mammalian hosts. Moreover, the identification of insect-specific 
flaviviruses [62-64] has added a novel angle to the analysis of flavivirus host restriction. 
Hopefully the access to full-length clones representing each cluster of flaviviruses will help 
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Mutagenesis and biochemical analysis of the XRN-1 
stalling signal for subgenomic flavivirus (sf)RNA production 




Cells and mice infected with arthropod-borne flaviviruses produce a small subgenomic 
RNA that is co-linear with the viral 3’-untranslated region (3’-UTR). This small subgenomic 
flavivirus RNA (sfRNA) is generated through incomplete degradation of the viral genome 
by the host 5’→3’ exoribonuclease XRN-1, and has been implicated in cytopathogenicity 
and pathogenesis of the virus. A stem-loop structure stabilized by a pseudoknot interaction 
was determined to be essential for sfRNA production in yellow fever virus (YFV) and West 
Nile virus (WNV). Here, we show that a similar RNA structure with an equivalent function 
in the 3’-UTR of other members of the Flavivirus genus could replace that of YFV in stalling 
XRN-1 for the production of sfRNA. Compared to typical H-type pseudoknots, these XRN-1 
stalling signals of mosquito-borne flaviviruses are featured with a side stem-loop structure 
and a short linkage sequence between the stem-loop and the downstream pseudoknotting 
partner. In this study, mutations were introduced within the context of the YFV infectious 
clone so as to change the nucleotides conserved among mosquito-borne flaviviruses or 
to disrupt predicted secondary structures. All mutants constructed in this manner were 
replication competent. The side stem-loop was found to be indispensable for XRN-1 stalling, 
albeit with no sequence specificity. The short linker also contributes to the stability of the 
complex RNA structure that is responsible for XRN-1 stalling. In addition, mutation of the 
conserved nucleotides in the bottom stem (e1) region either diminished sfRNA production, 
or decreased cytopathogenicity of the virus in Vero cells, suggesting their involvement in 
stabilizing the XRN-1-stalling structure and/or in cytopathogenicity. 
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Introduction
The flaviviruses form a genus within the Flaviviridae that comprises more than 80 viruses. 
Phylogenetically, flaviviruses can be grouped into three clusters of related viruses that are 
in general also unified by their route of transmission: (i) mosquito-borne (e.g., West Nile 
virus [WNV] and yellow fever virus [YFV]), (ii) tick-borne, and (iii) no known vector (NKV) 
flaviviruses (such as Modoc virus [MODV]) [1]. In addition to the viruses assigned to the 
above-mentioned clusters within the Flavivirus genus, there is a rapidly expanding group of 
viruses that are currently considered tentative species of the Flavivirus genus. This group 
includes cell fusing agent virus (CFAV), Kamiti River virus (KRV) and Culex flavivirus (CxFV) 
that have all been exclusively isolated from mosquitoes or insect cell lines [2-4]. There is no 
evidence that these viruses are able to infect a vertebrate host and therefore they are often 
referred to as insect-specific flaviviruses. 
 Flaviviruses are small enveloped viruses with a positive-sense single-stranded RNA 
genome of approximately 11 kb in length, which is 5’ capped, yet not polyadenylated at its 
3’ terminus. The RNA encodes a single polyprotein of approximately 3500 amino acids that 
is co- and post-translationally processed by viral and cellular proteases into three structural 
proteins (C, prM, and E) and seven nonstructural proteins (NSs). This single ORF is flanked 
by 5’- and 3’-untranslated regions (UTRs) (reviewed in [5]). 
 The flavivirus 3’-UTR comprises a variable region (VR) that is located proximal to 
the translation termination codon and is characterized by low sequence similarity and the 
presence of the distal ‘core element’, which contains conserved RNA elements essential 
for viral translation, replication, pathogenesis and possibly assembly [6-13]. Based on its 
position within the genome, sequence/structure similarity, as well as functional implications, 
the core element of mosquito-borne flavivirus can be divided into three domains: 1) the 
‘promoter’ region that is indispensable for genome replication and includes the 3’ stem-loop 
structure (3’SL) and conserved sequence 1 (CS1); 2) an enhancer region that is nonessential 
for replication yet enhances RNA synthesis and/or translation efficiency, consisting of the 
CS2 (conserved sequence 2) containing dumb-bell like structure and its duplicate(s) in the 
case of some mosquito-borne flaviviruses; 3) the XRN-1 stalling structure that is required for 
subgenomic flavivirus (sf)RNA production. 
 The sfRNAs were initially detected in mice infected with Murray Valley encephalitis 
virus (MVEV) [14] and were characterized in cell culture using Japanese encephalitis virus 
[15]. Recently, Pijlman et al. demonstrated that the production of these sfRNAs relies on 
the host enzyme XRN-1 and that their production is an important determinant for viral 
cytopathogenicity and pathogenesis [16]. Recent studies demonstrated that irrespective of 
their host species and route of transmission, all flaviviruses including the tentative members 
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of the genus, produce one or two sfRNAs [14-20]. They vary from 0.3 kb to 0.5 kb, which 
correlates with the length of the core element of the viral 3’-UTR. Biochemical assays with 
purified yeast XRN-1 as well as specific knockdown experiments confirmed that sfRNAs are 
produced through incomplete degradation of the viral genomic RNA by the highly processive 
5’→3’ exoribonuclease XRN-1, a cellular enzyme that plays a key role in P-body associated 
RNA degradation [16;19;20]. 
 Based on the combined outcome of primer extension analysis on viral RNA from 
infected cells, comparative computer-aided RNA folding, RNA structure probing, site-
directed mutagenesis of infectious cDNA clones and in vitro XRN-1 assays, it was predicted 
that the XRN-1 stalling site in the genome of mosquito-borne flaviviruses would fold into 
a unique RNA pseudoknot structure. Although this structure is reminiscent of an H-type 
RNA pseudoknot, it differs in that it is characterized by a structurally conserved side stem-
loop (Fig. 1) and a relatively short linker sequence [16;18;19]. Apart from the generally well 
conserved RNA structural elements of the XRN-1 stalling site, Pijlman et al. also identified 
several nucleotides that appear to be conserved within the XRN-1 stalling sequence of 




















































































































































































































Fig. 1 Model for the YFV, WNV and MODV XRN-1 stalling signals
Nucleotides 10,531-10,629 of the YFV-17D genomic sequence were predicted to form complex stem-loop structures 
that are responsible for the stalling of XRN-1, and thus the production of YFV sfRNA. The predicted secondary 
structure is represented here: the bottom stem is named e1, the upper stem e2, and the side hairpin e3. The loop 
sequence GCUGU (pk3’, highlighted in grey) within the stem-loop e2 was predicted to interact with downstream 
nucleotides ACAGC (pk3, highlighted in grey), shown with a connecting line, forming a pseudoknot structure 
(PSK). Nucleotides within this region that were found to be conserved among the mosquito-borne flaviviruses are 
highlighted in red. The two conserved nucleotides (A-10540 and C-10593), which were mutated as described in 
the text, are highlighted in yellow. The position where stretches of A and U were inserted to construct the linker 
insertion mutants are indicated with a green arrow. 
XRN-1 stalling signal from WNV-NY99 (nt10,501-10,581) and MODV (nt 10,252-10,343) that were used to 
replace that of YFV in the SLE chimeras are shown here, with sequences involved in pseudoknot interaction (PSK) 
highlighted in grey and labeled as pk’ and pk. Nucleotides within WNV-NY99 XRN-1 stalling signal that were found 
to be conserved among the mosquito-borne flaviviruses are highlighted in red, and the side stem-loop structure 
that was used to replace e3 of YFV in the FLYF-e3WNV mutant is highlighted in blue.
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mosquito-borne flaviviruses (Fig.1). For YFV-17D, it was shown that a sequence of ~80 
nucleotides comprising the stem-loop structure SLE as well as the downstream nucleotides 
complementary to the bulge in SLE was sufficient to function as XRN-1 stalling signal in an 
heterologous expression system [19]. Similar RNA structures, although slightly different in 
some details, were also predicted to be XRN-1 stalling sites of NKV flaviviruses and insect-
specific flaviviruses [20]. 
 In this chapter, we report the results of a more detailed mutagenesis study of the YFV-
17D XRN-1 stalling site, which aimed to investigate the importance of the unique structural 
features and conserved nucleotides of this particular RNA pseudoknot in sfRNA production 
and its contribution to cytopathogenicity. 
Materials and Methods
Cell culture
The origin and culture conditions of the BHK-21J and Vero E6 cells used in this study have 
been described before [21]. 
Recombinant DNA techniques and plasmid construction
Unless described in more detail, general standard nucleic acid methodologies were used 
throughout this study [22]. Competent Escherichia coli DH5α were used for cloning [23]. 
The nucleotide numbering of constructs containing YFV-derived inserts and the resulting 
full-length clones was based on the published YFV-17D sequence [24] (GenBank accession 
no. X03700).
 The shuttle plasmid pBsk-YFV9845-10861 [19] that contained the complete YFV-17D 3’ 
UTR was used as a template for site-directed mutagenesis using the QuickChange strategy 
(Stratagene) for the introduction of mutations into the stem-loop E (SLE) region (nomenclature 
according to [25]). The nucleotide sequence of the SfiI - XbaI fragment encompassing the 
SLE of the mutated pBsk-YFV9845-10861 derivatives was verified by sequencing and cloned into 
pACNR-FLYF17Da [21] to yield full-length YFV-17D cDNA clones with mutations of interest.
In vitro RNA transcription and the production of virus stocks
Plasmid DNA for in vitro RNA transcription was purified using the Nucleobond AX DNA 
isolation kit (Macherey-Nagel). All plasmids were linearized with AflII, and used for in vitro 
transcription, as described previously [26].
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 Stocks of the cDNA-derived viruses were obtained by electroporating BHK-21J cells 
with full-length YFV transcripts [26]. Medium was harvested when cytopathic effect (CPE) 
became visible. Virus titers were determined by plaque assay on BHK-21J cells, as described 
previously [26;27].
Analysis of viral RNA synthesis and sfRNA production
Approximately 1 million BHK-21J cells were seeded in a 10-cm2 plate and were subsequently 
infected with either the parental YFV-17D or mutant viruses at m.o.i. 5. 3[H]-uridine labeling 
was performed in the presence of actinomycin D at 24-30 hpi as described previously [21]. 
Total 3[H]-uridine labeled RNA was isolated using Tripure (Roche), denatured with glyoxal 
and analyzed on 0.8% agarose gels [22].
 YFV sfRNA production was analyzed using non-radioactive RNA that was obtained 
as described above and used for Northern blotting followed by hybridization as reported 
previously [19]. 
Immunostaining of viral infectious centers on Vero cells 
Vero cells were seeded in 10-cm2 plates and were infected in duplicate with an amount of 
virus that was expected to yield a countable number of individual, non-overlapping foci 
using a similar procedure as for a standard plaque assay. After the regular 4-day incubation 
at 37°C with 5% CO2, the Avicel overlay was removed and the cells were fixed with 3.5% 
formaldehyde for 20 minutes. One of the duplicates was stained with crystal violet to 
monitor plaque formation, whereas the other plate was used for immunostaining of YFV 
plaques or infectious centers using a monoclonal antibody directed to NS5 [28] as described 
previously for Modoc virus [29]. 
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Results
The YFV XRN-1 stalling signal can be replaced by XRN-1 stalling sequences of other flaviviruses 
without dramatically affecting sfRNA production and viral cytopathic effect on Vero cells.  
 Given the observation that all members of the Flavivirus genus produce an sfRNA in 
infected cells, we were curious to find out whether the YFV XRN-1 stalling signal could be 
exchanged by the stalling sequence of another flavivirus without affecting sfRNA production 
and plaque phenotype of the chimeric YFV. Two recombinant viruses were constructed in 
which the YFV SLE region (nt 10,531-10,629) was replaced by a functionally comparable 
sequence of WNV (nt 10,501-10,581) [18] or MODV (nt 10,252-10,343) [30], respectively 
(Fig. 1). Virus stocks of these recombinant viruses were obtained by harvesting the media 
from BHK-21J cells that had been transfected with in vitro transcribed RNA derived from 
pACNR-YFV-SLE-WNV or pACNR-YFV-SLE-MODV. These viruses were subsequently used to 
infect cells to monitor viral RNA synthesis and sfRNA production. Northern blot hybridization 
analysis of the RNA from cells infected with these viruses, using oligonucleotide YFV1632 
as a probe, revealed they all produced two sfRNAs (Fig. 2A and 2B). The size variation of 
these sfRNAs correlated with the size differences between either the WNV- or the MODV-
derived insert that had been used to replace the YFV XRN-1 stalling signal. Primer extension 
was used to to determine the 5’ end of the sfRNAs produced by the recombinant viruses 
and revealed that XRN-1 was stalled at exactly the same nucleotide as in WNV and MODV, 
respectively [18;20] (data not shown). Plaque assays with these recombinant viruses on 
Vero cells were used to obtain an indication as to whether the sfRNAs produced by these 
viruses were serving a similar function in promoting cytopathogenicity as the authentic 
YFV-17D sfRNA. As illustrated in Fig. 2C, YFV-SLE-MODV was able to form plaques on Vero 
cells, whereas YFV-17D-ΔSLE, which does not produce any sfRNA [19], was not able to form 
plaques on Vero cells, despite the fact that this virus was forming infectious foci on Vero 
cells. Taken together, these results clearly demonstrated that the XRN-1 stalling signal from 
another flavivirus could substitute for that of YFV-17D without impairing virus replication 
and dissemination. Moreover, the chimeric viruses still maintained the ability to produce 
sfRNA and to induce cytopathic effect on Vero cells.  
Duplex formation of the bottom stem e1 is not sufficient for sfRNA 
production. 
Previous mutagenesis studies on the e2 region of the SLE [19] revealed that base-pairing 
of the top stem within the YFV XRN-1 stalling site was more important than the nucleotide 
sequence per se [19]. To gain a better understanding of the RNA structure requirements 
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Fig. 2 Analysis of SLE-chimeric mutants
A)  Analysis of sfRNA production. BHK cells were infected with viruses (M.O.I. 5) derived from the wildtype pACNR-
FLYF (lane 1), pACNR-YFV-WNV-SLE (lane 2) or were mock infected (lane 3). Intracellular RNA was isolated from 
infected cells at 30 hpi and was analyzed by Northern blot hybridization as described in the Materials and 
Methods section.
B)  Analysis of sfRNA production. BHK cells were infected with viruses (M.O.I. 5) derived from the wildtype pACNR-
FLYF (lane 2), pACNR-YFV-MODV-SLE (lane 3) or were mock infected (lane 1). Intracellular RNA was isolated from 
infected cells at 30hpi and analyzed by Northern blot hybridization as described in the Materials and Methods 
section.
C)  Morphology of plaques (upper panel) and foci (lower panel) produced by viruses derived from the wildtype 
pACNR-FLYF (left panels), pACNR-YFV-SLE-MODV (middle panels) and pACNR-FLYF-ΔSLE (right panels), which 
were analyzed with standard plaque assay and immunostaining methods on Vero cells as described in the 
Materials and Methods section. 
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in this study. Three YFV-17D mutants were created.  In mutant YFV-DD, the bottom four 
nucleotides of the 5’ arm of e1 (5’-UCAG-3’) were replaced by a complementary sequence 
(5’-CUGG-3’), whereas in YFV-CC, 3’ arm of the stem (5’-CUGG-3’) was replaced by its 
complement (5’-UCAG-3’). In both mutants, the base-pairing of the e1 stem region of the 
SLE was predicted to be disrupted. In the third mutant, the 5’- (5’-UCAG-3’) and 3’- (5’-
CUGG-3’) arms were swapped to create YFV-DC, in which the RNA secondary structure of 
the e1 region was expected to be restored. 3[H]-uridine labeling of BHK-21J cells infected 
with either wt YFV-17D or the CC, DD or DC mutants revealed that all three YFV-17D mutants 
replicated with similar efficiency as the parental virus (Fig. 3A). Northern blot analysis of YFV 
sfRNA production by these mutants revealed that, as hypothesized, neither YFV-CC nor YFV-
DD produced detectable amounts of sfRNA (Fig. 3B). Surprisingly, mutant YFV-DC, in which 
the potential to form an SLE-e1-like stem was expected to be restored also failed to produce 
any sfRNA (Fig. 3B). Although the results presented above did not rule out the importance 
of base-pairing in the SLE-e1 stem, they clearly indicated that there are additional RNA 
sequence and/or structure requirements in this region for XRN-1 stalling.    
Nucleotides in stem e1 conserved within mosquito-borne flaviviruses are 
important for sfRNA formation.
The above findings led to the hypothesis that apart from the conserved duplex formation 
of the e1 stem, the actual nucleotide sequence in the e1 region of the SLE also contributes 
to XRN-1 stalling.  As highlighted in Fig. 1, several nucleotides that make up the SLE-e1 in 
mosquito-borne flaviviruses appear to be conserved, suggesting that they may play a role 
in efficient XRN-1 stalling. Point mutations including all three alternative nucleotides were 
therefore introduced at position A-10540 and C-10593. Based on the predicted structure 
for SLE-e1, an A-10540 to C or U mutation would introduce a bulge in the stem, whereas 
the A to G mutation would replace the original A-U base pair by a non-Watson-Crick G-U 
base pair. Likewise, C-10593 was mutated to an A, G or U, respectively. Except for the C to 
U mutation that would have the potential to maintain base-pairing, the other substitutions 
(C to A or G) were expected to disrupt the base-pairing in SLE-e1. Virus stocks of all these 
mutants were used to determine the replication efficiency by 3[H]-uridine RNA labeling and 
to analyze sfRNA production by Northern blot hybridization. As shown in Fig. 4A, all A-10540 
mutants replicated with similar efficiencies as the parental YFV-17D.  Surprisingly, Northern 
blot analysis of these mutants revealed that both the A→C and A→G mutants were able to 
produce sfRNA, albeit with lower efficiency compared to the wildtype virus, irrespective of 
whether base-pairing at this particular position was maintained. The A→U mutant did not 
yield sfRNA, revealing a yet-to-be-defined requirement for this specific position that must 
be unrelated to base-pairing. The C to A, U, G substitutions at position 10593 had no effect 
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Fig. 3 Analysis of SLE-e1 stem mutants
A)  Analysis of viral RNA synthesis. BHK-21J cells were infected with viruses (M.O.I. 5) derived from pACNR-FLYF 
(lane 1), pACNR-FLYF-CC (lane 3), pACNR-FLYF-DD (lane 4), pACNR-FLYF-DC (lane 5), or were mock infected (lane 
2). Intracellular RNA was isolated and analyzed by 3[H]-RNA labeling as described in the Materials and Methods 
section. 
B)  Analysis of sfRNA production. BHK cells were infected with viruses (M.O.I. 5) derived from the wildtype pACNR-
FLYF (lane 1), pACNR-FLYF-CC (lane 3), pACNR-FLYF-DD (lane 4), pACNR-FLYF-DC (lane 5), or were mock infected 
(lane 2). Intracellular RNA was isolated and was analyzed by Northern blot hybridization, as described in the 
Materials and Methods section. 
C)  Morphology of plaques (upper panel) and foci (lower panel) produced by viruses derived from the wildtype 
pACNR-FLYF (column 1), pACNR-FLYF-DD (column 2), pACNR-FLYF-CC (column 3), and pACNR-FLYF-DC (column 
4) were analyzed with standard plaque assay and immunostaining methods on Vero cells as described in the 
Materials and Methods section.  
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Fig. 4 Analysis of SLE-e1 conserved nucleotide mutants
A)  Analysis of viral RNA synthesis. BHK-21J cells were infected with viruses (M.O.I. 5) derived from pACNR-FLYF 
(lane 1), pACNR-FLYF-A10540C (lane 3), pACNR-FLYF-A10540G (lane 4), pACNR-FLYF-A10540T (lane 5), pACNR-
FLYF-C10593A (lane 6), pACNR-FLYF-C10593G (lane 7), pACNR-FLYF-C10593T (lane 8), or were mock infected 
(lane 2). Intracellular RNA was isolated and analyzed by 3[H]-RNA labeling as described in the Materials and 
Methods section.  
B)  Analysis of sfRNA production. BHK cells were infected with viruses (M.O.I. 5) derived from the wildtype pACNR-
FLYF (lane 1), pACNR-FLYF-A10540C (lane 3), pACNR-FLYF-A10540G (lane 4), pACNR-FLYF-A10540T (lane 5), 
pACNR-FLYF-C10593A (lane 6), pACNR-FLYF-C10593G (lane 7), pACNR-FLYF-C10593T (lane 8), or were mock 
infected (lane 2), and the production of sfRNA was analyzed by Northern blot hybridization, as described in the 
Materials and Methods section.
C)  Morphology of plaques (upper panel) and foci (lower panel) produced by viruses derived from the wildtype 
pACNR-FLYF (column 1), pACNR-FLYF-A10540C (column 2), pACNR-FLYF-A10540G (column 3), pACNR-FLYF-
A10540T (column 4), pACNR-FLYF-C10593A (column 5), pACNR-FLYF-C10593G (column 6), pACNR-FLYF-
C10593T (column 7) were analyzed with standard plaque assay and immunostaining methods on Vero cells as 
described in the Materials and Methods section. 
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on the YFV-17D replication efficiency either (Fig. 4A). However, no YFV sfRNA production 
was detected for the C→A or C→G mutants. On the contrary, sfRNA was produced in cells 
infected with the C→U mutant, in which the original G-C base pair had been replaced with 
a G-U base pair (Fig. 4B), suggesting that base-pairing of this particular residue is required 
for sfRNA production. Despite clearly detectable sfRNA production for mutants A→C, 
A→G, C→U, none of them was able to form plaques on Vero cells, and the size of their foci 
appeared to correlate with the amount of sfRNA produced (Fig. 4C). Mutant A10540G that 
produced most abundant sfRNA also yielded the biggest foci, whereas the A→U, C→A, C→G 
mutants that failed to produce sfRNA made the smallest foci on Vero cells (Fig. 4C).   
The side stem-loop structure e3 rather than the nucleotide sequence is 
essential for sfRNA production. 
Most if not all XRN-1 stalling sites that have been identified in flaviviruses are characterized 
by a small side hairpin that branches from the 5’ strand of the major hairpin [16;19;20] 
(Fig.1). This structure is referred to as SLE-e3 [25] in YFV and is quite variable in sequence 
among the different flaviviruses. Two YFV-17D mutants were created to study the role of 
SLE-e3 in stalling XRN-1. In YFV-∆SLE-e3 this side loop was deleted whereas in YFV-SLE-
e3WNV the YFV sequence of e3 was replaced by the equivalent structure in SL-II [18] of 
WNV, which shares little sequence similarity with that of YFV (Fig. 1). BHK-21J cells were 
infected with parental YFV-17D in parallel with these two mutant viruses. Virus replication 
efficiency was studied by 3[H]-uridine labeling of viral RNA. As expected, both YFV-∆SLE-e3 
and YFV-SLE-e3WNV were replication competent (Fig. 5A), although viral RNA synthesis 
was clearly less efficient in YFV-∆SLE-e3 compared to YFV-17D or YFV-SLE-e3WNV infected 
cells. The effect of deleting SLE-e3 or substituting it by the comparable WNV RNA structure 
on sfRNA production was analyzed by Northern blotting. As illustrated in Fig. 5B, no YFV 
sfRNA was detected in cells infected with YFV-ΔSLE-e3, whereas YFV-SLE-e3WNV produced 
quantities of sfRNA comparable with those generated by the wildtype virus. These results 
clearly demonstrated that this relatively small hairpin structure in the 5’ part of the XRN-1 
stalling signal is absolutely required for sfRNA synthesis. YFV-SLE-e3WNV formed plaques 
with a similar size as those of YFV-17D on Vero cells upon crystal violet staining, whereas no 
plaques were observed for YFV-ΔSLE-e3 under the same conditions (Fig. 5C). The results of 
the infectious center assay on Vero cells for YFV-17D and these two mutant viruses revealed 
that YFV-SLE-e3WNV formed similar foci as the wt virus and the tiny foci produced by YFV-
ΔSLE-e3 may be accounted for by a combined effect of the slower rate of RNA synthesis and 
a deficiency in sfRNA production of this particular mutant (Fig.5C). 
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Fig. 5 Analysis of SLE-e3 mutants
A)  Analysis of viral RNA synthesis. BHK-21J cells were infected with viruses (M.O.I. 5) derived from pACNR-FLYF 
(lane 2), pACNR-FLYF-ΔSLEe3 (lane 3), pACNR-FLYF- e3 WNV (lane 4), or were mock infected (lane 1), and viral 
RNA synthesis was analyzed by 3[H]-RNA labeling as described in the Materials and Methods section.  
B)  Analysis of sfRNA production. BHK cells were infected with viruses (M.O.I. 5) derived from the wildtype pACNR-
FLYF (lane 2), pACNR-FLYF-ΔSLEe3 (lane 3), pACNR-FLYF- e3 WNV (lane 4), or were mock infected (lane 1). 
Intracellular RNA was isolated and analyzed by Northern blot hybridization, as described in the Materials and 
Methods section. 
C)  Morphology of plaques (upper panel) and foci (lower panel) produced by of viruses derived from the wildtype 
pACNR-FLYF (column 1), pACNR-FLYF-ΔSLEe3 (column 2), and pACNR-FLYF- e3 WNV (column 3), were analyzed 




Extending the linker between S1 and L3 negatively affects sfRNA 
production.
Compared to the typical H-type pseudoknot, in which L1 spans S2 and crosses the major 
groove of the helix and L3 spans S1 and crosses the minor groove [31], the number of 
nucleotides between the YFV SLE equivalent in mosquito-borne flaviviruses and the 
downstream nucleotides that were predicted to be involved in the RNA pseudoknot 
interaction is relatively short. In fact, in the case of YFV, it was predicted to comprise only 
one nucleotide (a “G” residue), whereas in WNV the linker comprises two nucleotides 
(Fig.1). Although theoretically possible, it was hard to envision how such a short stretch 
of nucleotide(s) could cross the minor groove and contribute to the stability of the overall 
structure of the XRN-1 stalling site in mosquito-borne flaviviruses. It is also noteworthy 
that the comparable L3 region for the predicted XRN-1 stalling site of the NKV- and insect 
flaviviruses is significantly longer. This resulted in the hypothesis that optimizing the length 
of L3 might increase the stability of the predicted XRN-1 stalling structure, and thus the 
production of more sfRNA. To verify this hypothesis, five YFV-17D mutants were created in 
which the L3 linker sequence was extended by one, two, three, four, or six nucleotides. The 
inserted nucleotides consisted of “A” and “U” residues to minimize the possibility that these 
insertion would induce the formation of an alternative RNA structure that could interfere 
with the XRN-1 stalling properties of SLE. Insertion of these nucleotides had no effect on the 
overall rate of viral RNA synthesis of these particular mutants (Fig. 6A). However, contrary 
to our expectations, increasing the length of L3 had a negative effect on the quantity of YFV 
sfRNA that was produced. The insertion of a single nucleotide already diminished sfRNA 
production and extending the length of the insertion quickly led to the abolishment of 
sfRNA synthesis (Fig. 6B) and yielded viruses that were no longer capable of forming plaques 
on Vero cells (Fig. 6C). From these experiments, it can be concluded that extension of the 
predicted L3 RNA element of the YFV XRN-1 stalling RNA pseudoknot negatively affected 
XRN-1 stalling of this RNA structure.
119
RNA stRuctuRAl feAtuRes foR sfRNA pRoductioN
 1     2     3     4     5     6     7





 1     2     3     4     5     6     7





Fig. 6 Analysis of linker insertion mutants
A)  Analysis of viral RNA synthesis. BHK-21J cells were infected with viruses (M.O.I. 5) derived from pACNR-FLYF 
(lane 1), pACNR-FLYF-A (lane 3), pACNR-FLYF-AT (lane 4), pACNR-FLYF-AAT (lane 5), pACNR-FLYF-ATAT (lane 6), 
pACNR-FLYF-ATTAAT (lane 7), or were mock infected (lane 2). Intracellular RNA was isolated and analyzed by 
3[H]-RNA labeling as described in the Materials and Methods section. 
B)  Analysis of sfRNA production. BHK cells were infected with viruses (M.O.I. 5) derived from wildtype pACNR-FLYF 
(lane 1), pACNR-FLYF-A (lane 3), pACNR-FLYF-AT (lane 4), pACNR-FLYF-AAT (lane 5), pACNR-FLYF-ATAT (lane 6), 
pACNR-FLYF-ATTAAT (lane 7), or were mock infected (lane 2). Intracellular RNA was isolated and analyzed by 
Northern blot hybridization, as described in the Materials and Methods section.  
C)  Morphology of plaques (upper panel) and foci (lower panel) produced by viruses derived from the wildtype 
pACNR-FLYF (left panels), pACNR-FLYF-A (middle panels) and pACNR-FLYF-AAT (right panels) were analyzed with 




Subgenomic RNA production is a defined feature for some +ssRNA families, such as 
coronaviruses and togaviruses, while for flaviviruses it has long been accepted that plus-
strand genomic RNA, minus-strand RNA and replication-related replicative-form and 
intermediate RNAs are the only virus-derived RNA species present in infected cells. This 
notion was recently challenged by the identification of an additional non-coding subgenomic 
flavivirus RNA species (sfRNA) that is co-linear with the viral 3’-UTR [14-17;20]. Different from 
the corona- or togaviruses, for which subgenomic mRNA is generated during transcription 
by the viral RNA dependent RNA polymerase, flaviviruses appear to adopt a novel post-
transcriptional mechanism for sfRNA production, i.e., by the use of the host enzyme XRN-1 
[16;19].  
 XRN-1 is the main cellular exoribonuclease involved in 5’ → 3’ mRNA degradation 
in eukaryotes. It is a well conserved, highly processive enzyme that has been reported to 
be slowed down or stalled in vitro by some artificial high-ordered RNA structures, such 
as oligo(G) tracts and stable stem-loop structures near the 5’ end of an RNA [32]. A long 
stem structure with four Gs buried at the bottom was demonstrated to protect the 20S 
RNA Narnavirus genome from XRN-1 degradation [33]. For the production of sfRNA, XRN-1 
was proposed to be stalled upstream of a stem-loop structure stabilized by a pseudoknot 
interaction that is formed at the 5’ border of the flavivirus 3’-UTR core element, designated 
as SLE in YFV [19;25] and SLII in WNV [16;18]. Sequence comparison and computer-aided 
structure prediction revealed the presence of comparable RNA pseudoknot structures in the 
3’-UTR of all other members of the Flavivirus genus. In fact, these structures were shown 
to be able to stall XRN-1 both in vitro and in vivo resulting in the production of sfRNA in all 
flaviviruses [20;34]. 
 A pseudoknot is an RNA structure minimally composed of two helical segments 
connected by single-stranded regions or loops [35]. The best characterized type of 
pseudoknot is the hairpin type (H-type) pseudoknot, which has two base-paired stem regions 
(designated as S1 and S2) and, depending on the number of loop bases that participate 
in the pseudoknotting interaction, two or three single-stranded loops (L1, L2 and L3). The 
base-paired stems (i.e., S1 and S2) stack coaxially to form a quasi-continuous helix, and L1 
spans S2 and crosses the deep groove of the helix, whereas L3 spans S1 and crosses the 
shallow groove [31]. For the YFV XRN-1 stalling signal, the whole SLE could be considered 
as S1 that however is longer and different from a typical H-type pseudoknot S1, because it 
actually comprises two stems (designated as e1 and e2  [25], Fig. 1) that are separated by a 
side hairpin structure (e3). Compared to a typical H-type pseudoknot, the crossing sequence 
linking the two stems (L3) in the mosquito-borne flaviviruses is rather short, so it is hard 
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to imagine how such a short L3 (only one nucleotide in the case of YFV) would be able to 
manage that crossover, and more generally how these stems (e1, e2, e3 and S2 formed by 
pseudoknot interaction) are oriented in space.  
 Apart from this well conserved RNA pseudoknot structure, several apparently 
conserved nucleotides were identified in the bottom stem (e1) of the XRN-1 stalling site in 
mosquito-borne flaviviruses [16]. The special structural features of this type of pseudoknot 
probably determines its special function as a roadblock for the proceeding XRN-1, since no 
other pseudoknot structures tested thus far are able to fulfill the same function (unpublished 
data).  
 The objective of this study was to expand our knowledge on the critical RNA 
sequence/structure features that render SLE an efficient XRN-1 stalling site.  Mutations were 
introduced to alter the characteristic RNA structures and several, apparently conserved 
nucleotides of the typical XRN-1 stalling site for mosquito-borne flaviviruses as represented 
by YFV-17D.  The mutant viruses were compared to the parental virus in various aspects of 
viral life cycle, such as RNA synthesis efficiency, sfRNA production and cytopathogenicity. 
 Similar to what was previously described for the top-stem e2 of SLE [19], the side 
hairpin structure e3 is required for XRN-1 stalling, albeit with no sequence specificity, as the 
equivalent side stem-loop of WNV XRN-1 stalling structure (SL-II) that bears little sequence 
similarity to e3 could replace e3 without affecting viral genomic RNA synthesis or sfRNA 
production. On the contrary, base-pairing at the bottom stem e1 does not appear to be the 
sole requirement for successful XRN-1 stalling. As expected, YFV mutants in which the base-
pairing within stem e1 was disrupted were unable to produce sfRNA and had an attenuated 
phenotype. Surprisingly, the mutant virus in which base-pairing at e1 was predicted to be 
restored was unable to produce sfRNA, despite the fact that this mutant virus replicated with 
nearly the same efficiency as the parental virus. This finding suggests that in addition to the 
RNA structure, the nucleotide sequence of stem e1 is also of functional importance in stalling 
XRN-1. This is clearly different from what has been reported for YFV SLE stem e2 [19] and 
what was observed for the side stem-loop e3, for which base-pairing appears to be the sole 
determinant for XRN-1 stalling. Identical results were obtained when making comparable 
mutations in the equivalent region of MODV (Royo and Bredenbeek, unpublished results). 
 To determine whether specific nucleotides within stem e1 play essential roles in 
XRN-1 stalling, two nucleotides conserved in the XRN-1 stalling site of mosquito-borne 
flaviviruses were targeted for mutagenesis in the background of YFV-17D. Restoration of the 
base-pairing potential did seem to restore sfRNA formation, since both the A10540G and 
C10593U mutants were able to produce sfRNA, yet the A10540G mutant that was expected 
to introduce a small bulge in e1 was also able to generate sfRNA in infected cells. Strikingly, 
none of these single-nucleotide substitution mutants were able to form plaques on Vero 
cells, irrespective of the amount of sfRNA produced. An interesting finding was that the foci 
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size on Vero cells appeared to be correlated with the amount of sfRNA produced. In fact, 
all sfRNA-null mutants made in this study were consistently less cytopathogenic on Vero 
cells, forming tiny foci and no plaques, and those capable of producing sfRNA yet with lower 
efficiency formed bigger foci. One possible explanation is that cytopathogenic phenotype is 
somehow related to sfRNA quantity; therefore, sfRNA produced by the substitution mutants 
may have been too low to induce CPE and thus plaque formation on Vero cells. Alternatively, 
the changed nucleotides could somehow alter sfRNA conformation, resulting in the loss of 
cytopathogenicity. Notably, this difference in plaque/foci formation was not observed when 
BHK-21J cells were infected. On BHK-21J cells, all of the sfRNA mutants produced plaques, 
with sizes similar to that produced by parental YFV-17D. This cell line specificity could not 
be explained by innate immune evasion, a function proposed for sfRNA [36], since neither 
of these cell lines could produce type I interferon, suggesting sfRNA is involved in other 
interferon-independent pathways that contribute to cell death.
 Although the mutagenesis study underlined the importance of both sequence and 
structure features present in YFV SLE region for sfRNA production and functionality, it 
does not provide us with sufficient information to speculate on the conformation adopted 
by this special pseudoknot structure that stalls the highly processive XRN-1. Hopefully, 
the 3-D structure of this RNA region will be resolved in the near future to direct further 
mutagenesis studies. We have to bear in mind, however, that crystallization with or without 
the presence of viral/host factors could dramatically change RNA conformation. The 3-D 
structure obtained with these methods might not represent the whole picture in infected 
cells, where RNA could dynamically change conformation and interact with other proteins 
or nucleic acid sequences. For example, the conserved nucleotides located in the bottom 
e1 stem could be interacting with other nucleotides, thus stabilizing the higher-order RNA 
structure; alternatively, they could bind proteins (XRN-1, for instance), which either locks 
it at this position or induces a switch in RNA 3-D conformation. In this sense, structure 
probing, especially the recently proposed in vivo probing techniques [37], could present us 
with RNA conformations in a physiologically relevant environment. Instead of exhaustive 
mutagenesis studies, specific mutagenesis studies directed by structural information 
coupled with chemical probing and biochemical analysis would hopefully help solve the 
unanswered questions surrounding the XRN-1 stalling signal and provide more insights into 
sfRNA function.  
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yellow fever virus cytopathogenicity 
by cells expressing subgenomic flavivirus (sf)RNA 




All flaviviruses produce a small, non-coding RNA derived from viral 3’ untranslated region (3’-
UTR) during infection. This RNA is denoted subgenomic flavivirus (sf)RNA, and is produced 
from incomplete degradation of the viral genomic RNA by the host exoribonuclease XRN-1. 
XRN-1 processing was predicted to be stalled by a non-H-type RNA pseudoknot structure 
formed at the 5’ border of the viral 3’-UTR core region. Although the precise function of 
sfRNA remains to be elucidated, sfRNA production correlates with cytopathogenicity and 
pathogenesis during viral infection. In this study, expression plasmids for the production 
of the yellow fever virus (YFV) and West Nile virus (WNV) sfRNAs were constructed and 
were shown to produce sfRNAs that were identical to those derived from viral infection 
both in vitro and in vivo. With the expression plasmids, SW13 cell populations constitutively 
expressing WNV or YFV sfRNA were established and shown to enhance cytopathic effect 
upon infection by wildtype YFV-17D or a mutant virus YFV-17D-BB that was deficient in 
sfRNA production. These cell lines could be used to test other hypothesis regarding sfRNA 
functionality in the presence or absence of viral infection and provide more insight into the 
molecular determinants for cytopathogenicity of flaviviruses. 
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Introduction 
Flaviviruses are small, enveloped viruses with a positive-sense single-stranded RNA genome. 
It has long been held that only three species of virus derived RNA are present in cells infected 
with flavivirus, i.e., positive-sense genomic RNA, negative-sense RNA, and intermediates 
generated during RNA replication (replicative-form RNA). However, this notion has been 
challenged by the recent discovery of another small viral RNA that is co-linear with the 
distal part of the flavivirus 3’ untranslated region (3’-UTR) [1-5]. This RNA was denoted 
subgenomic flavivirus (sf)RNA and has been found to be produced in both mammalian and 
insect cell lines infected with arthropod-borne (arbo), no-known-vector (NKV) and insect-
specific flaviviruses [1-4;6]. The production of sfRNA was proposed to be a hallmark for the 
Flavivirus genus, since this feature has been found to be conserved within members of the 
Flavivirus genus, whereas related viruses belonging to other genera of the Flaviviridae do 
not produce similar RNA species [2;5].
 Unlike subgenomic plus- and/or minus-strand RNAs generated by other plus-
strand RNA viruses like corona- and togaviruses, the sfRNA is not produced by the viral 
RNA-dependent RNA polymerase. It is, in fact, an incomplete degradation product of the 
viral genomic RNA by a host ribonuclease, XRN-1, which is stalled at the 5’ border of the 
3’-UTR core element of the viral genome [2;3;5;7] that contains essential RNA elements 
for virus replication, translation and possibly encapsidation [8]. XRN-1 is well conserved 
among eukaryotes and is a highly processive 5’→3’ exoribonuclease associated with mRNA 
turnover. After shortening of the poly(A) tail and decapping by DCP1 and DCP2, mRNA with 
a 5’ monophosphate becomes susceptible to XRN-1 hydrolysis. All the enzymes involved in 
the 5’→3’ mRNA decay pathway have been shown to localize in mRNA-processing bodies 
(P-bodies) [9]. This rather unexpected involvement of XRN-1 in the flavivirus life cycle has 
been firmly established using in vitro assays with commercially available purified yeast XRN-
1 as well as XRN-1 knockdown experiments in cell culture [2;10]. 
 The actual stalling site for XRN-1 was mapped to a non-H-type RNA pseudoknot 
structure that is predicted to be present in the 3’-UTR of every member of the Flavivirus 
genus that yet has little to no sequence similarity, especially when viruses from different 
clusters are compared [5;11]. This RNA pseudoknot, or the production of sfRNA, is not 
required for viral RNA synthesis, polyprotein translation or virion formation, as sfRNA-null 
mutants in which either this RNA pseudoknot was deleted or mutated still replicated with 
similar efficiency as the wildtype viruses and demonstrated growth kinetics that were at 
most slightly delayed compared to the parental viruses [2;3;7;12]. However, flaviviruses that 
did not produce sfRNA showed a remarkable reduction of cytopathogenicity in cell culture 
[2;12] and pathogenesis in mice [2;7]. The molecular mechanisms behind these observations 
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remain to be uncovered. Several possible functions associated with sfRNA were proposed. 
The sfRNA was proposed to be part of the viral immune evasion strategy, subverting type 
I interferon mediated innate immune response in mammalian hosts [13] and suppressing 
the major antiviral pathway, i.e., RNA interference in insect cells [14]. Besides, sfRNA was 
hypothesized to be a precursor for the production of a microRNA (miRNA) in insect cell lines 
[15]. These suggested sfRNA function, however, do not provide a unifying explanation as to 
why all flaviviruses, irrespective of their host, produce sfRNA. A recent study revealed the 
interaction between sfRNA and a more universal pathway, i.e., sfRNA sequestering XRN-1 of 
the infected cells and thus altering overall gene expression profile [10]. 
 In this chapter, we describe the construction and characterization of cell lines that 
express either the YFV or WNV sfRNA and demonstrate that these cell lines can be used to 
trans-complement the lack of cytopathogenicity of a YFV mutant that does not produce 
sfRNA as well as enhance the cytopathogenicity of wildtype YFV on SW13 cells. 
Materials and methods 
Cell culture 
BHK-21J [16] and SW13 cells were grown at 37°C in 5% CO2 in Dulbecco’s modified Eagle’s 
medium (DMEM; Lonza) supplemented with 8% fetal calf serum (Bodinco BV), 100 U/mL 
penicillin (Lonza), 100 U/mL streptomycin (Lonza) and 5% non-essential amino acids (GE 
Healthcare). HEK293T cells were grown under the same condition, except for the addition 
of L-glutamine (2 mM; Lonza) into culture media. 
Recombinant DNA techniques and plasmid construction 
In general, standard nucleic acid methodologies were used [17]. Competent E. coli DH5α 
was used for cloning [18]. The complete 3’-UTR sequence of YFV-17D and WNV were cloned 
as 3’-trailer downstream of enhanced green fluorescent protein (eGFP) coding sequence in 
the mammalian expression vector pcDNA3. The hepatitis delta virus ribozyme (HDVr) was 
derived from a West Nile virus replicon cDNA and was fused to the last nucleotide of the 
flaviviral 3’-UTR in the pcDNA3 constructs by PCR [19]. As a control, plasmid pcDNA3-eGFP-
YFV3’-UTR-BB was constructed, in which the stem-loop structure in the XRN-1 stalling RNA 
pseudoknot within pcDNA3-eGFP-YFV3’-UTR was disrupted by Quickchange site-directed 
mutagenesis (Strategene). A previous study showed that this mutation incapacitated the 
stalling site and thus disabling the production of sfRNA [3]. The characteristics of the viral 
3’-UTRs that were cloned in the pcDNA3-eGFP-HDVr vector are summarized in Fig. 1B.
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Plasmid transfection and generation of eGFP-flavivirus3’-UTR expressing 
cell populations 
Transfection of DNA into SW13 cells was mediated by polyethylenimine (PEI; Polysciences 
Inc.). Briefly, 13 μg of plasmid DNA was diluted in 150 mM NaCl to a total volume of 430μl. 
Subsequently, 50 μl PEI (1 mg/ml) was added to 380μl of 150 mM NaCl and thoroughly 
mixed with the DNA containing solution. The mixture was incubated for 10 minutes at 
room temperature and was added to ~80% confluent SW13 cells in a 75 cm2 flask. After 
a 24 h incubation of cells with DNA-PEI complexes, culture medium was refreshed. Two 
days post transfection, cells were put under selective pressure by adding 250μg/mL G418 
(Geneticin; GE Healthcare) to the medium of SW13 cells. After two weeks of selection, cells 
were analyzed on a FACSAriaIII machine (BD Biosciences) and the top 10% eGFP expressing 
cells were collected. These cells were maintained in selective media that contained 250 μg/
mL G418. 
 For transient expression experiments, HEK293T cells were used given their favorable 
response to DNA transfection. The cells were grown to 70 - 80% confluency in 3.5 cm2 dishes 
and 1.5 μg of the expression plasmids were transfected using a downscaled version of the 
protocol described above (total volume added for transfection was 110 μl).
In vitro XRN-1 assay 
In vitro XRN-1 assay was performed as described previously [3]. Briefly, pcDNA3-eGFP-YFV3’-
UTR and pcDNA3-eGFP-YFV3’-UTR-BB plasmids were linearized at the unique XhoI site 
downstream of the HDVr and purified by phenol-chloroform extraction. Approximately 1-2 
μg of the linearized DNA was used as template for in vitro RNA transcription using T7-Scribe™ 
RNA IVT Kit (Cell Script). After DNase treatment, RNA was purified by LiCl precipitation. 8 μg 
of RNA was incubated with 1.32 units of tobacco acid pyrophosphatase (TAP; Epicentre) at 
37°C for 2 h to obtain RNA with a 5’ monophosphate. After phenol-chloroform extraction 
and ethanol precipitation, 4 μg of TAP-treated RNA was incubated with 1 Unit of XRN-1 
(Terminator 5’-phosphate-dependent exonuclease; Epicentre) at 30°C for 1.5 h.
 
Northern blot analysis 
Total RNA was isolated from infected or transfected cells using Tripure (Roche). For Northern 
blotting, 10μg of total RNA isolated from either infected or transfected cells or 0.2μg of 
XRN-1 treated in vitro transcribed RNA was denatured with formaldehyde, separated on 
a formaldehyde containing 1.5% agarose gel and blotted onto Hybond-N+ membrane (GE-
Healthcare). RNA was immobilized by baking the membrane at 80°C for 2 - 3 h. The blots 




SW13 cells expressing the YFV-17D or WNV sfRNA were seeded in 6-well clusters. The cells 
were washed once with PBS and inoculated with 100-200 pfu of YFV-17D or YFV-17D-BB 
(titers determined on BHK cells). After 1 h of adsorption at 37°C, the inocula were removed 
and the cells were overlaid with complete DMEM medium containing 1.2% Avicel (FMC 
BioPolymer). Plaques were visualized by crystal violet staining at 4 days post infection. 
Results
Construction of expression plasmids for the production of authentic WNV 
or YFV-17D sfRNA
The basic vector that is used for this study was pcDNA3-eGFP, in which eGFP was inserted 
into pcDNA3.1 (Invitrogen) by using the BamHI and EcoRI sites. The complete WNV 3’-UTR 
and the HDVr sequence were obtained by PCR from the WNV replicon [19] and cloned into 
pcDNA3-eGFP with EcoRI and XhoI sites , resulting in the construction of pcDNA3-eGFP-
WNV3’-UTR. This plasmid was further used to construct similar plasmids containing the 3’-
UTR of other flaviviruses like YFV-17D. Generally, complete flavivirus 3’-UTR fragments were 
produced by PCR using a forward primer that contained an EcoRI adaptor sequence and a 
reverse primer that is complementary to the last ~35 nt of the flavivirus fused to the most 
5’ 35 nt of the HDVr sequence, within which a unique RsrII site was included that was used 
for cloning. The general feature of the expression cassette cloned in pcDNA3.1 vector was 
depicted in Fig. 1A-1. 
 Transfection of these plasmids into mammalian cells was expected to result in the 
transcription of mRNA that is terminated at the transcription termination site present in 
pcDNA3.1 and get polyadenylated (Fig. 1A-2). This “precursor” RNA was expected to be 
cleaved in cis by the HDVr (Fig. 1A-2), resulting in the eGFP mRNA containing a complete 
flavivirus 3’-UTR sequence (Fig. 1A-3). If this RNA would enter the 5’→3’ RNA decay pathway, 
it would be decapped and then hydrolyzed by XRN-1 (Fig. 1A-3) until the enzyme reaches the 
XRN-1 stalling site that is present in the viral 3’-UTR, resulting in the production of authentic 
flavivirus sfRNA (Fig. 1A-4).     
In vitro and in vivo analysis of YFV sfRNA production from pcDNA3-eGFP-
YFV3’-UTR 
To verify that pcDNA3-eGFP-YFV3’-UTR can be used as a template for the production of 
YFV sfRNA, the plasmid was linearized with XhoI and used as the template for in vitro 
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transcription of the eGFP-YFV3’-UTR RNA. Plasmid pcDNA3-eGFP-YFV3’-UTR-BB was used as 
a negative control. RNA transcribed from this plasmid was not expected to produce sfRNA 
due to the disruption of the RNA structure that was required to stall XRN-1. After treatment 
Fig. 1
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Figure 1. Characteristics of the expression plasmids for the production of flavivirus sfRNA 
A)  Schematic representation of sfRNA production from pcDNA3-eGFP-flavivirus3’-UTR plasmids 
 General outline of the cassettes that were cloned in the pcDNA3 vector downstream of the CMV promoter 
(black) that drives RNA polymerase II transcription: eGFP coding sequence (green), YFV-17D or WNV 3’-
UTR sequence (yellow), the hepatitis delta virus ribozyme sequence (HDVr; grey) and the RNA polymerase 
II transcription terminator and polyadenylation sequence (blue). Unique DNA restriction enzyme recognition 
sites used to construct the plasmids are also depicted. 
 Transcription of eGFP mRNA by cellular RNA polymerase II and co-transcriptional cleavage by HDVr
 Ribozyme cleaved, decapped eGFP RNA becomes susceptible to XRN-1 hydrolysis.
 Stalling of XRN-1 at the non-H-type pseudoknot present in the flavivirus 3’-UTR results in the production of 
flavivirus sfRNA.
B)  Information of viral 3’-UTR sequences that were cloned as 3’-trailer downstream of eGFP coding sequence in 
the pcDNA3-eGFP-flavivirus3’UTR plasmids. 
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with TAP, the in vitro transcripts with 5’ monophosphate were incubated with XRN-1 and 
subsequently analyzed by Northern blotting and hybridization using oligonucleotide 1632 
that was complementary to nt 10,690 to 10,708 in the YFV 3’-UTR as a probe. As shown in 
Fig. 2A, two bands were observed in all four lanes of the Northern blot that represented the 
eGFP gene containing RNAs that were not digested by XRN-1 and that either still contained 
the HDVr sequence (eGFP RNA+HDVr) or from which the HDVr sequence and poly(A) tail 
were removed due to the autocatalytic cleavage of the HDVr sequence (eGFP RNA). Upon 
treatment with XRN-1, two faster migrating RNA species representing the YFV sfRNA with or 
without the HDVr and the poly(A) sequence were detected for the transcript containing the 
wildtype YFV-17D 3’-UTR sequence (lane1). In contrast, eGFP-YFV3’UTR-BB transcript from 
pcDNA3-eGFP-YFV3’UTR-BB that was treated in the same manner did not yield detectable 
amounts of sfRNA, despite the production of mRNA (lane 3). Neither sfRNA-related bands 
were detected in samples that were not subjected to XRN-1 treatment (lanes 2 & 4).
 To determine whether transfection of mammalian cells with these expression 
plasmids would result in the production of authentic sfRNA, HEK293T cells were transfected 
with pcDNA3-eGFP-YFV3’-UTR or pcDNA3-eGFP-YFV3’-UTR-BB plasmids. At 48 h post 
transfection, total RNA was isolated from the cells and analyzed for sfRNA production 
by Northern blot hybridization, using oligonucleotide 1632 as a probe. Intracellular RNA 
isolated from HEK293T cells transfected with pcDNA3-eGFP-YFV3’-UTR contained two 
sfRNAs (Fig. 2B, lane 2) that co-migrated with the two sfRNAs produced in BHK-21J cells 
infected with YFV (Fig. 2B, lane 1). No sfRNA was detected in HEK293T cells transfected with 
the mutant plasmid pcDNA3-eGFP-YFV3’-UTR-BB, despite the efficient transcription of the 
mRNA, as indicated by two arrows that represented eGFP mRNA with or without HDVr and 
the poly(A) sequence. Two other less prominent RNA species were consistently observed 
in intracellular RNA isolated from HEK293T cells transfected with the plasmids. The faster 
migrating RNA (labeled as A) could represent the YFV sfRNA to which the HDVr and poly-A 
sequence were still attached due to incomplete cleavage of the precursor RNA by the 
ribozyme. Alternatively, this RNA A could originate from an alternative weak XRN-1 stalling 
site that is upstream of the XRN-1 stalling site in the viral 3’-UTR. A similar explanation could 
be valid for the production of RNA B. 
 Taken together, these in vitro and in vivo data clearly demonstrated that these 
pcDNA3-eGFP-flaviviral3’-UTR plasmids could be used for the production of authentic 
flavivirus sfRNAs. 
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Figure 2. In vitro and in vivo production of sfRNA from pcDNA3-eGFP-YFV3’-UTR and pcDNA3-eGFP-YFV3’-UTR-
BB 
A)  Northern blot using a YFV 3’-UTR specific probe (oligonucleotide YFV1632) on in vitro transcripts of pcDNA3-
eGFP-YFV3’-UTR (lanes 1 and 2) and pcDNA3-eGFP-YFV3’-UTR-BB (lanes 3 and 4). RNA in lanes 2 and 4 was 
treated with tobacco acid pyrophosphatase (TAP), whereas RNA in lanes 1 and 3 was treated with TAP and 
subsequently with purified yeast XRN-1. Bands corresponding to the eGFP RNA with or without HDVr and sfRNA 
with or without HDVr are indicated by arrows. 
B)  Northern blot using oligonucleotide YFV 1632 as a probe on intracellular RNA isolated from HEK293T cells 
that were transfected with pcDNA3-eGFP-YFV3’-UTR (lane 2) or pcDNA3-eGFP-YFV3’-UTR-BB (lane 3). RNA was 
isolated at 48 h post transfection. Intracellular RNA isolated from BHK-21J cells infected with YFV was analyzed 
in parallel and served as sfRNA size marker (lane 1). Bands corresponding to YFV genome, eGFP RNA with or 
without HDVr and sfRNA 1 and 2 are indicated by arrows. Two less prominent bands labeled as A and B are 
discussed in the text. 
136
Chapter 6
Establishment of SW13 cell populations constitutively expressing YFV-17D 
or WNV sfRNA 
After establishing that transcripts derived from pcDNA3-eGFP-YFV3’-UTR were able to 
produce authentic sfRNA both in vitro and in vivo, populations of SW13 cells constitutively 
expressing YFV-17D or WNV sfRNA were established. To achieve this objective, SW13 cells 
were transfected with pcDNA3-eGFP-YFV3’-UTR or pcDNA3-eGFP-WNV3’-UTR, respectively. 
From 48 h post transfection onwards, the cells were grown in selective medium containing 
250 mg/ml G418.  After an additional 14 days of culturing under selective pressure, these 
cell cultures contained mixed populations of eGFP expressing and non-eGFP expressing 
G418-resistant SW13 cells, as was revealed by FACS analysis (Fig. 3A, middle panels) or 
fluorescent imaging (Fig. 3B, upper panel). The top 10% eGFP expressing SW13 cells in both 
cell populations were isolated by FACS to obtain a more homogeneous population of cells 









Figure 3. eGFP expression in G418 resistant SW13 cells transfected with pcDNA3-eGFP-YFV3’-UTR and pcDNA3-
eGFP-WNV3’-UTR plasmids 
A)  FACS analysis of the G418 resistant SW13 cells transfected with pcDNA3-eGFP-YFV3’-UTR (left panels) or 
pcDNA3-eGFP-WNV3’-UTR (right panels) before and after eGFP expression-based cell sorting. The top panel 
shows fluorescence in non-transfected cells.  The percentage gated represents the percentage of cells with 
eGFP expression level higher than that of non-transfected SW13 cells.
B)  G418 resistant SW13 cells obtained after transfection with the pcDNA3-eGFP-WNV3’-UTR plasmid were seeded 
on coverslips before (upper panel) and after cell sorting (lower panel). After fixation with 3.7% formaldehyde, 
cells were stained with Hoechst (blue) and visualized using a fluorescence microscope.
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the largest quantities of sfRNA. As shown in the bottom panels of Fig. 3A, the cell sorting 
resulted in a significant increase both in the percentage of eGFP expressing cells as well as 
in the level of eGFP expression in the sorted cells, which correlated with fluorescent imaging 
results (Fig. 3B).  
Trans-complementation of a YFV-17D sfRNA-null mutant using SW13 cell 
populations constitutively expressing YFV-17D or WNV sfRNA
The established cell populations were subsequently used to trans-complement the YFV-17D-
BB mutant [3] that could not produce YFV sfRNA and was unable to form plaques on SW13 
cells. After expansion of the sorted SW13 cell populations expressing the eGFP-YFV3’-UTR 
or eGFP-WNV3’-UTR, these cells as well as the parental, non-transfected SW13 cells were 
seeded in 10 cm2 plates and infected with approximately 100 to 200 pfu (titers determined 
on BHK cells) of the parental YFV-17D or YFV-17D-BB. After 1 h of adsorption, the inocula 
were removed and Avicel containing overlay was added. Four days later, these plaque 
assays were fixed and stained with crystal violet to visualize plaque formation. As shown 





Figure 4. Plaque morphology of YFV-17D and YFV-17D-BB on SW13 cells that do or do not express flavivirus 
sfRNA 
SW13 cells and G418 resistant SW13 cells expressing YFV or WNV sfRNA were infected with either parental YFV-
17D (upper panels) or YFV-17D-BB that is deficient in sfRNA production (lower panels), and plaque morphology was 
analyzed as described in the Materials and Methods section. 
138
Chapter 6
SW13 cells, however on cells expressing eGFP-YFV3’-UTR mRNA and thus YFV sfRNA, this 
sfRNA-null mutant virus was able to form small but clearly identifiable plaques, suggesting 
that the cytopathic characteristics of YFV-17D on SW13 cells were restored by the trans-
complementation of the YFV sfRNA produced in these cells (Fig. 4). More surprisingly, SW13 
cells expressing the eGFP-WNV3’-UTR mRNA and thus the authentic WNV sfRNA were also 
capable of trans-complementing the lack of cytopathogenicity of the YFV-17D-BB mutant, 
as judged from the obvious plaque formation in the lower right panel of Fig. 4. The validity 
of the observed trans-complementation of the YFV-17D-BB mutant in cells producing either 
YFV or WNV sfRNA was reinforced by the observation that infection of these cells with 
parental YFV-17D (capable of producing sfRNA) resulted in the formation of plaques that 
were much clearer and larger than those formed on the parental SW13 cells, where YFV-
17D infection resulted in not well-defined and turbid plaques (Fig. 4, upper left panel). The 





Figure 5. Kinetics of eGFP expression of G418 resistant SW13 cells transfected with pcDNA3-eGFP-YFV3’-UTR and 
pcDNA3-eGFP-WNV3’-UTR plasmids after continuous passaging
SW13 cells producing YFV or WNV sfRNA were analyzed by flow cytometry directly after cell sorting (upper panels) 
and after two weeks in culture (lower panels). The y-axis representing cell counts is plotted against eGFP expression 
level (x-axis).
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likely originated from higher concentrations of sfRNA that were produced in these eGFP-
flavivirus3’-UTR mRNA expressing cells.      
Decrease of eGFP expression in SW13 cell populations over cultivation
Despite the promising results presented above, the described cell populations were 
apparently under genetic pressure to minimize the expression of the eGFP-flavivirus3’-
UTR RNA and/or the production of sfRNA. As shown in Fig. 5, only a few passages under 
standard culture condition (in the presence of G418) already resulted in the accumulation 
of cells expressing lower levels of eGFP in comparison to the cells directly after sorting, as 
monitored by flow cytometry. These more heterogeneous cell populations in terms of eGFP 
expression and therefore most likely also in the amount of sfRNA produced were no longer 
able to complement the lack of cytopathogenicity of the YFV-BB-mutant (data not shown).  
Discussion 
It is now generally accepted that all flaviviruses produce subgenomic noncoding RNA 
(sfRNA) that results from the stalling of host 5’→3’ exoribonuclease XRN-1 by an RNA 
pseudoknot structure formed at the 5’ border of the distal, more conserved core element of 
the viral 3’-UTR [1-3;5;7;11]. The production of sfRNA in cells infected with mosquito-borne 
and no-known-vector (NKV) flaviviruses is associated with viral cytopathogenicity in cell 
culture [2;5;12] and pathogenesis in mice [2], as was shown with WNV, YFV-17D and Modoc 
virus (MODV) mutants that were deficient in sfRNA production, although the underlying 
mechanism is currently not well understood.  Several other potential functions of sfRNA in 
the virus life cycle have also been suggested. The sfRNA was reported to be involved in viral 
evasion of host immune responses in WNV infected mammalian cells [13] and antagonizing 
RNA interference in both mammalian and insect cells infected with WNV and DENV [14]. 
It has also been hinted that WNV sfRNA might actually function as a precursor for a 
virus-derived miRNA in WNV infected mosquito cells [15] and as an inhibitor of Japanese 
encephalitis virus minus strand RNA synthesis and genome translation [21]. In view of the 
conservation of sfRNA production in the whole Flavivirus genus, it is rather surprising that 
sfRNA appears to play various roles. Perhaps there is a major benefit for flavivirus fitness 
and survival to select in favor of this feature during evolution and host adaptation, and these 
seemingly disparate pathways are somehow intertwined in a yet to be uncovered manner.
 As new tools for further unveiling sfRNA function, this report describes the 
establishment of SW13 cell lines that produce authentic YFV-17D or WNV sfRNA. In order 
to produce sfRNAs identical to those generated during infection, the complete WNV or 
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YFV-17D 3’-UTR sequence was cloned as a 3’-trailer downstream of the recombinant eGFP 
coding sequence that is under the transcriptional control of a cytomegalovirus (CMV) 
early promoter. The autocatalytic hepatitis delta virus ribozyme (HDVr) was introduced to 
achieve authentic, non-polyadenylated 3’ end for YFV or WNV sfRNA. In vitro assays with 
commercially available purified XRN-1 and transfection of HEK293 and SW13 cells with the 
expression plasmids revealed that the XRN-1 stalling site was fully functional and that sfRNA 
was produced from the transcribed recombinant eGFP mRNA. A trans-complementation 
assay was used to evaluate whether these produced sfRNAs were biologically active. The 
ability of a YFV sfRNA-null mutant to form plaques on these cell lines was used as a readout 
for cytopathogenicity. Not only the YFV sfRNA, but surprisingly also the WNV sfRNA were 
both able to complement the lack of cytopathogenicity of the YFV-17D-BB mutant [3] on 
SW13 cells, as judged by the clearly visible plaques formed on the sfRNA expressing cells. The 
involvement of sfRNA in enhancing cytopathogenic effect (CPE) was further corroborated by 
the observation that the parental YFV-17D producing sfRNA [2;3] formed larger and clearer 
plaques on the SW13 cells expressing YFV or WNV sfRNA as compared to those formed on 
original SW13 cells. This enhanced cytopathogenicity of YFV-17D in SW13 cells expressing 
YFV and WNV sfRNA was most likely due to the higher concentrations of sfRNA produced in 
these cells in comparison to the original SW13 cells infected with YFV-17D.
 The fact that WNV sfRNA can trans-complement the cytopathogenicity of YFV-17D 
mutants like YFV-17D-BB seems to indicate that the enhancement of cytopathogenicity 
by sfRNA could be associated with conserved RNA sequences and/or structures, such as 
conserved sequence 1 and 2 (CS1, CS2), or pseudoknot 1 and 2 that are present in the 3’-
UTR core region of the mosquito-borne flaviviruses [22-24], or to a broader extent, RNA 
elements conserved among the whole Flavivirus genus, for example, the 3’ stem-loop (3’ SL) 
[22;23]. It is therefore tempting to construct cell lines harboring sfRNA from other clusters 
of flaviviruses, and to evaluate their ability of cross-cluster complementation. If cross-cluster 
complementation is not possible, RNA elements that are featured in the mosquito-borne 
flaviviruses can be further pinpointed. It was previously reported that dengue virus (DENV) 
and YFV-17D mutants that lacked the CS2 sequence showed similar replication efficiency 
as the wildtype viruses, but were significantly less cytopathogenic [20;25]. To test whether 
it is indeed the CS2 region or other conserved RNA elements that are essential for the 
enhancement of cytopathogenicity, cell lines expressing sfRNA that lack certain sequences 
and/or structures or sfRNA derived from chimeric 3’-UTR that combines conserved RNA 
elements from different clusters will be informative. 
 On the other hand, if cross-complementation is possible between viruses belonging 
to different clusters of flaviviruses, RNA elements conserved among the whole genus might 
be involved in the induction of cytopathic effect by mosquito-borne flavivirus in mammalian 
hosts. Alternatively, the stalling of XRN-1 at the 5’ end of the sfRNA, irrespective of the origin 
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of sfRNA, may actually sequester this ribonuclease. Given the high concentration of sfRNA 
especially during the later stages of infection [1-3;5;21], it is likely that the squelch of XRN-1 
by sfRNA will impose a significant impact on the host 5’→3’ mRNA decay pathway and thus 
disrupt the homeostasis in the cells and, especially in combination with an ongoing infection, 
induce CPE. In fact, a recent publication by Moon et al. demonstrated that XRN-1 was indeed 
sequestered by WNV and DENV sfRNA in mammalian cells, resulting in significant changes 
in the mRNA transcription profile due to the alteration of mRNAs stability [10]. To further 
corroborate the causal relationship between XRN-1 suppression and cytopathogenicity, 
cells expressing XRN-1 stalling sites from other flaviviruses or even strong XRN-1 stalling 
sites from other origins [26;27] would be of great value. 
 The affected mRNA turnover pathway, and therefore the disruption of cell homeostasis 
also provides an explanation as to why the SW13 cells that continuously expressed the eGFP 
mRNA and thus the XRN-1 suppressing sfRNA were relatively unstable and showed a reduced 
level of eGFP expression and sfRNA production upon repeated passaging. To counteract the 
negative effect from altered expression profile, it is likely that cells, especially those that 
produced high concentrations of sfRNA, were actively down-regulating the expression of the 
flaviviral 3’-UTR containing eGFP mRNA via genetic (for instance by deleting part of the viral 
3’-UTR while keeping the G418 resistance gene) or epigenetic (such as by methylation of the 
CMV promoter) means; or the high expressors were gradually lost from the population due 
to apoptosis. Irrespective of the cause, the accumulation of lower expressors unfortunately 
minimizes the experimental window for these cells and restricts the use of this sfRNA 
producing cell line approach. Ideally, inducible cell lines are better suited for this type of 
study, in that transcription would be shut off during routine passage, while GFP and thus 
sfRNA expression could be turned on for the study of sfRNA functionality.  
 In summary, cells expressing authentic sfRNA could serve as powerful tools for a 
better understanding of sfRNA function. Combined with biochemical analysis and other 
approaches, it will hopefully help elucidate how this RNA species contributes to viral fitness, 
and point out alternative strategies for vaccine and/or medication development for the 
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In spite of the increasing incidence of non-communicable diseases, infectious diseases 
remain among the leading causes of human mortality and morbidity, accounting for more 
than 20% of the 57 million deaths worldwide in 2008 [1]. Contrary to predictions in the 
early 1960’s [2], our battle with infectious agents is far from reaching an end. With the old 
foes and newly emerging nuisances, it is just more realistic to accept the ever-continuing 
struggle with pathogens as a perpetual war. Among the emerging and reemerging infectious 
diseases, those caused by arthropod-borne viruses (arboviruses) display unique features, 
making them difficult to tackle. These viruses establish persistent infection in invertebrate 
vectors (e.g., mosquitoes, ticks, midges, sandflies), and can be transmitted to vertebrate 
hosts (humans, other mammals and birds) under favorable conditions [3;4]. Except for 
African swine fever virus, all arboviruses that infect vertebrates are RNA viruses [5], which 
is probably explained by the greater genetic plasticity and higher mutation rates exhibited 
by RNA viruses, which likely facilitate alternating replication in vertebrate and invertebrate 
hosts. Notorious arboviruses include members of the Bunyaviridae such as Rift Valley 
fever virus and Crimean-Congo hemorrhagic fever virus, as well as West Nile virus (WNV), 
Japanese encephalitis virus (JEV) and Dengue virus (DENV), which all belong to the Flavivirus 
genus within the Flaviviridae. 
 In order to curb the spread of diseases caused by arboviruses, a comprehensive 
understanding of the molecular characteristics of their replication, virus-host interactions 
and host adaptation is of great value. Compared to our understanding of DNA viruses, 
however, our knowledge of the molecular biology and biochemistry of RNA viruses was 
lagging behind in the early days, since most of the molecular biology techniques aimed at 
modifying nucleic acids available were directed at DNA substrates. The development of the 
so called “infectious cDNA clone technology”, however, greatly spurred RNA virus research, 
especially that of plus-strand RNA viruses. For these viruses, the genomic RNA not only 
serves as the genetic material, it is also directly translated into viral proteins. Therefore, 
the introduction of a plus-strand RNA virus genome into a cell can initiate the complete 
viral life cycle and result in the production of progeny virions that can start the next round 
of infection. Based on this principle, the infectious clone technology was developed and 
became widely used for RNA viruses like picornaviruses [6-15] and alphaviruses [16-19], 
yet this approach turned out to be more challenging when applied to flaviviruses, largely 
due to the genetic instability of full-length flavivirus cDNAs during propagation in E. coli 
[20-22]. Initially the instability problem was circumvented by using an in vitro ligation 
approach in which full-length templates for run-off RNA transcription were constructed 
by in vitro ligation of appropriate restriction fragments [20;21]. Alternative strategies that 
were subsequently developed to overcome the instability included: 1) the use of different 
bacterial strains for cDNA transformation and propagation [22]; 2) insertion of short introns 
to prevent the unwanted expression of ORFs present in the viral genome that are potentially 
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toxic to E. coli [23]; 3) exploiting low-copy number vectors for the assembly of full-length 
flavivirus cDNA clones [24;25]. 
 A stable full-length clone for yellow fever virus strain 17D (YFV-17D) was successfully 
constructed in a low-copy number vector [25], which not only helped to deepen our insights 
into the molecular biology of this prototypic flavivirus [25], but also facilitated the design and 
construction of YFV-17D based recombinant vaccines [26-41]. Ever since its development 
in the 1930s [42], YFV-17D has stood as a paradigm for a successful live attenuated viral 
vaccine, with a great record of safety and efficacy, rendering it an appealing vector for 
genetically engineered recombinant vaccines against other diseases. In Chapter 2, YFV-
17D was exploited to express the glycoprotein (GPC) sequence of Lassa virus (LASV). The 
recombinant virus was proposed as a bivalent vaccine candidate against both YFV and LASV 
that circulate in the same region in West Africa. While characterizing the recombinant YFV-
17D expressing LASV GPC, genetic instability was encountered, as illustrated by the gradual 
and partial loss of the insert. Considering the duplication of the YFV NS1 signal peptide 
coding sequence flanking the GPC insert, we tried to stabilize the clone by changing the 
codons of the downstream signal peptide so as to minimize sequence similarity, which was 
postulated to induce homologous recombination and thus the loss of the insert. This strategy, 
however, turned out to be unsuccessful. Detailed analysis of recovered recombinant viruses 
strongly suggested that the large size of the insert was the major problem, which has been 
encountered and reported in other studies aimed at constructing recombinant flaviviruses 
[30;37]. Despite the lack of direct evidence for insert size limitations, most likely due to size 
restrictions of the icosahedral capsid, our success in stabilizing the viruses by using smaller 
inserts corresponding to the individual subunits GP1 and GP2 of the LASV GPC, provided 
support for this hypothesis. Therefore, it is advisable to take the length of the heterologous 
insert into consideration while constructing recombinant flaviviruses or RNA viruses with an 
icosahedral capsid structure in general. 
 Another approach for the construction of infectious clones is the so-called infectious 
DNA (iDNA) or DNA/RNA layered approach, by which +ssRNA viruses are recovered in vivo 
after transfection of plasmid DNA carrying the viral genomic cDNA under the transcriptional 
control of a eukaryotic promoter. Using iDNA, the procedure for recovering infectious virus 
particles can be simplified, since there is no need for in vitro transcription; moreover, DNA is 
much more stable at room temperature in comparison to the RNA genome or RNA viruses. 
The first infectious cDNA clone for an animal RNA virus was reported for poliovirus [43], 
and was later described for viruses belonging to other groups [44;45]. Attempts to make 
infectious YFV DNA were again hampered by the genetic instability of the plasmid in E. 
coli. The addition of the cytomegalovirus (CMV) promoter sequence at the 5’ end of the 
YFV-17D cDNA appeared to exacerbate the instability problem. Spurious transcription from 
eukaryotic promoters in bacteria were proposed to be the cause, and several strategies 
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to reduce the expression of toxic products were proposed, both at the transcriptional 
level or at the translational level [46]. In Chapter 3, we managed to stabilize the YFV-17D 
infectious DNA by replacing the low-copy number vector pACNR with a bacterial artificial 
chromosome (BAC), pBeloBAC11, which further reduced the copy number in E. coli. The 
iDNA was characterized in cell culture and was proven to be able to produce infectious 
progeny viruses.
 As proof of concept, the immunogenicity of the YFV-17D iDNA was studied in mice. 
Unfortunately, mice are not ideal animal models for YFV, because they rapidly resolve 
the infection after subcutaneous or intravenous administration or develop neurotropic 
symptoms upon intracerebral inoculation, whereas human infection leads to viscerotropic 
diseases, instead of encephalitis or other neurological disorders. The mechanism behind 
the murine resistance to YFV, be it the vaccine strain 17D or the virulent YFV-Asibi strain 
[47], is not fully understood and was postulated to be related to the murine innate immune 
response towards YFV infection [47;48]. We did not detect any neutralizing antibodies in 
the sera of HLA-A2.1 transgenic C57BL/6 mice vaccinated with the infectious YFV-17D DNA, 
despite readily detectable YFV specific CD8+ T cell response (Chapter 3). It was not clear to 
what extent the genetic background of C57BL/6 mice could affect B cell activation by YFV 
antigens, yet the lack of viremia in the sera seemed to suggest quick and efficient clearance 
of the virus. During the course of this study, Meier et al. reported a study with interferon 
α/β receptor deficient mice (A129 mice), and proposed to use these mice as better small 
animal models for the study of YFV-Asibi infection and YFV-17D vaccination [47]. Therefore, 
we tested immunogenicity of the YFV-17D iDNA in both the interferon receptor knockout 
A129 mice and the congenic 129 mice. We were indeed able to detect humoral immune 
responses in A129 mice vaccinated with YFV17D iDNA, but not in the immuno-competent 
129 mice, confirming the role of the murine innate immune system in the rapid clearance of 
YFV infection in mice. Due to time and funding constraints, however, our experiments were 
relatively limited, so larger scale vaccination-challenge experiments in A129 mice as well as 
in primates are needed to further evaluate the potential of the YFV-17D iDNA as a vaccine 
candidate, and as a platform for the development of DNA based recombinant YFV vaccines. 
To spare vaccine dose and to facilitate the application in human beings, more acceptable 
delivery routes (microneedle patch, for instance [49]) could be explored.  
 Despite the success of the YFV-17D vaccine [50-53] and the promise of the YFV-17D 
based chimeric vaccine platform [33;34;54-61], arthropod-borne (arbo-) flaviviruses still 
pose a great threat to human beings. A better understanding of viral-host interactions will 
provide valuable guidelines for the development of better vaccines and/or treatments. The 
host environment is by nature hostile towards any parasites, with no exception to viruses. 
The biological instinct is to either keep the pathogens at bay or to distinguish the non-self 
from self and to destroy the ‘invader’ upon their intrusion. During their evolution, mammals 
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have developed an armamentarium involving a network of pathways. The first line of 
defense is the innate immune response, and it comes as no surprise that almost all animal 
viruses have evolved strategies to evade or delay the host’s innate immune responses. In 
fact, flavivirus-encoded proteins have been shown to inhibit both the interferon induction 
pathway and the interferon signaling pathways (reviewed in [62;63]). Interestingly, the 
recently identified subgenomic flavivirus RNA (sfRNA) has also been implicated as a viral 
innate immune evasion strategy [64]. 
 Whereas subgenomic RNA production is a well known characteristic for certain 
+ssRNA families (e.g., coronaviruses and alphaviruses), the flavivirus subgenomic RNA that 
is colinear with the distal part of the viral 3’-UTR was not discovered in cells or animals 
infected with flavivirus until recently [65-68]. This unique small RNA species is clearly 
different from subgenomic (m)RNAs produced by other plus-strand RNA viruses in that it 
does not encode for any viral protein. Even more remarkably, sfRNA is not directly produced 
by transcription involving the viral RdRP. Instead, sfRNAs were confirmed to be incomplete 
5’→3’ degradation products of the viral genomes by the host exoribonuclease XRN-1 [68;69]. 
Though uncommon to RNA viruses that in general possess a compact genome, virus-derived 
noncoding RNAs are, on the other hand, transcribed by many DNA viruses, which have been 
found to interact with various cellular pathways and to serve distinct functions. For example, 
Marek’s disease virus noncoding RNA was found to be a precursor in the production of 
miRNA [70], whereas Herpesvirus saimiri noncoding RNA serves as an antagonist for cellular 
miRNA [71]. A 2.7kb CMV-encoded RNA was reported to regulate mitochondria-induced cell 
death [72]. In fact, WNV sfRNA was suggested to be further processed to yield an miRNA-like 
small RNA that was identified in infected mosquito cells [73], although it cannot be ruled 
out that the WNV genome RNA actually serves as the precursor for this small RNA, given 
the sequence identity between the sfRNA and viral 3’-UTR. However, it is more likely that 
viral genomic RNA, intertwined with viral as well as host proteins and wrapped in translation 
and replication complexes, is inaccessible to the miRNA machinery, whereas sfRNA has 
been found to localize to the P-bodies, where shRNA that is produced by Drosha in the 
nucleus undergoes further processing and is eventually assembled into the RISC complex 
[68]. The sfRNA has also been shown to interfere with RNAi in both mammalian and insect 
cells [74], and was suggested to be correlated with viral cytopathogenicity and pathogenesis 
[68;69]. Nevertheless, contrary to the CMV-encoded 2.7kb RNA that prevents cells from 
entering apoptosis, flavivirus subgenomic RNA appeared to enhance cytopathic effect (CPE) 
during viral infection, since mutants incapable of producing sfRNA were unable to induce 
plaque formation in several mammalian cell lines, yielded relatively small infectious centers, 
and were less pathogenic in small animal models compared to sfRNA-producing wildtype 
viruses [68;69] (Chapters 4 and 5). It is paradoxical that killing instead of sustaining the host 
could benefit the virus, or does the accumulation of sfRNA serve as a temporal switch from 
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replication to the release of progeny viruses that can potentially be facilitated by the onset 
of CPE?  
 In order to complete their replicative cycle and perpetuate, arboviruses also need to 
survive and thrive in arthropod vectors, where RNAi plays a major role in the host responses 
that combat infection. Just as plant and insect viruses, arboviruses have also evolved 
strategies to counteract this host response by expressing RNA interference suppressors 
(RSS). Strikingly, no flavivirus-encoded RSS proteins have been identified thus far, yet the 
noncoding sfRNA was proposed to (at least in part) fulfill the role of RNAi suppressor in 
insect cells [74]. 
 Given the different experimental settings and approaches used for the study of sfRNA 
function, it is rather difficult to reach a consensus on sfRNA functionality. It is also hard to 
envision how these apparently different functions in immune modulation, RNAi suppression, 
miRNA production and inhibition of viral minus strand RNA synthesis and translation 
[64;73-75] are somehow connected to contribute to virus fitness. On the one hand, the 
conservation of sfRNA production throughout the Flavivirus genus seems to suggest a crucial 
function that has been preserved through evolution. Alternatively, sfRNA may interact with 
distinctive host factors to fulfill disparate roles in viruses that belong to different clusters 
and exhibit a unique host range. It is beneficial for arbo-flaviviruses to suppress the RNAi 
pathway in insects so as to reach high titers that will maximize their chances of transmission 
to a mammalian host. RNAi suppression would also benefit replication of insect-specific 
flaviviruses in insects. If this is the sole function of sfRNA, however, what would be the 
rationale of sfRNA production in NKV flaviviruses that do not require an arthropod vector for 
viral transmission. On the other hand, an immune evasion strategy in mammalian hosts will 
be beneficial for both the arbo- and NKV- flaviviruses, but does not provide an explanation 
for sfRNA production by insect flaviviruses. In this sense, there must have been either 
functional divergence during evolution or the use of a certain conserved pathway, such as 
RNAi, apoptosis, or RNA degradation pathways, which somehow contributes to viral fitness 
in disparate hosts. 
 In order to test the proposed sfRNA functions in an experimental setting independent 
from viral replication or viral protein expression, yet still pertaining to the intracellular 
physiological environment, mammalian and insect cell lines expressing sfRNA of flaviviruses 
belonging to various clusters could be very helpful. We have established mammalian cell 
lines harboring a gene cassette containing the complete 3’-UTR sequence of YFV-17D or 
WNV downstream of a reporter gene (eGFP) under the transcriptional control of a CMV 
promoter. These cell lines constitutively express authentic YFV-17D or WNV sfRNA. Our 
data showed that not only the YFV-17D sfRNA, but also the WNV sfRNA could complement 
the lack of cytopathogenic effect of an sfRNA-null YFV mutant (Chapter 6). This finding can 
be explained if conserved RNA elements within the 3’-UTR of mosquito-borne flaviviruses 
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interact with either host factors or viral components and promote cytopathogenicity. 
Alternatively, the inhibition of XRN-1 activity [76] per se might enhance cytopathology upon 
virus infection. We can test the latter hypothesis by using mammalian cell lines expressing 
XRN-1 stalling signals from other flaviviruses (e.g., NKV flaviviruses) with the trans-
complementation approach. In addition, insect cell lines expressing sfRNA from insect-
specific or arbo-flaviviruses can be established to study whether sfRNA by itself antagonizes 
cellular RNA interference pathways, and whether perturbation of this pathway contributes 
to the fitness of flaviviruses belonging to other clusters, or unrelated insect or arboviruses 
in general.
 Although no consensus has been reached regarding sfRNA functionality, the 
production of sfRNA has been unambiguously confirmed to be driven by a host enzyme, XRN-1 
[68;69;77;78]. XRN-1 is a well conserved and highly processive cellular exoribonuclease that 
functions as the key enzyme in the 5’→3’ mRNA degradation pathway in eukaryotic cells. So 
far, only a few non-viral RNA structures like oligo(G) stretches and large thermodynamically 
favored stem-loop structures have been reported to be able to stall XRN-1, although the 
stalling efficiency of the stem-loop structures was much lower compared to that achieved 
by oligo(G) tracts or flavivirus stalling signals [79]. Some other structures of viral origin have 
also been reported to defy 5’→3’ degradation, such as the long stem structure with four 
Gs buried at the bottom of the 20S RNA of Narnavirus [80], and a 58-nucleotide sequence 
containing stem-loop structures responsible for the accumulation of small viral non-coding 
RNA in plants and protoplasts infected with red clover necrotic mosaic virus (RCNMV) [81]. 
For the production of sfRNA, XRN-1 was proposed to be stalled upstream of a complex 
RNA structure involving a stem-loop structure that is stabilized by a pseudoknot interaction 
[69;77;78;82]. 
 With their relatively small genome size and limited coding capacity, it is not 
uncommon for RNA viruses to usurp specific RNA motifs or versatile RNA structures to fulfill 
important roles in their replication. Pseudoknots, RNA tertiary structures involving at least 
two interacting stem-loop structures, are especially prevalent in RNA viruses [83] and have 
been identified as essential regulators in transcription and replication, inducers of ribosomal 
frameshifting, or structures that help to maintain RNA conformation for enzymatic function, 
as in ribozymes or telomerases (reviewed in [83]). A frameshift-inducing pseudoknot was 
recently identified in the NS1 coding sequence of flaviviruses belonging to the JEV serogroup. 
This pseudoknot is required for a frameshift that results in the production of a larger version 
of the viral NS1 protein [84]. Additional RNA pseudoknots were predicted to be formed in 
the 3’-UTR of the mosquito-borne flaviviruses, namely PSK1, PSK2 and PSK3 [85]. PSK1 and 
PSK2 were shown to be important for viral replication and/or translation [86] (Bredenbeek 
et al., unpublished data), whereas the more upstream pseudoknot (PSK3) was found to be 
nonessential for virus replication [69]. This XRN-1 stalling RNA pseudoknot structure exhibits 
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special features that distinguish it from classical H-type RNA pseudoknots. It does bear some 
structural resemblance to the RNase L antagonizing enterovirus RNA, which competitively 
inhibits the antiviral endoribonuclease domain of RNase L, thus protecting the viral genome 
from endoribonuclease cleavage [87]. However, in vitro studies did not provide convincing 
evidence for inhibition of RNase L activity by sfRNA [64]. Interestingly, the non-H-type 
RNA pseudoknot structure in sfRNA was found to inhibit the enzymatic activity of another 
cellular ribonuclease, i.e., XRN-1, such that cellular mRNA turnover is perturbed, resulting 
in a different gene expression profile in cells that are infected with wildtype WNV producing 
sfRNA versus cells infected with a mutant WNV that is unable to stall XRN-1 or uninfected 
cells [76]. The accumulation of uncapped mRNA could potentially affect other cellular 
pathways, such as apoptosis and the stress response, possibly explaining the observation 
that sfRNA-deficient WNV and YFV-17D mutants are less cytopathogenic in certain cells of 
mammalian origin.
 Irrespective of their interaction partner, the function that RNA pseudoknot 
structures fulfill largely depends on the RNA conformation as well as its thermostability. 
It can be envisioned, therefore, that the change of a single nucleotide within the XRN-
1 stalling structure may incapacitate XRN-1 stalling (Chapter 5). Despite our extensive 
mutagenesis studies of the XRN-1 stalling site of YFV-17D and MODV (Chapter 4 and Chapter 
5), representing the mosquito-borne and NKV flaviviruses, a solid conclusion regarding the 
sequence/structure requirements for XRN-1 stalling is far from being reached. It is hard to 
envision how the loops and stems are oriented in space, or how XRN-1 binding might change 
the 3-D conformation, and we are not yet clear whether there is any specific nucleotide that 
is critical in the RNA-protein interaction. A better understanding of this structure probably 
requires additional data from in vivo biochemical probing analysis [88] and mutagenesis 
studies and would ideally involve structural biology (e.g., X-ray crystallography or N.M.R.). 
 Thanks to the versatile tools and novel techniques developed in molecular biology 
in the last two decades of the previous century, we have been able to construct infectious 
clones of flaviviruses, with which extensive knowledge has been gained on virus biology 
and which have been used to develop vaccines against pathogenic flaviviruses such as JEV 
[39;40]. Nonetheless, question marks still remain regarding the molecular determinants 
of host restriction, sfRNA function and the sequence/structure requirements for sfRNA 
production, etc. Studies aiming to address these fundamental questions will help fill our 
knowledge gap in the understanding of virus-host and/or virus-vector interaction, which will 
in turn point out directions for the design of better vaccines and antivirals to combat the (re)
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Although mankind has claimed victories over many pathogens in recent history, infectious 
diseases still remain among the leading causes of human morbidity and mortality. In 
contrast to the (nearly) eradicated smallpox virus and poliovirus that have human beings 
as their sole host, arthropod-borne viruses (arboviruses) are more difficult to eliminate, 
due to their use of invertebrate vectors for replication and transmission to humans and 
other mammalian hosts. Among the emerging and reemerging infectious agents, viruses 
belonging to the Flavivirus genus pose great threats to humans all over the world, causing 
febrile diseases, hemorrhagic fever, encephalitis or even death. A general introduction to 
flaviviruses is presented in Chapter 1 that could help better understand and appreciate the 
topics covered by this thesis. 
 In order to conquer these medically important viruses, a comprehensive 
understanding of their molecular biology, as well as their interactions with the host and 
the vector is required. The successful development of reverse genetic systems for arbo-
flaviviruses has not only facilitated the research into their biology but also opened up 
new possibilities to attenuate these viruses for the development of vaccine candidates 
to protect mankind and livestock from the diseases caused by mosquito- and tick-borne 
flaviviruses. The experimental chapters in this thesis mainly focus on the construction and 
characterization of flavivirus infectious clones and the application of these useful tools to 
address fundamental questions on virus biology or to explore novel vaccine platforms based 
on the yellow fever virus vaccine strain (YFV-17D).
 With a great record of safety and efficacy and the availability of a full-length cDNA 
clone, YFV-17D has been explored as a vector for the development of chimeric or recombinant 
vaccines. Chapter 2 describes the construction and characterization of recombinant YFV-
17D viruses expressing Lassa virus (LASV) glycoprotein coding sequences as bivalent vaccine 
candidates against wildtype YFV and LASV that circulate in the same region in West Africa. 
 Despite successful mosquito control and vaccination campaigns in the past, 
resurgence of yellow fever has been observed in recent years, which is mainly due to a 
build-up of unprotected populations in high-risk areas. Chapter 3 of this thesis describes the 
construction and characterization of an alternative YFV-17D vaccine candidate based on a 
DNA launched YFV-17D infectious clone. With the incorporation of eukaryotic transcription 
promoter and terminator sequences and a hepatitis delta virus ribozyme sequence, YFV-17D 
infection could be initiated by the introduction of this YFV-17D infectious DNA (iDNA) into 
cells or organisms. The immunological characteristics of the YFV-17D iDNA were evaluated in 
murine models. This DNA/LAV (live attenuated vaccine) layered approach could potentially 
reduce the costs of YFV-17D vaccine production and facilitate vaccine transportation and 
distribution. 
 In contrast to the pathogenic arthropod-borne flaviviruses, no known vector (NKV) 
flaviviruses that have been exclusively isolated from mammals are less-well studied, which 
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is in part due to the lack of infectious clones. Chapter 4 describes the construction and 
characterization of the first NKV flavivirus infectious clone, which was further utilized to 
study the functional significance of RNA elements present in Modoc virus (MODV) 3’-UTR 
(untranslated region), as a representative of the NKV flaviviruses. The differences/similarities 
between NKV flavivirus 3’-UTR and that of vector-borne flaviviruses are discussed in this 
chapter. 
 A recently discovered common feature for all flaviviruses is the production of a small 
flavivirus RNA (sfRNA) in infected cells or animals. The production of this sfRNA results from 
the incomplete degradation of the viral genome by the host exoribonuclease, XRN-1. XRN-1 
was predicted to be stalled by a non-H-type RNA pseudoknot structure that is present is the 
3’-UTR of every flavivirus studied thus far. Chapter 5 presents a detailed mutagenesis study 
of many of the unique sequence and structural characteristics of the XRN-1 stalling site in 
mosquito-borne flaviviruses using YFV-17D as a model. The impact of these mutations on 
virus replication, sfRNA production and viral cytopathogenicity were analyzed in detail.
 Chapter 6 describes the establishment of mammalian cell lines that constitutively 
expressed sfRNA from YFV-17D and WNV, which were further analyzed for their ability to 
trans-complement the cytopathogenicity of a YFV-17D mutant that was deficient in sfRNA 
production. Surprisingly, trans-complementation of the sfRNA-null YFV-17D mutant was not 
only observed in cell lines expressing the YFV-17D sfRNA but also in cell lines expressing the 
sfRNA of WNV. This cell line approach could be valuable to further our understanding of 
sfRNA function within flavivirus life cycle. 
 Chapter 7 of this thesis is a short epilogue, in which the findings presented in the 
experimental chapters are summarized and discussed in the context of recently published 
findings and future research directions are suggested to improve the YFV-17D based vaccine 






Alhoewel de mensheid in de laatste eeuw grote successen heeft geboekt in het bestrijden 
van parasieten, bacteriën en virussen, zijn infectieziekten nog steeds een belangrijke oorzaak 
van morbiditeit en mortaliteit bij mensen.   
 In tegenstelling tot het reeds geëlimineerde pokkenvirus (variola) en het bijna 
uitgeroeide poliovirus, welke beide uitsluitend de mens als gastheer gebruik(t)en, is het 
vrijwel onmogelijk om de pathogene flavivirussen uit te roeien. Dit is vooral een gevolg van 
het feit dat deze virussen naast de mens een geleedpotige gastheer, zoals een teek of mug, 
gebruiken als een vector voor de verspreiding en als gastheer voor de vermeerdering van het 
virus. Verschillende van deze zogenaamde “arthropod-borne” (arbo) flavivirussen, zoals het 
West Nile virus (WNV) in Noord-Amerika, het dengue virus (DENV) in Zuidoost-Azië en het 
gele koortsvirus (YFV) in Afrika en Zuid-Amerika behoren tot de belangrijkste zogenaamde 
“emerging” en “re-emerging” virussen. Ieder jaar infecteren deze virussen grote aantallen 
mensen, hetgeen kan resulteren in een levensbedreigende encefalitis (WNV) dan wel zeer 
ernstige hemorragische koorts (DENV en YFV). 
 Naast fundamenteel onderzoek aan de moleculaire biologie van de replicatie van 
flavivirussen worden in dit proefschrift, aan de hand van de vaccinstam van het gele koorts 
virus, ook alternatieve mogelijkheden gepresenteerd voor de vervaardiging en het gebruik 
van geattenueerde flavivirussen als recombinant vaccin. 
 Hoofdstuk 1 geeft een overzicht van de biologie van de flavivirussen. De moleculaire 
biologie, alsmede de onderlinge verwantschap en de transmissieroutes van de verschillende 
flavivirussen worden in dit hoofdstuk beschreven. Deze uit fundamenteel- en veldonderzoek 
verkregen kennis is cruciaal voor het begrijpen van de complexe virus – gastheer interacties 
en dient als basis voor de ontwikkeling van strategieën om de invloed van flavivirus infecties 
op de maatschappij en economie terug te dringen.  
 De overige hoofdstukken van dit proefschrift beschrijven de vervaardiging van 
zogenaamde “infectieuze cDNAs” van flavivirussen en het gebruik daarvan voor zowel 
de toepassing als alternatieve recombinante vaccins tegen flavivirussen, alsmede voor 
fundamenteel onderzoek in de moleculaire biologie van deze virussen. 
 Bescherming tegen infectie van het eerder genoemde gele koorts virus is mogelijk 
door vaccinatie met de van het wildtype virus afgeleide, maar geattenueerde YFV-17D stam. 
Het YFV-17D vaccin is uitermate doeltreffend en veilig. Tientallen miljoenen mensen zijn 
inmiddels door vaccinatie met dit virus beschermd tegen gele koorts. 
 In hoofdstuk 2 wordt beschreven hoe deze gunstige eigenschappen van het YFV-17D 
virus gebruikt kunnen worden om met moleculair biologische technieken een recombinant 
virus te construeren dat in principe niet alleen bescherming geeft tegen gele koorts, maar 
ook tegen een ander pathogeen, in dit geval het Lassa virus. De in dit hoofdstuk beschreven 
in vivo experimenten met de cavia als diermodel tonen aan dat deze benadering in principe 
succesvol kan zijn. 
165
Samenvatting
 Ondanks de beschikbaarheid van een goed vaccin is er de laatste decennia sprake 
van een hernieuwde verspreiding van het gele koorts virus en een toename van het aantal 
gele koorts- infecties van mensen in met name Afrika. Dit is onder andere het gevolg van het 
teruglopende aantal gevaccineerden in gebieden waar het virus endemisch is. In hoofdstuk 
3 van dit proefschrift wordt een alternatief YFV-17D vaccin beschreven dat is gebaseerd 
op infectieus YFV-17D RNA dat zowel in celkweek als in muizen tot expressie komt na 
immunisatie met DNA in plaats van het virus. Alhoewel verder onderzoek zeker noodzakelijk 
is, blijkt uit de analyse van immunologische karakteristieken van de met het YFV DNA 
gevaccineerde muizen, dat deze strategie in principe werkt. Het gebruik van infectieus DNA 
als vaccin zou in de toekomst de productie van het YFV-17D vaccin kunnen vereenvoudigen, 
terwijl de betere thermostabiliteit van DNA, in vergelijking tot het huidige YFV-17D vaccin 
de distributie zal vergemakkelijken.
 Naast de voor mensen pathogene arbo-flavivirussen is er een groep minder goed 
bestudeerde flavivirussen waarvoor geen vector bekend is. Deze “no known vector” 
(NKV) flavivirussen zijn uitsluitend in zoogdieren aangetroffen. Ook mensen kunnen door 
sommige van deze NKV flavivirussen worden geïnfecteerd, maar infectie is tot op heden 
niet geassocieerd met ziekte. In hoofdstuk 4 van dit proefschrift wordt de constructie en 
karakterisatie van de eerste infectieuze cDNA kloon voor een NKV flavivirus beschreven. Deze 
Modoc virus kloon is vervolgens gebruikt om de structuur en functie van geconserveerde 
RNA elementen in het 3’ uiteinde van het virale genoom in de replicatie van het virus te 
bestuderen. Uit dit onderzoek blijkt dat het 3’ uiteinde van Modoc virus naast RNA sequenties 
welke qua structuur en functie geconserveerd zijn tussen de NKV- en arbo-flavivirussen, 
RNA elementen bevat welke uniek zijn voor de NKV flavivirussen en essentieel zijn voor virus 
replicatie. 
 Tot voor kort werd algemeen aangenomen dat in tegenstelling tot diverse groepen 
andere RNA virussen, zoals de Nido- en Alphavirussen, flavivirussen geen subgenome 
RNAs zouden produceren. Uit recent onderzoek is echter gebleken dat naast het genoom 
RNA, alle flavivirussen een niet-coderend RNA molecuul met een lengte van 250 tot 500 
nucleotiden produceren. Dit zogenaamde “small flavivirus” (sf) RNA heeft exact dezelfde 
nucleotidensequentie als het 3’ uiteinde van het virale genoom. Productie van dit sfRNA is 
echter niet het resultaat van virale transcriptie, maar het gevolg van de onvolledige afbraak 
van het virale genoom door het gastheer endo-ribonuclease XRN1. Een unieke tertiaire RNA 
structuur in het 3’ uiteinde van het genoom stopt de van 5’ naar 3’ verlopende hydrolyse 
van het virale RNA door XRN1, hetgeen resulteert in de accumulatie van sfRNA. In hoofdstuk 
5 worden de resultaten van een uitgebreide mutagenese van deze XRN1-stoppende RNA 
pseudoknot structuur in YFV-17D beschreven. Uit de verkregen resultaten blijkt dat voor 
het succesvol stoppen van XRN1 en dus sfRNA productie, niet alleen de structuur van de 
RNA pseudoknot, maar ook specifieke nucleotiden op bepaalde posities in deze structuur 
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van belang zijn. De aangebrachte mutaties blijken echter geen significante invloed op de 
genoom RNA synthese en virusproductie te hebben.
 Uit eerder onderzoek is gebleken dat de productie van sfRNA bij WNV en YFV 
correleert met de pathogeniciteit van het virus. Het moleculair-biologische principe dat 
aan deze waarneming ten grondslag lag was echter onbekend. In hoofdstuk 6 wordt de 
constructie van cellijnen beschreven, die constitutief het sfRNA van YFV-17D of WNV 
produceren. Uit het beschreven werk blijkt dat het mogelijk is om de cytopathogeniciteit 
van een sfRNA- negatieve mutant van YFV-17D te herstellen door trans-complementatie 
met het sfRNA dat in deze cellijnen wordt geproduceerd. Het maakt hierbij geen verschil of 
het aangeboden sfRNA van YFV of WNV afkomstig is. Blijkbaar is de functie van het sfRNA 
niet virusspecifiek en goed geconserveerd bij de arbo-flavivirussen.
 Het laatste hoofdstuk van dit proefschrift is een korte epiloog waarin de experimentele 
resultaten uit hoofdstuk 2 t/m 5 worden samengevat en bediscussieerd in de context 
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